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Abstract 
The genus Acinetobacter is amongst the most common causes of nosocomial bacterial infections. 
Even though Acinetobacter baumannii is the most frequent identified species causing a wide range 
of infections in humans, other species such as Acinetobacter pittii, Acinetobacter nosocomialis, 
Acinetobacter haemolyticus, Acinetobacter johnsonii, Acinetobacter lwoffii and Acinetobacter 
ursingii are sporadically observed as nosocomial pathogens. The four species that show similar 
phenotypes were grouped together as “Acinetobacter calcoaceticus – A. baumannii (ACB) complex”, 
i. e. A. baumannii, A. nosocomialis, A. pittii and less clinically important A. calcoaceticus. Owing to 
the high complexity within Acinetobacter genus, it is difficult to differentiate Acinetobacter into 
species level and these organisms are frequently misidentified. 
Acinetobacter spp. exhibit a great propensity to acquire antimicrobial resistance determinants and 
rapidly develop multidrug-resistant (MDR) phenotypes especially resistance to carbapenems, the last 
resort of antimicrobials to treat Acinetobacter infections. A high prevalence and endemic situations 
of carbapenem-resistant A. baumannii (CRAB) have been observed in multiple geographical areas 
such as Asia-Pacific and South America where predominant A. baumannii clonal lineages were noted. 
The international clone (IC) 2 is recognised as the most successful clone of A. baumannii causing 
outbreaks and persisting in hospital environments worldwide, particularly in Asia. Despite the 
increased amount of research on Acinetobacter epidemiology, potential virulence and evolution, little 
is known about the factors that may have contributed to the success of this well-known clone, IC2. 
The broad objectives of my PhD are to 1) develop a rapid method to assist in species identification 
of Acinetobacter non-baumannii, 2) determine the molecular epidemiology of A. baumannii, 
primarily from Thailand and 3) describe the genome of A. baumannii IC2 isolates from Thailand and 
compare these genome data with A. baumannii IC2 isolates from Japan, Malaysia and Singapore. 
Firstly, a multiplex PCR was developed to detect intrinsic oxacillinases encoding genes (blaOXAs), 
which assisted in rapid identification of multiple Acinetobacter species including A. 
lwoffii/Acinetobacter schindleri, A. johnsonii, A. calcoaceticus, A. haemolyticus and Acinetobacter 
bereziniae. Additionally, 30 novel blaOXAs variants were identified in this study. The investigation of 
Acinetobacter spp. collected worldwide revealed that acquired-type blaOXAs disseminated globally in 
Acinetobacter spp. as opposed to A. baumannii causing carbapenem resistance particularly in A. pittii. 
Carbapenem resistance was also observed in A. pittii from Australia and Thailand. Through the 
genomes of the two A. pittii strains ST119 and a novel ST655, several classes of antimicrobial 
resistance genes including a novel blaOXA-421, blaOXA-23, blaOXA-96, blaOXA-10, blaIMP-4, blaVEB-7, 
 ii 
blaCRAB-2, floR, cmlA1, aar-2 and dfrA10 were identified. This emphasises the importance of A. pittii 
as an impending multidrug resistance pathogen in this region. 
Secondly, to explore an endemic situation of multidrug-resistant Acinetobacter spp., 300 non-
repetitive ACB complex isolates, mainly A. baumannii from the largest tertiary hospital in Thailand 
were characterised for their molecular epidemiology and antimicrobial resistance mechanisms. Of 
these, 270 isolates were carbapenem-resistant and 92.2% resistant to amikacin. A. baumannii IC2 was 
the dominant clone of A. baumannii (80%) and blaOXA-23-like was detected in most of CRAB isolates. 
The genomes of 13 representative isolates of A. baumannii (n=11), A. nosocomialis (n=1) and A. 
pittii (n=1) were analysed via whole genome sequencing. Antimicrobial resistance island, AbaR4-
type containing Tn2006, was found in all CRAB isolates. armA was the only 16S rRNA methylase 
gene found that caused resistance to amikacin (located within Tn1548) and in close proximity to 
macrolide resistance genes (mphE and msrE). csu locus, bap, bfmRS and pga locus associated with 
biofilm formation were found in all IC2 isolates in addition to the typical set of antimicrobial 
resistance genes; blaOXA-23, blaOXA-66, blaADC, strA, strB and tetB in this clone. Therefore, the presence 
of arrays of antimicrobial resistance genes and biofilm-related loci may contribute to the spread and 
persistence of A. baumannii IC2 in this hospital. 
Lastly, comparative genome analysis was performed on 21 representative Acinetobacter spp. isolates 
from Thailand and other countries, i.e. Japan, Malaysia and Singapore. The range of the CRAB 
genome size was 3.9 - 4.1 Mb with GC content approximately 39%. Interestingly, the susceptible A. 
baumannii genome size was 3.7-3.8 Mb. The size difference was due to the absence of resistance 
genes and regions for bacterial competition and biofilm formation in susceptible isolates. The genetic 
contexts of key antimicrobial resistance genes and resistance islands were investigated. Our study 
confirmed that the antimicrobial resistance genes and other genomic features of IC2 isolates were 
homogenous. The diversity was mainly found in the composition of the antimicrobial resistance genes 
of IC2 isolates and locus for capsule synthesis (K locus). The genome and composition of 
antimicrobial resistance genes between IC2 isolates from Thailand and all IC2 from other countries 
were closely related. Two IC2 carbapenem-susceptible isolates from Japan harboured less 
antimicrobial resistance genes (blaOXA-66, strA, strB, sul2 and tetB). The locus for the outer core of 
lipid A-core moiety (OC locus) was generally conserved - OCL1 was a common type within IC2. 
Such variations observed of the K locus may impact in the difficulties to generate human immune 
response to A. baumannii. Lastly, one key feature of IC2 was the integrity of all chromosomal regions 
for type VI secretion system (T6SS) and biofilm formation (csu). In contrast, these regions in non-
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IC2 isolates were disrupted. This may indicate the incapability of non-IC2 isolates to persist in the 
hospital environment. 
The study of various aspects of carbapenem-resistant Acinetobacter spp. in our region has revealed 
specific insights into this pathogen locally and globally. These include the species identification, 
molecular epidemiology and the genome of Acinetobacter spp. Genomic analysis has described all 
necessary attributes of the superiority of IC2 to spread further under antimicrobial pressure and harsh 
environments. Further research is required to understand greater detail of these many unique findings. 
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Chapter 1. Introduction 
1.1 Synopsis 
Nosocomial infections represent an important problem in public health and are increasing throughout 
the world. There has been an increase in morbidity and mortality due to such infections [1]. The 
difficulty to treat and eradicate microorganisms causing nosocomial infections from the hospital 
environment is a major challenge to physicians and healthcare workers [2]. 
Gram negative pathogens have been the focus of recent clinical attention due to their increasing 
frequency in causing hospital-acquired infections. In this group, Acinetobacter spp. is emerging as a 
pathogen that frequently causes infections in patients in intensive care units [3]. The most common 
Acinetobacter spp. involved in hospital infections is Acinetobacter baumannii [4]. Within the last 
three decades, A. baumannii has exhibited a high propensity to develop antimicrobial resistance, 
including resistance to carbapenems, one of the last line drugs for treatment A. baumannii infection, 
which leaves us with few remaining treatment options (i.e. tigecycline and colistin). 
A high prevalence of carbapenem-resistant Acinetobacter spp. was observed throughout the world, 
particularly in the Asia-Pacific region [5, 6]. In multiple locations throughout the world pandrug-
resistant strains have been identified [7-10], implying resistance to all commercially available 
antimicrobials. The acquisition of plasmids, transposons or integrons, carrying clusters of genes 
harbouring resistance to several antimicrobial families simultaneously, plays an important role in 
acquiring multidrug resistance.  
The molecular epidemiology of multidrug-resistant A. baumannii from different countries has been 
studied with increasing intensity in recent years. The vast majority of isolates disseminated worldwide 
belong to just one or two clones, which were described as International clone (IC) 1 and 2 [11]. The 
global spread of successful international clones underlines the importance of molecular 
epidemiologic and genome-wide studies in order to obtain a greater understanding of population 
genetics and adaptive mechanisms amongst these powerful these clones. 
In the paper “Molecular epidemiology and mechanisms of carbapenem resistance of Acinetobacter 
spp. in Asia and Oceania”, I focused on the studies from Asia and Oceania to illustrate and better 
understand the population structure of carbapenem-resistant Acinetobacter spp. in these regions. 
Several typing methods, epidemiology, and mechanisms of carbapenem resistance in A. baumannii 
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were outlined. In addition, we elucidated the distribution of oxacillinases and metallo-β-lactamases, 
the most important β-lactamase classes causing carbapenem resistance in A. baumannii.  
 3 
1.2 Molecular epidemiology and mechanisms of carbapenem resistance 
Acinetobacter spp. in Asia and Oceania 
 
EPIDEMIOLOGY
Molecular Epidemiology and Mechanisms of Carbapenem
Resistance of Acinetobacter spp. in Asia and Oceania
Witchuda Kamolvit,1,2 Hanna E. Sidjabat,1 and David L. Paterson1
Acinetobacter baumannii is emerging as a pathogen that is commonly involved in nosocomial infections.
A. baumannii has exhibited the ability to develop multidrug resistance (MDR), including resistance to carba-
penems, the last-line class of antibiotics to treat these infections. In particular, MDR A. baumannii International
Clone (IC) 2 has disseminated worldwide causing substantial problems in hospitals, including in Asia and
Oceania. The global spread of this clonal lineage emphasizes the importance of tracking molecular epidemio-
logy to obtain greater understanding of the population dynamics of A. baumannii. Carbapenem resistance in
A. baumannii occurs mainly as a result of acquisition of OXA-type carbapenemase genes, and to some extent by
acquisition of metallo-b-lactamase genes. The acquisition of carbapenemase genes, particularly the blaOXA-23,
blaOXA-40, and blaOXA-58, by specific clonal lineages may be one of the attributes responsible for the relative
homogeneity of the MDR A. baumannii population.
Introduction
Acinetobacter is a nonlactose fermenting and strictlyaerobic gram-negative genus.22 This genus currently
comprises 44 species; 9 genomic species and 35 validly named
species (www.bacterio.cict.fr/a/acinetobacter.html). Owing to
their high phenotypic and genetic similarities, four of these
species are grouped as the ‘‘A. calcoaceticus-A. baumannii
(ACB) complex.’’ They include Acinetobacter calcoaceticus
(genomic species 1), Acinetobacter baumannii (genomic
species 2), Acinetobacter pittii (genomic species 3), and Aci-
netobacter nosocomialis (genomic species 13TU). Among the
ACB complex, A. baumannii, A. pittii, and A. nosocomialis,
which are also recognized as the A. baumannii group, are the
most clinically important species. Meanwhile, A. calcoaceti-
cus is considered as a nonpathogenic environmental organism
and is rarely isolated from clinical specimens.45,71
Due to high similarities of phenotypic and genotypic char-
acteristics, it is difficult to identifyAcinetobacter spp. into their
species level.6 Available automated systems used in routine
diagnostic laboratories, such as API-20NE, Vitek 2, and
Phoenix, are not able to distinguish the species among the
ACB complex. Furthermore, phenotypic and genotypic
methods, such as DNA-DNA hybridization and amplified
rRNA gene restriction analysis are time-consuming.7,99 Se-
quencing methods of rpoB and 16S–23S rRNA gene spacer
region are reliable for such species identification.11,55 A rapid
PCR-based method for gyrB is another reliable tool for species
differentiation among the ACB complex.33 In this review, we
verified that publications within the literature had applied
proper methods for species identification. The term ‘‘Acine-
tobacter spp.’’ in this review was used where the methods
could not identify species level of Acinetobacter spp.
Within the last few decades, A. baumannii has alarmingly
emerged as one of the most important nosocomial pathogens.
Infections caused by A. baumannii as a nosocomial pathogen
includes ventilator-associated pneumonia, bloodstream in-
fection, wound infection, and meningitis. There are few
therapeutic options that can overcome this organism.77 Car-
bapenems are one such remaining option as the last-line drugs
for treatment of infections caused by A. baumannii. Un-
fortunately, resistance to carbapenems has become common
among A. baumannii worldwide. It is worth noting that
A. baumannii is naturally resistant to several antibiotics such
as ampicillin, narrow-spectrum cephalosporins, trimethoprim,
and ertapenem.56 A high prevalence of carbapenem-resistant
A. baumannii is observed in several geographic areas such as
Asia-Pacific (APAC), Latin America, and the Mediterra-
nean.15,35,44,96 The SENTRY antimicrobial surveillance pro-
gram has shown a continuing decrease in the imipenem
susceptibility rates among Acinetobacter spp. collected from
different regions (Fig. 1).
The susceptibility rate to imipenem in the APAC region
declined from 73.7% in 2001–2004 to 37.4% in 2009
1UQ Centre of Clinical Research, The University of Queensland, Brisbane, Australia.
2Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
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(Fig. 1).26,27 This high rate of carbapenem resistance was
observed in most countries from this region. Moreover,
pandrug-resistant A. baumannii isolates (resistant to all
available class of antibiotics) have also been increasingly
identified in Asia.4,16 This highlights the increasing trend of
antibiotic resistance in A. baumannii in the APAC region,
especially resistance to carbapenems.
Molecular Typing Methods for A. baumannii
A number of molecular typing methods have been used to
understand the molecular epidemiology of A. baumannii. The
most commonly used typing techniques include (1) DNA-
based fingerprinting methods, pulsed-field gel electrophoresis
(PFGE),85 amplified fragment length polymorphism analy-
sis,21 and multiple-locus variable-number tandem-repeat
analysis96 and (2) PCR-based and sequencing methods, re-
petitive sequence-based PCR (rep-PCR) analysis,32 multi-
locus sequence typing (MLST),5,20 and sequence-based
typing and their allele-specific multiplex PCRs.95 Whole-
genome sequencing has also been used for this purpose.1,87
PFGE or restriction analysis of chromosomal bacterial DNA
is still currently considered as the gold standard for epidemi-
ologic typing and used in numerous A. baumannii outbreak
studies showing high discriminatory power.85 However, PFGE
is laborious, and thus, it is not a suitable technique for rapidly
resolving the molecular epidemiology of outbreaks and is not
suitable for comparing typing results between laboratories.
Amplified fragment length polymorphism (AFLP) analysis has
been used as a reference method to identify outbreak clones in
Europe, initially named European clones I, II, and III, which
had later spread worldwide21,98 and are now known as world-
wide clone, global clone, or international clone (IC) 1, 2, and
3.22,32 Up to now, there is no consensus regarding the termi-
nology. In recent literature,A. baumannii outbreak strains have
been designated as international clones over others, such as
worldwide clone or European clone.20,113 Therefore, ‘‘inter-
national clone’’ (IC) will be used in this review.
MLST is an objective method of typing microorganisms
that are suitable for population-based studies and global
epidemiologic analysis as it allows one to place tested
isolates among global isolates registered in centralized
A. baumannii MLST databases.5,20 This method is based on
comparison of the sequences of internal fragments of seven
housekeeping genes.5 Two MLST schemes are available for
Acinetobacter. The first MLST scheme was established by
Bartual et al. and is maintained at PubMLST (http://
pubmlst.org/abaumannii/). This scheme uses gltA, gyrB,
gdhB, recA, cpn60, gpi, and rpoD genes.5,106 The second
MLST scheme is maintained at the Pasteur Institute’s MLST
database (www.pasteur.fr/recherche/genopole/PF8/mlst/
Abaumannii.html). The method uses cpn60, fusA, gltA,
pyrG, recA, rplB, and rpoB genes, sharing three of them
with the PubMLST scheme.20
In Asia and Australia, PubMLST is used more frequently,
while groups in Europe recently prefer to use the Pasteur
Institute’s scheme.19,28,39 Both MLST schemes were appli-
cable to non-baumannii Acinetobacter spp.104,106 However,
the Pasteur MLST database has more designated STs for
non-baumannii species and strains than PubMLST. This
suggests that Pasteur MLST may be suitable for global ep-
idemiology study of non-baumannii Acinetobacter spp. We
have performed a population study on multidrug resistance
(MDR) A. baumannii on a global scale using the PubMLST
scheme. Our results showed that clonal complex 92 (CC92)
was the largest and most geographically diverse CC, which
corresponded to IC 2 based on previous typing methods, that
is, AFLP and rep-PCR.83
Multiplex PCR is an alternative method to differentiate
clonal lineages of A. baumannii. This method is a sequence-
based typing method for three specific genes: ompA, csuE,
and blaOXA-51-like which was developed by Turton et al.
95
Owing to higher numbers of polymorphism found in these
three genes, this approach has the possibility for greater
discrimination than schemes based on housekeeping genes
such as MLST.94,95 Through this method, 96 carbapenem-
resistant A. baumannii isolates from hospitals in 17 European
countries were characterized. Seven different sequence
groups (SGs) were identified, and three of these (SG 1, 2, and
3) corresponded to IC 2, 1, and 3, respectively. The majority
of isolates belonged to IC 2 and 1, and the remainder be-
longed to four novel groups.94 A group in Australia also used
this method to characterize Australian isolates, where the
majority of isolates belonged to IC 2 and 1.28
rep-PCR is another useful typing method, one of which is
a semiautomated and commercially available method called
DiversiLab (BioMe´rieux). This method utilizes a micro-
fluidic LabChip on a bioanalyzer to analyze the amplicons
and uses built-in software to build the dendrograms. This
method offers the advantages of rapid turnaround time, ease
of use, and the ability to maintain libraries of all typed
isolates that can be valuable for a future epidemiologic
study. Higgins et al. investigated a large global cohort of
imipenem-nonsusceptible A. baumannii isolates from 32
countries using the DiversiLab system.32 The result showed
the presence of at least eight distinct clonal clusters, which
were assigned as worldwide (WW) lineages 1–8. Three of
these clusters represented IC 1, 2, and 3 (WW 1, 2, and 3,
respectively) with a predominance of IC 2. Higgins et al.
also showed results comparable to those generated by the
DiversiLab system and those from PFGE and MLST.83,84
This suggests that the DiversiLab system is one of the more
reliable techniques for the global epidemiologic study of
A. baumannii.
FIG. 1. Imipenem susceptibility rates in Acinetobacter
spp. from Asia-Pacific (APAC), Europe, Latin America, and
North America (the SENTRY surveillance program).23,24
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Molecular Epidemiology of A. baumannii
in Asia and Oceania
The molecular epidemiology of A. baumannii in Asia and
Oceania has been studied with increasing intensity in recent
years using various typing methods. MLST has been most
frequently used. To better understand the molecular epide-
miology of A. baumannii in Asia and Oceania, here, we
have generated a snapshot of the A. baumannii population
structure from Asia and Oceania available in the PubMLST
database. This snapshot was generated using eBURSTv3
analysis (http://eburst.mlst.net/v3/enter_data/single/) (Fig.
2). We included A. baumannii isolates from nine countries:
Australia (n = 51), China (n = 125), India (n = 22), Japan
(n = 33), South Korea (n = 71), Malaysia (n = 2), Singapore
(n = 4), Thailand (n = 12), and Vietnam (n= 11).
A total of 331 A. baumannii isolates from 170 different STs
were available in the PubMLST database from Asia and
Oceania. These were grouped in 17 CCs and 68 singletons
(Fig. 2). Themost predominant CCwasCC92 (n=161, 48.6%),
which included isolates from all countries except India. CC92
corresponds to IC 2. Among CC92, ST92 (n = 72), ST75
(n = 23), and ST138 (n = 10) were the most identified STs in
the PubMLST database. ST92 was recovered from Australia,
China, Japan, South Korea, and Thailand from 2000 to 2010.
Additionally, we have sought additional ST information
from publications from the region available in PubMed.
ST92 was also found in India, the Philippines, and Taiwan,
however, these data were not available through the
PubMLST database.50 ST75 (also part of CC92) was re-
ported as a major ST that caused outbreaks in hospitals in
China and South Korea.17,60,74,114 A study from South
Korea demonstrated that ST75 and ST138 have increased in
2008–2010.74 The isolates of these two STs showed higher
carbapenem resistance rates than isolates of ST92, which
was the most prevalent ST in 2003–2007.
In Asia and Oceania, IC 1 and IC 3 are relatively un-
common compared to IC 2. CC109 (n= 15), which corre-
sponds to IC 1, was the second most common CC in Asia
and Oceania. More than 50% of the isolates clustered in this
CC were recovered from Australia. ST109 was the predicted
founder, which was first reported from Australia in 1997.
This ST was also found in Japan and South Korea.89 CC110,
which corresponded to IC 3, consisted of eight isolates from
South Korea (three), India (two), Australia, Japan, and
Vietnam. CC561, a newly described CC has been found in
bloodstream isolates in South Korea (2010–2011) and not
associated with IC 1, IC 2, or IC 3. Furthermore, A. bau-
mannii can be isolated from feces of pigs and cattle. How-
ever, none of these strains was associated with IC 1, IC 2, or
IC 3, which are the common clones of A. baumannii strains
in humans.30 This shows that lineages of A. baumannii from
animals and humans are distinct.
In conclusion, a few major clonal lineages, including IC
1, 2, and 3, were responsible for the spread of A. baumannii
in Asia and Oceania. CC92 (corresponding to IC 2) was the
most prevalent clonal lineage recovered from this region
(48.6%). There was an emergence of a single CC, CC561,
which was found only in South Korea (Fig. 2). Even though
CC92 is the most commonly identified clone over a decade,
a shift of STs into more carbapenem-resistant ones was
observed within CC92. This suggests that carbapenem re-
sistance may be responsible for an evolution within suc-
cessful clonal lineages, which may lead to a decrease in the
heterogeneity of the A. baumannii population.
Mechanisms of Carbapenem Resistance
in A. baumannii
Several molecular mechanisms are responsible for confer-
ring carbapenem resistance in A. baumannii. The most com-
mon mechanism of carbapenem resistance is the production of
carbapenem-hydrolyzing b-lactamases; oxacillinases (OXA-
type carbapenemases) and metallo-b-lactamases (MBLs).
Alteration of penicillin-binding proteins and loss of outer
membrane proteins,18,42,69,100 efflux pump mechanisms, and
other b-lactamases are also commonly implicated in carba-
penem resistance of A. baumannii.100
FIG. 2. A population
snapshot of Acinetobacter
baumannii isolates form Asia
and Oceania (data from
PubMLST). The number of
epidemic and clonal com-
plexes (CCs) with corre-
sponded international clones
(ICs) is indicated (dash line).
The circle represents an ST.
The relative size of the cir-
cles indicates their preva-
lence in the PubMLST
database. The lines connect-
ing each circle represent
single locus variant STs that
differ in only one of the se-
ven housekeeping genes.
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Oxacillinases
The name oxacillinase refers to the ability to hydrolyze
the isoxazolyl penicillin, oxacillin, much better than the
classical penicillins.10 The group of OXA-type carbapene-
mases exhibits carbapenem-hydrolysing activities, in con-
trast to most OXA-type b-lactamases which do not
hydrolyse carbapenems. Most of these enzymes are weak
carbapenemases. However, when overexpressed they are
able to confer carbapenem resistance.24
To date, several variants of acquired type OXAs found in
A. baumannii have been identified (Fig. 3A). Four major
subgroups of OXA-type carbapenemases include both (1)
acquired types (OXA-23, OXA-40, and OXA-58 like),
where their genes have been found either in the chromosome
or plasmid of some but not all A. baumannii isolates and (2)
the naturally occurring chromosomal OXA-51-like carba-
penemase.97 Additional groups of acquired OXA-type car-
bapenemases such as OXA-143 and OXA-235 like have also
recently been identified in A. baumannii.34,35
The acquisition mechanisms for OXA-encoding genes in
A. baumannii are not thoroughly understood. The blaOXA-23-like
and the blaOXA-40-like genes have been reported to be en-
coded on both the chromosome and plasmids.24,68,77,102 The
blaOXA-58-like genes were frequently identified as plasmid
mediated. Multiple genomic studies have revealed the piv-
otal role of insertion sequence (IS) elements. The presence
of ISAba1 upstream of blaOXA-23-like, blaOXA-235-like as well
as intrinsic chromosomal blaOXA-51-like provides promoter
sequences leading to overexpression of these downstream
genes conferring resistance to carbapenems.34,81,97 ISAba1,
ISAba2, ISAba3, and IS8 have been shown to enhance the
expression of blaOXA-58.
82 The overexpression of blaOXA-40-
like and blaOXA-143-like is not associated with IS elements and
their native promoters may be sufficient for over-
expression.92,111
Metallo-b-lactamases
MBLs, Ambler class B enzymes, bear two zinc ions in
their active sites and are capable of hydrolyzing all b-lactam
antibiotics except aztreonam. IMP, VIM, SIM, and NDM, a
recently described MBL, have been identified in Acineto-
bacter spp. from Asia and Oceania.76,81,101 Among these
MBLs, IMP was the most commonly reported in A. bau-
mannii until 2007. However, NDM has often been reported
in various Acinetobacter species since its emergence in
2009.101,110 Generally, MBLs are less commonly found in
A. baumannii than the OXA-type carbapenemases, most of
which, with the exception of NDM, are captured by in-
tegrons as gene cassettes. NDM in comparison is found to
mobilize through a composite transposon, Tn125, among
Acinetobacter spp.79 Furthermore, A. baumannii has also
been theorized to be the platform for the origin of NDM.93
FIG. 3. (A) Unrooted neighbor-joining tree based on amino acid of five groups of OXAs (OXA-23 like, OXA-40 like,
OXA-58 like, OXA-143 like, and OXA-235 like) that were identified in Acinetobacter species. Horizontal bar; 6%
sequence divergence. *OXA enzymes were reported from Asia and Oceania. (B) Unrooted neighbor-joining tree based on
nucleotide sequences of all blaOXA-51-like identified in A. baumannii from Asia and Oceania, except blaOXA-138, blaOXA-194
to blaOXA-197 that were found in Acinetobacter nosocomialis. Horizontal bar; 0.3% sequence divergence. ICs associated
with each cluster of blaOXA-51 variants were indicated.
105 Both trees were generated by using Geneious version 7.1 created
by Biomatters (www.geneious.com).
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A rarely reported MBL, the GIM-1 enzyme, has been
recently reported in A. pittii isolates in Germany, but has not
yet been recovered in Asia and Oceania.44
Distribution of OXAs and MBLs in Asia and Oceania
The distribution of acquired type OXA and MBL genes is
very diverse (Table 1). The acquisition of the blaOXA-23-like has
become the most common cause of carbapenem resistance in
A. baumannii in Asia and Oceania.50 OXA-23 was initially
described in 1985 as ARI-175 and is the most widely spread
acquired OXA carbapenemase in this region and worldwide.
Other variants of OXA-23, such as OXA-27 (Singapore),
OXA-49, OXA-146, OXA-422, and OXA-423 (China), were
identified in carbapenem-resistant A. baumannii isolates
(Table 1).2,103 OXA-165 to OXA-171 were reported from
Thailand (accession no. HM488986 to HM488992). OXA-23-
like enzymes have also been found inA. pittii,A. nosocomialis,
and A. calcoaceticus.51,52 Several variants of OXA-23 like
(OXA-23, OXA-102, OXA-103, OXA-105, OXA-133, and
OXA-134) were found on the chromosome of Acinetobacter
radioresistens suggesting that A. radioresistens is the pro-
genitor of the blaOXA-23-like genes.
66,80
The prevalence of the OXA-40-like cluster causing carba-
penem resistance inAcinetobacter spp. fromAsia and Oceania
is low. OXA-72 was first identified in A. baumannii from
Thailand in 2004 (GenBank accession no. AY739646). This
enzyme was recovered from A. baumannii isolates from India
and southern Taiwan, where OXA-72-producingA. baumannii
has been reported to cause hospital outbreaks.54,63,65 OXA-40-
like carbapenemases have been found in non-baumannii spe-
cies such as A. pittii and A. nosocomialis.15,103
OXA-58-like enzymes comprise OXA-58, OXA-96,
OXA-97, OXA-164, and OXA-420. OXA-58 in A. bau-
mannii was detected across Asia and Oceania, including
Australia, China, India, Singapore, South Korea, and Tai-
wan (Table 1). Interestingly, the ratio of OXA-58-like en-
zymes among carbapenem-resistant Acinetobacter was
above 40% from certain hospitals in Taiwan.40,61 OXA-96,
which differs from OXA-58 by one amino acid substitution,
was only described in an A. baumannii isolate from Singa-
pore in 2006.51 OXA-420 has been recently detected in A.
baumannii from Nepal (GenBank accession no. AB983359).
Of note, OXA-58-like enzymes were frequently identified in
A. pittii isolates from Singapore and Taiwan.40,51,52
OXA-182, a member of OXA-143-like enzymes, has
emerged in South Korea.49 This enzyme shares 93% identity
with OXA-143, which is reported to be highly prevalent in
Brazil.35,67 The study from South Korea showed that OXA-
182 was identified in imipenem-nonsusceptible A. baumannii
isolates recovered as early as 2002 and in A. nosocomialis
from year 2004 to 2007.49
OXA-51-like enzymes are intrinsic for A. baumannii and
have also been recovered in Taiwan from A. nosocomia-
lis.9,62 OXA-51 like is the most diverse group of ox-
acillinase with more than 100 variants identified.24,78
Furthermore, the sequences of OXA-51-like genes showed a
correlation with their epidemiologic grouping, that is, OXA-
69, OXA-66, OXA-71, OXA-51, OXA-65, OXA-64, and
OXA-68 correspond to IC 1, 2, 3, 4, 5, 7, and 8, respec-
tively.25,112 OXA-51-like enzymes that were identified in
Asia and Oceania are shown in Fig. 3B. OXA-66 was found
in Australia, China, Hong Kong, India, Japan, Singapore,
South Korea, and Taiwan.23,25,51,64,72,103 OXA-138 and
OXA-194 to OXA-197 recovered from A. nosocomialis in
Taiwan were also clustered with OXA-66. OXA-69 identi-
fied in Australia, India, and Pakistan was grouped with
OXA-371 from Nepal.25 OXA-51 was detected in Japan and
India.23 OXA-68 (Hong Kong and Singapore)8 was clus-
tered with OXA-144 (Pakistan) and OXA-426 (China).
OXA-64 was only reported from Singapore.29 There was no
report of OXA-65 and OXA-71 in Asia and Oceania.
Even though MBLs are less frequently identified in
A. baumannii in Asia and Oceania, a relatively high prevalence
of MBL-producing Acinetobacter spp. isolates was observed
in some countries, such as India and South Korea.58,73,86
Several variants of IMP-type enzymes were identified in
Japan, including IMP-1, IMP-11, and IMP-19 (Table 1). IMP-2
was identified in A. baumannii isolates from a hospital in
India.73 This enzyme shares 84.9% amino acid identity with
IMP-1. IMP-4, which had 95.6% amino acid identity with
IMP-1, was first described in Acinetobacter spp. isolates from
Hong Kong14 and was subsequently reported from Australia
and Singapore as well.51,76 IMP-8 and IMP-14 were only
identified in Taiwan and Thailand, respectively.46,59
VIM-like enzymes were sporadically reported from India,
South Korea, and Taiwan.49,59,73 SIM-1 was identified in
China and South Korea.58,115 NDM-1 was recently recov-
ered from Acinetobacter spp. isolates from India, Bangla-
desh, Pakistan, Japan, and China.101 These isolates from
China included nonclinical samples recovered from hospital
sewage and meat-producing animals.105,117
MBLs were identified in several Acinetobacter species,
including A. baumannii, A. baylyi, A. bereziniae, A. cal-
coaceticus, A. haemolyticus, A. johnsonii, and A. junii, A.
lwoffii, A. nosocomialis, and A. pittii.53,59,76,88,101,107,108,115
MBLs identified in Acinetobacter spp. are listed in Table 1.
Conclusion
Carbapenem resistance in A. baumannii has had a drastic
increase in Asia and Oceania within the last decade. The
increase of carbapenem resistance in non-baumannii Aci-
netobacter spp. has also been observed. Production of OXA
carbapenemases and MBLs is the main mechanism of car-
bapenem resistance in A. baumannii. OXA-23-like enzymes
are the most commonly identified carbapenemases in A.
baumannii from Asia and Oceania. Other groups of OXA
carbapenemases and MBLs are sporadically reported from
different countries. It is worth noting that NDM can also be
isolated from meat-producing animals in China. Thus, the
spread of NDM-producing Acinetobacter may be hastened
by its appearance in the food chain and subsequently be-
come a real threat in Asia and Oceania.
CC92, which corresponds to IC 2, is the most successful
and widely disseminated clone of A. baumannii in Asia and
Oceania. Carbapenem resistance may be one of the adaptive
mechanisms responsible for a decrease in heterogeneity
among the A. baumannii population. To address this in-
crease of carbapenem resistance Acinetobacter spp., proper
species identification and typing methods are essential for
early detection and monitoring in epidemiology investiga-
tions. Factors that have contributed to the ability of Acine-
tobacter spp. to spread and persist in the hospital
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Table 1. Acquired-Type OXAs and MBLs in Acinetobacter Identified in Asia and Oceania
Enzymes Species Country Reference/accession no.
OXA-type
carbapenemases
OXA-23 like
OXA-23 Acinetobacter baumannii AU, CH, JP, HK, IN,
SP, KO, TW, TH, VT
13,36,37,48,52,53,60,83,90,91
Acinetobacter nosocomialis CH, KO, SP 50,52,103
Acinetobacter pittii CH, KO, SP 51,60,103
OXA-27 A. baumannii SP 2
OXA-49 A. baumannii CH AY288523
OXA-146 A. baumannii CH ACI28281
Acinetobacter calcoaceticus CH FJ194460
OXA-165
to OXA-171
A. baumannii TH HM488986
to HM488992
OXA-422, OXA-423 A. baumannii CH KM433671, KM433672
OXA-40 like
OXA-40 A. baumannii IN, TW 15,48
A. nosocomialis TW 15
OXA-72 A. baumannii TH, TW AY739646,65
A. pittii CH 103
OXA-58 like
OXA-58 A. baumannii AU, CH, IN, JP,
KO, SP, TW
28,48,52,53,61,88,114
A. nosocomialis SP, TW, 52,61
A. pittii JP, SP, TW 40,52,107
OXA-96 A. baumannii SP 51
OXA-420 A. baumannii NP AB983359
OXA-143 like
OXA-182 A. baumannii KO 49
MBLs IMP like
IMP-1 A. baumannii IN, JP, KO, TW 43,57,73,74
A. nosocomialis JP, KO 49,53
A. pittii JP, KO, TW 40,49,53
A. calcoaceticus JP 53
Acinetobacter lwoffii JP 53
IMP-2 A. baumannii IN 73
IMP-4 A. baumannii HK 14
A. nosocomialis HK, SP 14,51
A. pittii HK, SP 14,51
Acinetobacter junii AU 76
IMP-8 A. baumannii TW 59
A. pittii TW 40
IMP-11 A. pittii JP 107
IMP-14 A. baumannii TH 46
IMP-19 A. baumannii JP 108
Acinetobacter bereziniae JP 107
Acinetobacter johnsonii JP 108
A. junii JP 108
A. nosocomialis JP 107
A. pittii JP 107
VIM like
VIM-1 A. baumannii IN 73
A. lwoffii IN 3
VIM-2 A. baumannii IN, KO, TW 49,59,73
A. nosocomialis KO 88
A. pittii KO 49
VIM-3 A. baumannii TW 59
VIM-11 A. baumannii TW 59
A. haemolyticus TW 59
SIM-1 A. baumannii KO 58
A. bereziniae KO 49
Acinetobacter baylyi CH 115
NDM-1 A. baumannii BA, CH, IN, JP, PK 12,31,41,47,70
A. johnsonii CH 117
A. junii CH 116
A. lwoffii CH 38
A. pittii CH 109
AU, Australia; BA, Bangladesh; CH, China; JP, Japan; HK, Hong Kong; IN, India; KO, South Korea; NP, Nepal; PK, Pakistan; SP,
Singapore; TH, Thailand; TW, Taiwan; VT, Vietnam.
MBL, metallo-b-lactamases.
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environment have yet to be determined. The genome-wide
approach may provide such insight for prevention and
control of further Acinetobacter spp. transmission.
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1.3 Genome and resistance island of A. baumannii 
The sizes of Acinetobacter spp. genomes varied from 4.9 Mb observed in A. bereziniae (GenBank 
accession no. APQG00000000) to 2.7 Mb in Acinetobacter nectaris (GenBank accession no. 
AYER00000000). The highest GC content at 41.5% was identified in the genome of Acinetobacter 
brisouii while the lowest GC content was 36.6% in A. nectaris [12]. 
Amongst A. baumannii genomes, the range of estimated size is 3.7 – 4.2 Mb with GC content 
approximately at 39% [13]. Multiple genomic studies demonstrated the great diversity amongst 
Acinetobacter genus and with A. baumannii [7, 12, 14]. The comparative genomic approach of 
multidrug-resistant A. baumannii strains and fully susceptible strains identified a genomic island 
containing a large cluster of antimicrobial and heavy metal resistance genes and was designated as 
“AbaR” [15]. AbaR usually located in a specific chromosomal ATPase gene, comM. [16]. 
The first and the largest cluster, AbaR1, was recovered from French strain AYE, which belongs to 
IC1 [15]. This 86.2-kb resistance island is a large composite transposon that carries horizontally 
transferred genes conferring resistance to a broad range of antimicrobial families. Later on, AbaR3 
and AbaR5 which are related to AbaR1 were discovered in A. baumannii of IC1 [7, 17]. AbaR3 is 
largely a subset of AbaR1 at 49 kb; on the other hand, AbaR5 is most similar to AbaR3 and shares 
the same general structure. The catA1 and blaTEM genes found in AbaR3 are not present in AbaR5, 
due to an IS26-induced deletion of 6.7-kb region in AbaR5. AbaR1 also lacks the blaTEM genes found 
in AbaR3 due to a deletion caused by the same IS26 [16, 18]. Studies on various isolates belonged to 
IC1 identified several new variant of AbaR3 and showed that AbaR3 was the original form of 
resistance island of IC1horbouring Tn6019 and Tn6018 as a backbone [16, 18-21]. 
AbaR2 identified in an IC2 strain ACICU is approximately 19.5 kb and lacks arsenic, mercury and 
tetracycline resistance operons on the 5’ end compared to which is found in standard AbaR [22]. 
Therefore, this island plays a significant but less dominant role in resistance to the clinically important 
classes of antimicrobials including carbapenems. AbaR4 was firstly discovered in susceptible strain 
ATCC 17978 and related to resistance islands found in IC2 strains [7, 16]. The backbone of AbaR4-
type of IC2 strain, Tn6022, composed of transposition module (tni), uspA (universal stress protein 
encoding gene) and sup (sulphate permease) [23]. AbaR4-type was also identified as a common 
location for Tn2006 containing blaOXA-23, which conferred carbapenem resistance phenotype [7, 24, 
25]. 
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1.4 Hospital adaptiveness of A. baumannii 
The rapid emergence and global dissemination of distinct A. baumannii clonal lineages as a major 
nosocomial pathogen is remarkable and emphasizes its successful adaption to the present day hospital 
environment. Little is known concerning the origin of these clonal lineages. It is possible that each 
distinct cluster has originated from a different location and then spread into a new niche. The spread 
may be due to occupational transmission, such as cross-transmission from colonised or infected 
patients via the hands of health-care workers [26, 27]. 
The role of the hospital environment as a reservoir for A. baumannii is supported by the fact that this 
organism can be recovered from patients and various hospital environmental sources during outbreaks 
[28]. A number of studies show that particular strains can be isolated from the same hospital during 
a long period of time [28-30]. The ability to survive under desiccative conditions as well as resistance 
to disinfectants and antimicrobials demonstrate how well A. baumannii can adapt and lead to long-
term persistence in the hospital environment. The following aspects that may contribute to its 
persistence will be discussed and putative genes for hospital adaptiveness are proposed in Table 1. 
 
Table 1. Putative genes for hospital adaptiveness. 
Name of gene or 
protein 
Function Reference 
csuC and csuE 
 Secretion and pili assembly 
 Biofilm formation 
[31] 
blaPER-1 
 β-lactamase production 
 Associated with cell adhesiveness 
[32, 33] 
Bap 
 Intercellular adhesion 
 Biofilm maturation 
[34] 
pga  PNAG synthesis [35] 
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1.4.1 Biofilm formation 
Biofilm formation is hypothesized to mediate the prolonged survival of Acinetobacter in healthcare 
settings [36, 37]. A. baumannii clinical isolates can survive following long periods of desiccation and 
can form biofilm on biotic and abiotic – nonliving surfaces. However, no statistically significant 
difference between the response to drying, measured by the survival time on glass coverslips, of 
outbreak strains versus those of sporadic strains was found by Jawad et al. [36]. A number of studies 
showed that the ability to form biofilm is common among unrelated clinical isolates of A. baumannii 
[33, 38], particularly related to device-associated infections [38]. Additionally, correlations between 
the biofilm-forming property and broad-spectrum antimicrobial resistance phenotypes in some 
clinical isolates was reported [33]. 
The high capacity for biofilm production amongst extended-spectrum β-lactamase (ESBL) producing 
A. baumannii isolates, blaPER-1, was observed [33]. Lee et al. confirmed this by elucidating that cell 
adhesiveness and biofilm formation on the surface of polystyrene, a polymer that is widely used in 
many kinds of medical devices, were significantly higher in isolates harbouring the blaPER-1 gene as 
compared with isolates without this gene [32]. Nevertheless, some studies showed that there was no 
correlation between blaPER-1 positive isolates and biofilm producers [33, 39]. Therefore, it is 
considered that the presence of blaPER-1 is more crucial for cell adhesion than biofilm formation. The 
reasons for this have not yet been fully explored since there is no data available on the knockout of 
blaPER-1 in A. baumannii. 
Many regulatory networks are believed to be associated with the expression of the biofilm phenotype, 
such as cellular appendages, adhesions and cell density-sensing molecules. The somatic pili that 
mediate the initial steps of biofilm formation on polystyrene found in the A. baumannii 19606 strain 
are the product of chaperon-usher secretion system called CsuA/BABCDE [31]. Similar operons were 
also discovered in the genome of strains AYE [40] , ACICU [22], AB0057 and 17978 [41]. On the 
contrary, no similar loci coding for this secretion system were located in the genome of A. baumannii 
SDF, isolated from body lice collected from homeless people and Acinetobacter sp. ADP1. 
Additionally, the inactivation of the chaperone-encoding genes, csuC and csuE led to an obliteration 
of pili production and biofilm formation [31]. The expression of this operon is regulated by a two-
component system BfmRS containing a sensor kinase encoded by bfmS and a response regulator 
encoded by bfmR [42]. 
In the A. baumannii clinical strain 307-0294, biofilm-associated protein (Bap) which was first 
characterized in S. aureus, was found to act in intercellular adhesion which then supported biofilm 
maturation [34]. Another study from Choi et al. showed that A. baumannii clinical isolates contained 
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pga locus encoding protein which synthesizes surface polysaccharide poly-β-(1-6)-N-acetyl 
glucosamine (PNAG). Deletion of this locus resulted in loss of the strong biofilm phenotype, which 
was restored by complementation [35]. 
1.4.2 Desiccation tolerance 
Acinetobacter spp. is found to survive far better on fingertips or on dry surfaces when tested under 
simulated hospital environmental conditions than other genera of Gram negative bacilli [43, 44]. It 
has been shown that A. baumannii survives desiccation beyond 30 days and much better than other 
Acinetobacter spp. such as A. johnsonii, A. junii and A. lwoffii [43, 44]. However, skin carriage of A. 
baumannii is very rare, whilst A. johnsonii, A. lwoffii and A. radioresistens predominate on both 
patient and healthy human skin [45, 46]. Although there was no statistically significant difference 
between the survival times of sporadic strains and outbreak strains of A. baumannii [36], desiccation 
tolerance may contribute to the propensity to cause prolonged nosocomial infection outbreaks and 
may explain why certain strains are able to establish themselves in hospital environment while others 
are only sporadically isolated. 
1.4.3 Biocide resistance 
The co-resistance to antimicrobials and biocides, including disinfectants and antiseptics, may 
contribute to the selection of drug-resistant strains and to epidemic spread within the hospital [47]. 
Correlation between decreased susceptibility to disinfectants and antimicrobial resistance have been 
found in various organisms such as Pseudomonas aeruginosa, Proteus spp., Providencia spp., 
Serratia marcescens, MRSA and vancomycin-resistant enterococci [48-51]. A similar hypothesis has 
also been proposed for A. baumannii [52, 53]. An in vitro study using currently used disinfectants 
(propenol, combination of 1-propanol, 2-propanol and mecetronium ethylsulphate, PVP-iodine, 
tricolsan and chlorohexidine) showed no significant differences in susceptibility between ten 
outbreak-related and ten sporadic strains. However, a relevant number of viable bacteria remained if 
contact times were less than 30 seconds or diluted agents were used [53]. Although resistance to 
disinfectants is probably not a major factor involved in the epidemic spread of A. baumannii, slightly 
deviated conditions from recommended procedures leading to decreased concentrations or exposure 
times may be important for nosocomial cross-contamination and help promote viability of A. 
baumannii in hospital environments. 
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1.5 Virulence and pathogenicity of A. baumannii 
Despite convincing evidence supporting A. baumannii as a successful nosocomial pathogen, the 
knowledge of the factors determining epidemicity, virulence factors and pathogenicity is still not well 
defined. However, the ability of Acinetobacter spp. to adhere to epithelial cells, produce enzymes and 
toxins and possess anti-phagocytic surface components are considered to be significant virulence 
mechanisms of this genus [54]. Moreover, comparative genomic studies between A. baumannii and 
the environmental A. baylyi (non-pathogenic) revealed potential virulence genes in A. baumannii 
involved in pili biogenesis, iron regulation and quorum sensing [55]. More recent studies suggested 
that type VI secretion systems (T6SS) responsible for eliciting immune response in eukaryotic cell 
may play a role in inter-bacterial and host-bacterial interactions in A. baumannii [56, 57]. 
1.5.1 Colonization and adherence 
Its ability to cause colonization on human skin and inanimate surfaces also has an important role in 
infection, epidemic spread and environmental persistence [2]. As adherence of microorganisms to 
host cells is the initial step of the colonization process, an in vitro study of A. baumannii adherence 
was performed by Lee et al [58]. Their study showed that A. baumannii could adhere to human 
bronchial epithelial cells. Although strains of IC2 had a relatively high capacity for adhering to these 
cells compared to IC1 strains, there was no significant correlation of the outbreak-associated strains 
with the ratio of infected cells. 
Following adhesion, A. baumannii is able to invade and promote the apoptosis of eukaryotic cells 
[59]. A major surface protein, outer membrane A of A. baumannii has been demonstrated as a 
potential virulence factor in inducing cell death through mitochondrial and nuclear targeting [59, 60]. 
Purified Omp38 also induced apoptosis of human bronchial epithelial cells and human monocytes. 
Apoptosis of epithelial cells may disrupt the mucosal lining and allow the bacterial access or their 
products into the deep tissues [61]. 
1.5.2 Surface polysaccharide 
Surface polysaccharide, capsular (K antigen) and lipopolysaccharide (LPS) carrying O-antigen, are 
known as core virulence factors in many Gram-negative bacteria. It has been demonstrated that 
surface polysaccharide promoted motility and acts as a barrier for bactericidal activity [62]. K1 
antigen in A. baumannii showed an ability to improve growth significantly in human ascites fluid, 
human serum resistance and survival in a rat soft-tissue infection mode [63]. A recent study in A. 
baumannii genomes revealed that A. baumannii lacked a ligase encoding gene waaL required for 
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addition of O-antigen to lipooligosaccharide (LOS) resulting in failure to form LPS [64]. In Gram-
negative bacteria, these regions responsible for capsule and the outer core (OC) of LOS are variable 
and cause antigen heterogeneity [65, 66]. 
1.5.3 Iron regulation 
The ability of A. baumannii to grow under iron-deficient conditions is known to be associated with 
invasiveness. A. baumannii can express a variety of molecules regarding iron acquisition, including 
the iron-regulated catechol siderophore compounds, catechol-hydroxamate siderophore - 
acinitobactin and also a hemin utilisation system [67]. Furthermore, there is a wide variability within 
members of the same set of isolates or their nosocomial origin in the expression of molecules involved 
in iron regulation [68]. 
1.5.4 Quorum sensing 
Quorum sensing (QS), a known autoinducer-receptor mechanism, is one type of bacteria cell-cell 
communication. This mechanism plays a role in the production of virulence factors, motility, 
nodulation, sporulation, plasmid transfer, antimicrobial production, as well as biofilm formation [69, 
70]. There was an association between Acyl Homoserine Lactones (AHL) mediated QS and 
phenotypes that benefit the AHL-producing community, including biofilm formation [71]. Most 
Acinetobacter spp. strains produce more than one AHL. However, none of the AHL signals could be 
specifically assigned to a particular species of the Acinetobacter spp. [72]. Acinetobacter spp. quorum 
signals are not homogenously distributed, thus it is difficult to distinguish between virulent and non-
virulent strains in terms of quorum sensing signals. Quorum sensing genes, abaI and abaR of 
Acinetobacter spp., were acquired horizontally from Halothiobacillus neapolitanus [73]. 
Communication among bacteria pertaining to cell density is integral to maturation of A. baumannii 
biofilm [74]. Mutation in abaI which produces the AHL molecule resulted in reduction in biofilm 
when compared with its isogenic parental strain [75]. Exogenous addition of purified Acinetobacter 
acyl homoserine lactone restored biofilm maturation in an abaI mutant [76]. 
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1.6 Aims 
ACB complex has its own challenge for the species identification with A. baumannii recognised as 
the most important nosocomial pathogen [77]. In early 1990s, carbapenem resistance was first 
recognised in A. baumannii (CRAB) and the prevalence of CRAB has drastically increased 
worldwide [78]. Apart from carbapenem resistance in A. baumannii, the co-resistance to broad-
spectrum aminoglycosides and other non-β-lactams restricts the treatment of this organism to very 
few antimicrobial options [79, 80]. 
Carbapenem resistance imparted by oxacillinases in Acinetobacter spp. is a growing problem in many 
regions of the world [24]. However, there are many gaps in the current literature regarding specific 
resistance to carbapenems and the genomes of ACB complex in Asia and Oceania. A comprehensive 
review of the epidemiology and mechanisms of carbapenem resistance within Acinetobacter spp. in 
this thesis was used to provide the basic understanding of the most recent studies in A. baumannii in 
Asia and Oceania [81]. Prior to studies in this thesis, there was limited description of the genomes of 
Acinetobacter spp. not only from South East Asia, but also from Asia and Oceania in general. 
Over the past two decades, characterisation by molecular epidemiology has been used to understand 
the types of dominant clones and worldwide distribution of A. baumannii clones [11, 82]. A 
successful clone of carbapenem-resistant A. baumannii IC2 has been the major driving force for the 
spread of carbapenemase among A. baumannii [11]. Little attention has been given to non-baumannii 
Acinetobacter. In particular to Thailand, the molecular and genome description of Acinetobacter spp. 
was limited [83-86]. 
The specific aims of the serial experiments described in this thesis are as follows: 
1. To determine the molecular epidemiology of A. baumannii, primarily from Thailand. 
2. To detect species specific intrinsic oxacillinases and description of non-baumannii Acinetobacter, 
in particular, A. pittii. 
3. To describe the genome of A. baumannii IC2 isolates from Thailand and compare these genome 
data with A. baumannii IC2 isolates from Japan, Malaysia and Singapore. 
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Chapter 2. Detection of species specific intrinsic oxacillinases and 
characterisation of pathogenic non-baumannii Acinetobacter spp.
2.1 Synopsis 
Acinetobacter is a complex non-fermentative gram-negative bacteria genus comprising of more than 
40 species [77]. Although the most common Acinetobacter species involved in hospital infections is 
A. baumannii, other species, such as A. pittii, A. nosocomialis, A. haemolyticus, A. johnsonii, A. lwoffii 
and A. ursingii, are sporadically recovered from clinical specimens and involved in nosocomial 
infections [87].  
Due to high similarities of phenotypic and genotypic characteristics, it is difficult to differentiate 
Acinetobacter spp. into species level [88]. Available semi-automated systems used in routine 
diagnostic laboratories, such as API-20NE and Vitek 2 system are not be able to distinguish amongst 
Acb complex  while phenotypic and genotypic methods, such as DNA – DNA hybridization and 
amplified rRNA gene restriction analysis (ARDRA) are laborious [89, 90].
In this Chapter, two main research studies performed on non- baumannii Acinetobacter spp. were 
included. The first paper, we detected naturally occurring oxacillinases that are species specific using 
a multiplex PCR and sought a use of this method to aid in species identification. In addition, thirty 
novel OXA variants were discovered amongst Acinetobacter isolates used in this study. The second 
paper provides the first whole genome sequence of IMP and OXA-58-like-carrying A. pittii ST119 
in Australia. This strain harboured several classes of antimicrobial resistance genes as well as a 
novel blaOXA variant, blaOXA-421. Further, the investigation of acquired OXA-type carbapenemases 
in Acinetobacter non-baumannii isolates collected worldwide was demonstrated in the Appendix 
A2.4. 
Multiplex PCR to detect the genes encoding naturally occurring
oxacillinases in Acinetobacter spp.
Witchuda Kamolvit1,2, Paul G. Higgins3*, David L. Paterson1 and Harald Seifert3
1UniversityofQueenslandCentre forClinical Research, TheUniversityofQueensland,Brisbane,Australia; 2FacultyofMedicine, SirirajHospital,
Mahidol University, Bangkok, Thailand; 3Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne,
Goldenfelsstrasse 19-21, 50935 Cologne, Germany
*Corresponding author. Tel:+49-221-47832011; Fax:+49-221-47832002; E-mail: paul.higgins@uni-koeln.de
Received 27 August 2013; returned 26 September 2013; revised 5 November 2013; accepted 11 November 2013
Objectives: Bacteria of the genus Acinetobacter are increasingly being isolated in hospitals and are recognized as
emerging nosocomial pathogens. Species identification is difficult and there is a need for simple molecular
methods to differentiate between the species. Naturally occurring oxacillinase genes (blaOXA) have been identified
in several Acinetobacter species and their detection by PCR can aid in species identification. The aim of this study
was to develop a multiplex PCR to identify intrinsic blaOXA genes (i.e. blaOXA-134-like, blaOXA-211-like, blaOXA-213-like,
blaOXA-214-like and blaOXA-228-like) from Acinetobacter spp. for use as a tool for rapid species identification.
Methods: Primers were designed to selectively amplify internal fragments of intrinsic blaOXA from Acinetobacter
lwoffii/Acinetobacter schindleri (blaOXA-134-like),Acinetobacter johnsonii (blaOXA-211-like),Acinetobactercalcoaceticus
(blaOXA-213-like), Acinetobacter haemolyticus (blaOXA-214-like) and Acinetobacter bereziniae (blaOXA-228-like). Multiplex
PCR was performed in a total of 100 Acinetobacter isolates. Flanking primers were designed for each blaOXA
subgroup and products were sequenced.
Results: All A. lwoffii, A. schindleri, A. johnsonii, A. calcoaceticus, A. haemolyticus and A. bereziniae isolates were
positive for their species-specific amplicons while other Acinetobacter species were negative. Thirty blaOXA novel
variants were identified; the majority of these (21/30) were from A. calcoaceticus. ISAba11 was found upstream
of blaOXA-214 in four A. haemolyticus isolates, but was not associated with carbapenem resistance.
Conclusions: This multiplex PCR specifically detected each of the five different blaOXA subgroups. Therefore, this
method has the potential to aid in the identification of these species and monitor the spread of these genes
into other Acinetobacter species.
Keywords: species identification, carbapenemases, intrinsic OXA
Introduction
Bacteria of the genus Acinetobacter are recognized as pathogens
that frequently cause nosocomial infections.1 Although the
most common Acinetobacter species involved in hospital infec-
tions are those belonging to the Acinetobacter baumannii group
(A. baumannii, Acinetobacter nosocomialis and Acinetobacter
pittii), other species, such as Acinetobacter haemolyticus, Acineto-
bacter johnsonii, Acinetobacter lwoffii and Acinetobacter ursingii,
are sporadically recovered from clinical specimens and involved
in nosocomial infections.2 Acinetobacter calcoaceticus, although
an environmental organism, is often found as a colonizer and is
frequently misidentified as A. baumannii.3
Species identification of Acinetobacter in routine diagnostic lab-
oratories isdifficultandtheseorganismsare frequentlymisidentified.4
Phenotypic and molecular techniques for species identification, such
asDNA–DNAhybridizationandamplified rRNAgene restrictionana-
lysis (‘ARDRA’), are laborious and difficult to interpret, while semi-
automated systems, such as API-20NE and Vitek 2, identify many
Acinetobacter as A. calcoaceticus–A. baumannii (Acb) complex.5,6
Sequencing methods based on the rpoB gene, its flanking spacer
regions and the 16S–23S rRNA gene spacer region are reliable
for species identification, but it is unlikely that these sequencing
techniqueswill beusedroutinely.7,8Morerecently,a rapidPCR-based
method for detecting gyrB genes was described by Higgins et al.9,10
This tool can also be utilized for species identification amongst bac-
teria of the Acb complex.
Genes encoding naturally occurring oxacillinases (OXAs)
have been identified in several Acinetobacter species, such as
blaOXA-23-like (Acinetobacter radioresistens), blaOXA-51-like
(A. baumannii), blaOXA-134-like (A. lwoffii/Acinetobacter schindleri),
blaOXA-211-like (A. johnsonii), blaOXA-213-like (A. calcoaceticus),
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blaOXA-214-like (A. haemolyticus) and blaOXA-228-like (Acinetobacter
bereziniae).11–15 The PCR detection of blaOXA-51-like has been pro-
posed as a method to identify A. baumannii.16 Amongst other
species, the detection of blaOXA-134-like has been shown to be an al-
ternative for rapid identification ofA. lwoffiiandA. schindleri.17 This
suggests that the detection of the genes harbouring intrinsic OXAs
may be applied as a tool to identify these Acinetobacter species.
The aim of this study was to develop and evaluate a multiplex
PCR assay to detect five species-specific gene subgroups encoding
the intrinsic OXA-134-like, OXA-211-like, OXA-213-like, OXA-214-
like and OXA-228-like as a potential method to rapidly identify
A. lwoffii/A. schindleri,A. johnsonii,A. calcoaceticus,A.haemolyticus
and A. bereziniae, respectively.
Materials and methods
Bacterial isolates
A total of 100 clinical isolates and type and reference strainswere included.
A. calcoaceticus (25),A. bereziniae (9), A. haemolyticus (5), A. johnsonii (11),
A. lwoffii (10) and A. schindleri (2) were selected from our own clinical
culture collection.9,18 Clinical isolates of the species Acinetobacter junii
(2), A. pittii (2), A. baumannii (8), A. nosocomialis (4), Acinetobacter
beijerinckii (5), Acinetobacter guillouiae (2), A. radioresistens (2), A. ursingii
(2) and the unnamed Acinetobacter genomic species 14 (2) were also
included as controls. Species identification had been performed previously
and was confirmed for all isolates by partial rpoB sequencing.8
The A. baumannii isolates were chosen to represent a broad range of
blaOXA-51-like variants (OXA-65, -66, -95, -223 and -241) and acquired
blaOXA (OXA-23, -40, -58, -72, -143, -235 and -236). In addition, the follow-
ing type or reference strains were used: A. baumannii ATCC 19606T, A. bere-
ziniaeATCC17924T,A. calcoaceticusATCC23055T,A. johnsoniiATCC17909T,
A. junii ATCC 17908T, A. lwoffii NCTC 5866, A. radioresistens SEIP 12.81,
A. pittii ATCC 19004Tand Acinetobacter genomic species 6 ATCC 17979T.
Primer design
All primers used in this studywere designed using Primer3 software (http://
bioinfo.ut.ee/primer3/). The DNA sequences of each blaOXA subgroup avail-
able in GenBank and those fromwhole genome sequences (Table S1, avail-
ableasSupplementarydataat JACOnline)werealigned. Consensus regions
of each subgroupwere used todesignfivepairs of primers corresponding to
their subgroups (Table 1). To aid identification in a multiplex format, the
sizes of PCR products were designed so that there was100 bp difference
between each subgroup.
Multiplex PCR
Multiplex PCR was undertaken in a final volume of 25 mL using Taq PCR
Master Mix (Qiagen, Hilden, Germany) with a final concentration of
0.2 mM for each primer. Template DNA for PCR was isolated from an agar
plate; a 1 mL loopful of a colony was suspended in 100 mL of PCR-grade
water, boiled for 10 min, snap-cooled and briefly centrifuged. The amplifi-
cation conditions were 948C for 3 min, followed by 30 cycles of 948C for
20 s, 558C for 20 s and 728C for 1 min, and final extension for 10 min. PCR
products were analysed on agarose 1.2% (w/v) gels, stained with ethidium
bromide and visualized on a UV transilluminator.
DNA sequencing and accession numbers
Flanking primers of each blaOXA subgroup were designed (Table 1) based
on available genome sequences in the NCBI database. PCR amplification
was performed following the same conditions as the multiplex PCR
using Phusion hot-start high-fidelity DNA polymerase (Thermo Fisher
Scientific, Schwerte, Germany) and products were sequenced in both
directions. Novel sequences were assigned numbers by the Lahey
b-lactamase database (http://www.lahey.org/studies/) and submitted
to EMBL/GenBank under accession numbers KF203096–KF203109
(blaOXA322-335), KF297577–KF297585 (blaOXA348-356), KF421160–KF421163
(blaOXA357-360) and KF460531–KF460533 (blaOXA361-363).
Results
All primers used in this study are listed in Table 1. Sequencing rpoB
variable regions 1 and 2 confirmed the species identity of the
isolates. The blaOXA primers were initially tested as a multiplex
againstall isolates inorder toevaluate their specificityandsensitiv-
ity. When an isolate gave a positive PCR product, the blaOXA gene
was re-amplified using the flanking primers and sequenced. This
strategy allowed us to design new primers where appropriate. For
example, the original primers designed to amplify blaOXA-134-like
(A. lwoffii/A. schindleri) also amplified blaOXA-228-like (A. bereziniae).
In this case, newprimers were designed and tested as a singleplex
to determine the optimum conditions before multiplexing (data
not shown).
Themultiplex PCRassayusing five pairs of primers amplified the
intrinsic blaOXA genes of each subgroup as predicted. The PCR pro-
ducts, ranging from 158 to 693 bp, were easily separated and
visualized on an agarose gel (Figure 1). All A. lwoffii/A. schindleri,
A. johnsonii,A. calcoaceticus,A. haemolyticus andA. bereziniae iso-
lates were positive for their species-specific amplicons whilst all
isolatesof theotherAcinetobacter specieswerenegative (including
A. baumannii isolates harbouring other intrinsic and acquired
blaOXAs). A modification of this multiplex, addition of rpoB prim-
ers 696F and 1598R as internal control as previously described,
was also evaluated.17 The high annealing temperature we used
for themultiplex led toa reduced rpoBamplicon concentration, es-
pecially in isolates that were positive for blaOXA (data not shown).
However, species that are negative for blaOXA could be identified
by sequencing the rpoB PCR product.
Sequencing blaOXA identified 30 new variants (Table S2, avail-
able as Supplementary data at JAC Online). The majority of these
were from A. calcoaceticus, where we found 23/26 isolates with a
novel variant. Twenty-one new variants of blaOXA-213 were identi-
fied. The range of amino acid substitutions encoded by these
geneswhencomparedwithblaOXA-213was from23 (97.2%similar-
ity) to 59 (92.8%similarity). A premature stop codonwas identified
in three isolates: A. calcoaceticus (2) and A. johnsonii (1). Flanking
primers (G56/G57) gave an3 kb product size in four A. haemoly-
ticus isolates.Sequencingof theamplicons identifiedan ISelement
upstream of blaOXA-214 with a BLAST match to ISAba11 (97.8%).
The presence of ISAba11 was not associated with imipenem
or meropenem resistance by Etest using EUCAST guidelines for
interpretation. ISAba11 is an emerging IS family encoding trans-
posases.19 This IS element is not commonly responsible for carba-
penem resistance in Acinetobacter spp. However, ISAba11 was
reported to be related to high-level colistin resistance in A. bau-
mannii.20 Additionally there is a report that the blaNDM-1 region
in a plasmid found in A. pittii isolates was flanked by ISAba11
and ISAba125.21 We were unable to sequence blaOXA from four
isolates—A. lwoffii (2), A. johnsonii (1) and A. schindleri (1)—despite
redesigning primers several times. Sequence analysis based on
published and our own data revealed the DNA flanking these
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blaOXAs to be very variable and a clear consensus was not possible
(data not shown). However, these four isolates had their species
identity confirmed by rpoB sequencing and were positive bymulti-
plex PCR for their intrinsic blaOXA.
A phylogenetic tree of intrinsic blaOXAs both used and identified
in this studywas constructed (Figure2). Eachsubgroupclustered in
one of five distinct branches. The results show that A. lwoffii and
A. schindleri intrinsic blaOXAs were very similar and clustered
together in one main branch. Therefore, it was not possible to dif-
ferentiate between them in the current multiplex PCR format. To
further identify these species, an alternative method, such as
rpoB sequencing, should be applied.8
Discussion
The results of the multiplex PCR assay for genes encoding intrinsic
species-specific blaOXAs showed that the assaywaswell correlated
betweenOXA subgroup and predicted amplicon size. Therewas no
PCR product amongst the other Acinetobacter species tested,
suggesting the assay is specific and sensitive enough for detection
of intrinsic blaOXAs. Therefore, thismethodhas potential to be used
as an alternative, rapid tool to confirm species identification of
A. lwoffii/schindleri, A. johnsonii, A. calcoaceticus, A. haemolyticus
and A. bereziniae.
Intrinsic blaOXAs are capable of conferring carbapenem resist-
ancewhen overexpressed. For example, blaOXA-51-like, blaOXA-228-like
and blaOXA-23-like, when adjacent to insertion elements, cause car-
bapenem resistance.22–24 Some of these intrinsic genes have also
been detected in other species; blaOXA-23-like has become themost
commonly acquired carbapenem resistance determinant in
A. baumannii and is also found in other Acinetobacter species,
and blaOXA-51-like was reported in A. nosocomialis.
25–27 In these
instances mobilization was associated with ISAba1, which
encodes not only a transposase but also a promoter, leading to
overexpression of theOXAand resulting in carbapenem resistance.
1 2
158 bp
244 bp
401 bp
518 bp
693 bp
3 4 5 6 7
Figure 1. Example of an agarose gel showing Acinetobacter isolates for
which the species were determined by multiplex PCR. Lane 1, 100 bp
marker; lane 2, A. lwoffii/A. schindleri; lane 3, A. johnsonii; lane 4,
A. calcoaceticus; lane 5, A. haemolyticus; lane 6, A. bereziniae; lane 7,
negative control.
Table 1. Primers used in this study
Function Target Primer Sequence (5′ –3′) Amplicon (bp) Species
1 blaOXA-134-like G50 CAGGAAGTACAACGCATCCA 158 A. lwoffii, A. schindleri
G51 TGCTGGACTTGAGGATCAAA
blaOXA-211-like G24 CAACCAGCACCGAGGTATTT 244 A. johnsonii
G25 TGAACAGGCGTAATTTGCAG
blaOXA-213-like G26 TTTCCTGATTGGGAAAAGGA 401 A. calcoaceticus
G27 GCGACAATTTCTCCTTGTGG
blaOXA-214-like G48 TCTGAATCGTGCCAAAACTG 518 A. haemolyticus
G49 TTCCGTTCGGATCTTCAATC
blaOXA-228-like G30 GTTTGGCATTTTCAGGTTGTG 693 A. bereziniae
G31 TTAACGCAAATGCAGTCACC
2 flanking blaOXA-134-like V2_F GGCGAAGGTCAATCTCAAAA 1150 A. lwoffii
V2_R CGAGCAGACAGAGCAGAAGA
flanking blaOXA-211-like G34 GATGGCGTTGTAGATGCTGA 1281 A. johnsonii
G35 AAAGCAAACAAGAGACTTTGACG
flanking blaOXA-213-like G36 TTCCTTTGTTTATGCTTTCCTTTT 1103 A. calcoaceticus
G37 AGTGGCTTGATGCTGCTTTT
flanking blaOXA-214-like G56 GTTTTCTAGCTCGGCTTTCC 1132 A. haemolyticus
G57 TCAGCCATCAAGCCACATAC
flanking blaOXA-134-like G60 TCGTATTTTCAGGCAAAGCTG 1090 A. schindleri
G61 AAGCGCGTATCAAAAGGATG
flanking blaOXA-228-like F5 GCTAAAGTTTCTGCTGAGGA 1151 A. bereziniae
F6 CCAGTTACCCCCAATAAACT
Function 1, multiplex PCR primers; Function 2, sequencing primers.
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Therefore, detection of blaOXA should not be the only identification
method because there are no data on the distribution of these
blaOXAs into other species. However, in the present study we have
not detected these blaOXAs in other Acinetobacter species that
are not known to intrinsically harbour these genes.
We identified ISAba11 located upstream of blaOXA-214 in four
A. haemolyticus isolates. Even though our findings showed that
ISAba11wasnotassociatedwith carbapenemresistance inA. hae-
molyticus, this IS element is also found in A. baumannii19,20 and
may potentially help facilitate mobilization of blaOXA-214. Hence
the multiplex PCR we describe can also be used to screen isolates
to determine whether there is dissemination of these blaOXAs into
A. baumannii when there are no other carbapenem resistance
determinants detected.
Large variation in A. calcoaceticus blaOXA is unsurprising given
that this species iswidelydistributed in theenvironment.Converse-
ly, A. lwoffii, A. johnsonii, A. haemolyticus and A. bereziniae, which
are mostly recovered from human clinical specimens, show less
variationof theirblaOXAs. It is alsoworthnoting that theA. baumannii
intrinsic blaOXA-51-like also shows a lot of variation, but phylogen-
etic analysis of this species shows that blaOXA is related to epi-
demiological grouping and carbapenem resistance.28 The variation
in A. calcoaceticus blaOXA thus warrants further study.
In conclusion, thismultiplex PCR specifically detects each of the
five different blaOXA subgroups that are associated with a distinct
Acinetobacter species or, in the case of blaOXA134-like, two species.
Therefore, thismethod has the potential to aid in the identification
of these species andmonitor the spread of these genes into other
Acinetobacter species.
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Figure 2. Dendrogram of intrinsic OXAs identified and used in this study. The tree was constructed using Geneious version 6.1 created by Biomatters,
available from http://www.geneious.com. aNucleotide sequence of blaOXA acquired from the draft whole genome sequence in the NCBI database
where an OXA number has not been assigned. The locus tags for these blaOXA genes are: F955_00114, A. schindleri CIP107287; HMPREF0017_02813,
A. lwoffii SH145; HMP0015_3373, A. haemolyticus ATCC 19194; F926_00636, A. haemolyticus NIPH 261. bUnannotated raw genome data of blaOXA:
A. lwoffii TG19636; A. calcoaceticus TG19585.
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A Case of IMP-4-, OXA-421-, OXA-96-, and CARB-2-Producing
Acinetobacter pittii Sequence Type 119 in Australia
Witchuda Kamolvit,a Petra Derrington,b David L. Paterson,a,b Hanna E. Sidjabata
The University of Queensland, UQ Centre for Clinical Research, Brisbane, Queensland, Australiaa; Pathology Queensland, Herston, Queensland, Australiab
An IMP-4-producing Acinetobacter pittii strain coproducing oxacillinases was isolated from a leg wound of a 67-year-old female
patient. Identification to the species level by rpoB and gyrB sequencing andmultiplex-PCR-based analysis revealed that the iso-
late was A. pittii. Whole-genome sequencing of this A. pittii isolate determined the presence of blaOXA-96, blaCARB-2, and a novel
blaOXA-421 gene. The position of this novel blaOXA-421 gene was similar to that of blaOXA-51 in A. baumannii, downstream of the
phosphinothricinN-acetyltransferase gene and upstream of fxsA in the chromosome. This A. pittii isolate was found to belong
to sequence type 119 (ST119). Here, we report the first isolation of IMP-4-producing A. pittii ST119 with a novel blaOXA-421 gene
from a patient in Australia and characterize its draft genome.
CASE REPORT
A67-year-old diabetic woman suffered a fall leading to a dis-placed distal spiral tibial plateau fracture. In the weeks prior
to the fall, she had receivedmultiple antimicrobials (clindamycin,
lincomycin, cephalexin, ciprofloxacin, and ceftazidime) for an in-
fected hematoma of the breast and a series of lower respiratory
tract infections. The patient underwent definitive repair of the
fracture but postoperatively developed osteomyelitis. Debride-
ment of the leg wound was performed. Acinetobacter species and
vancomycin-resistant Enterococcus strains were isolated from the
tissue removed. ThisAcinetobacter species (CR12-42) was carbap-
enem resistant. Despite ongoing antibiotic treatment, the pa-
tient’s leg required amputation in March 2013, after continuous
inflammation, infections for more than 5months, and an episode
of severeClostridium difficile infection resulting in colectomy. The
leg infection was resolved by the amputation.
The initial identification of this Acinetobacter species was done
by Vitek 2. Antimicrobial susceptibility testing by Vitek 2
(bioMérieux) showed resistance to carbapenems, ceftazidime,
ceftriaxone, cefepime, gentamicin, tobramycin, trimethoprim-
sulfamethoxazole, ticarcillin-clavulanic acid, and ciprofloxacin
according to the EUCAST standard (1). The isolate was referred to
our laboratory at theUniversity of QueenslandCentre for Clinical
Research. The Acinetobacter isolate was identified to the species
level by a gyrB multiplex PCR, which revealed that CR12-42 was
Acinetobacter pittii (2). Partial rpoB sequencing (3) confirmed that
CR12-42 was A. pittii.
Phenotypic characterization to determine the class of carbap-
enemase was performed as previously described (4–6). The A.
pittii isolate showed ametallo--lactamase phenotype by produc-
ing a larger inhibition zone around carbapenem disks with EDTA
than around carbapenem disks alone (5-mm breakpoint in-
crease in the size of the inhibition zone). The isolate also produced
a positive result in the modified Hodge and Carba NP tests for
carbapenemase production. MICs were determined with Etest
(bioMérieux). The isolate was resistant to all of the carbapenems
tested, i.e., ceftazidime, cefotaxime, cefepime, cefoxitin, ticarcil-
lin-clavulanic acid, trimethoprim-sulfamethoxazole, and cipro-
floxacin (Table 1). Interestingly, this A. pittii isolate was suscepti-
ble to tetracycline,minocycline, colistin, and tigecycline (Table 1).
Carbapenem resistance in Acinetobacter species is commonly
associated with the presence of carbapenem-hydrolyzing class D
-lactamase- or oxacillinase-encoding genes such as blaOXA-23 and
blaOXA-51 in Acinetobacter baumannii (7, 8). A PCR assay and se-
quencing for all of the blaOXA genes frequently present in Acineto-
bacter species, i.e., blaOXA-23-like, blaOXA-51-like, blaOXA-40-like, and
blaOXA-58-like, were performed (7–9). The isolate was positive for
the blaOXA-58-like subclass and negative for other subclasses of
blaOXA. A PCR assay for ISAba1, the common insertion element in
A. baumannii, was also negative. A PCR assay and sequencing for
other carbapenemase-encoding genes (10, 11), i.e., blaIMP,
blaNDM, blaKPC, and blaVIM, were positive for blaIMP-4. A prepared
pair-ended library of the whole genomic DNA was sequenced via
IlluminaMiSeq to further characterize the resistancemechanisms
of A. pittii CR12-42 and to analyze its genome.
Whole-genome DNA sequencing produced a total of
138,932,382 paired-end reads with 30 average coverage. We
used the CLC genomic workbench version 7.5 (CLC Bio, Aarhus,
Denmark) for de novo assembly with a 500-bp minimum thresh-
old resulting in 127 contigs. The draft genome consisted of
4,372,178 nucleotides and was annotated by rapid annotations
using subsystems technology (RAST) (12). RAST annotation
showed that Acinetobacter calcoaceticus PHEA-2 (score, 503) and
Acinetobacter sp. strain SH024 (score, 436) are the two closest
neighbors ofA. pittiiCR12-42. Our isolate was related to only one
otherA. pittii strain, TG6411, but with a lower score of 221. A total
of 13A. pittii draft genomes have been described in the BioProject
(http://www.ncbi.nlm.nih.gov/bioproject/); however, draft ge-
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nomes of only three isolates were published, including one draft
genome of an NDM-1-producing A. pittii strain from China (13).
In silico identification of CR12-42 to the species level by using
rpoB and gyrB showed it to be 100% identical to A. pittii. A. pittii
belongs, together with Acinetobacter nosocomialis, within the A.
calcoaceticus-baumannii complex and was formerly named Acin-
etobacter genomic species 3 (14). In silico analysis of A. baumannii
multilocus sequence typing (MLST) by the Pasteur scheme
(http://www.pasteur. fr/recherche/genopole/PF8/mlst
/Abaumannii.html) identified A. pittii CR12-42 as being of se-
quence type 119 (ST119). The alleles found were cpn-60 (n 36),
fusA (n  20), gltA (n  38), pyrG (n  16), recA (n  38), rplB
(n 18), and rpoB (n 20). It has been reported thatMLSTby the
Pasteur scheme is capable of providing the ST ofA. pittii (15). The
clinical significance ofA. pittii ST119 is indicated by the fact that it
has been reported to be the predominant clone among theA. pittii
strains (18 out of 25) isolated in four hospitals in Japan (16).
Interestingly, these Japanese A. pittii isolates possessed a different
blaIMP variant, blaIMP-19 (16). Of note,A. pittii ST119 has not been
reported previously in Australia.
The resistance genes were screened with ResFinder (17). The
-lactamase-encoding genes blaIMP-4, blaOXA-96, and blaCARB-2
were identified. blaOXA-96 has a single nucleotide difference (a gua-
nine-for-adenine substitution at position 483) from blaOXA-58.
blaOXA-96 had been reported within an A. baumannii isolate from
Singapore that also harbored blaOXA-23 and blaOXA-64 (18). In our
isolate, blaOXA-96 had a genetic context similar to that of blaOXA-58,
which was bracketed by ISAba3 (GenBank accession number
JX968506) (Fig. 1).
In addition, a novel blaOXA gene, blaOXA-421, was identified
(Fig. 1). This gene had a genetic environment identical to that of
the chromosomal blaOXA-51 gene in A. baumannii (19), which in-
cludes two genes that are usually present upstream and down-
stream of blaOXA-51 in A. baumannii, the phosphinothricin N-
acetyltransferase-encoding gene and fxsA, respectively. blaOXA-421
has 95% identity with the previously reported blaOXA gene
(GenBank accession numberCP002177, locus tag BDGL_000903)
from the genome of A. calcoaceticus PHEA-2 (20), which is the
closest neighbor of our CR12-42 isolate, as previously mentioned.
The second closest relative of blaOXA-421 was blaOXA ofAcinetobac-
ter oleivorans, with 89% similarity (GenBank accession number
CP002080, locus tag AOLE_1170) (21). The other blaOXA genes
similar to blaOXA-421 were blaOXA-324, blaOXA-325, blaOXA-326,
blaOXA-332, and blaOXA-354 (88 to 89% similarity), which were re-
cently identified in A. calcoaceticus (22). The carbapenemase ac-
tivity of OXA-421 warrants further investigation.
The blaIMP-4 gene inA. pittiiCR12-42 was located inside a class
1 integron. Downstream from blaIMP-4 were qacG2 and the amino-
glycoside and chloramphenicol resistance genes aacA4 and catB2
(Fig. 1). This genetic context of blaIMP-4 in CR12-42 was found to
be identical to that in an IMP-4-producing A. baumannii strain
from Singapore (GenBank accession number DQ532122) (18).
TABLE 1MICs of antimicrobials for A. pittii CR12-42 as determined by
Etest
Antimicrobial(s) MIC (mg/liter) Interpretationa
Ertapenem 32 Resistant
Imipenem 24 Resistant
Meropenem 12 Resistant
Doripenem 32 Resistant
Cefepime 64 Resistant
Ceftazidime 256 Resistant
Cefotaxime 32 Resistant
Ceftriaxone 32 Resistant
Cefuroxime 256 Resistant
Cefoxitin 256 Resistant
Piperacillin-tazobactam 12 Resistant
Ampicillin-sulbactam 2 Susceptibleb
Ticarcillin-clavulanic acid 256 Resistant
Piperacillin 256 Resistant
Amikacin 12 Intermediate
Gentamicin 256 Resistant
Netilmicin 24 Resistant
Ciprofloxacin 3 Resistant
Tetracycline 0.75 Susceptibleb
Minocycline 0.023 Susceptibleb
Trimethoprim-sulfamethoxazole 32 Resistant
Colistin 0.094 Susceptible
Tigecycline 0.094 Susceptible
a Unless noted otherwise, MIC interpretations are based on EUCAST criteria (1).
b Ampicillin-sulbactam, tetracycline, and minocycline MIC interpretations are based on
CLSI criteria (33).
FIG 1 Genetic contexts of the four -lactamase-encoding genes in A. pittii CR12-42.
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blaIMP-4 has also been reported inAcinetobacter junii fromAustra-
lia; however, the genetic context was not characterized (23). Our
genetic context was also similar to that of blaIMP-4 in the IncHI2-
type plasmid fromEnterobacter cloacae andEscherichia coli and the
IncL/Mplasmid carrying blaIMP-4 in an E. cloacae strain fromAus-
tralia (24, 25). However, the plasmid backbone of these sequences
could not be identified within our draft genome. Further investi-
gation is needed to determine if blaIMP-4 is located on a plasmid or
the chromosome of CR12-42.
A carbenicillinase gene, blaCARB-2 was identified with Res-
Finder. blaCARB-2, which was also designated blaPSE-1, was first
reported in Pseudomonas aeruginosa (26). The genetic context of
blaCARB-2 in CR12-42 was also potentially a class 1 integron with a
truncated integrase (intI1) located upstream of blaCARB-2 (Fig. 1).
Other resistance genes found in this strain included sul1 (sulfon-
amide resistance),msr(E) andmph(E) (macrolide resistance), and
aac-3-IId (aminoglycoside resistance). Consistent with this, theA.
pittii strain was resistant to gentamicin and tobramycin but sus-
ceptible to amikacin. Of note, no 16S rRNAmethylase was found
in this isolate.
Regardless of its resistance to multiple antimicrobials, A. pittii
CR12-42 remained susceptible to tetracycline and minocycline,
which was consistent with the absence of a tetracycline resistance
gene within the draft genome. In addition, theMIC of ampicillin-
sulbactam remained low (2mg/liter), despite the presence ofmul-
tiple carbapenemase-encoding genes. Further, sulbactam is
known to have activity against A. baumannii (27). In a study by
Higgins et al., the ampicillin-sulbactamMIC50 of 115 A. bauman-
nii strains was 2mg/liter (27). Ampicillin-sulbactam susceptibility
was also shown in the majority of the previously reported A. pittii
ST119 strains harboring blaIMP-19 (94%) in Japan (16). In addi-
tion, 94% of these were susceptible to minocycline, similar to the
antimicrobial phenotype of CR12-42 (16). Apart from the differ-
ence in blaIMP variants, CR12-42 has an antimicrobial phenotype
and genotype identical to those of A. pittii ST119 from Japan.
IMP-producing Enterobacteriaceae strains have been fre-
quently reported in Australia. Although OXA-23-like is the main
subclass of carbapenemases identified in A. baumannii, IMP-4 is
occasionally identified in A. pittii in locations such as Hong Kong
and Singapore (18, 28). Other variants of blaIMP, such as blaIMP-1,
blaIMP-8, blaIMP-11, and blaIMP-19, have been described inA. pittii in
Southeast Asia (16, 29, 30).A. pittii has also recently been reported
to produce NDM (31, 32).
Generally,A. baumannii is considered themost important and
the most prevalent Acinetobacter species causing infections. How-
ever,A. pittii has caused hospital outbreaks in TheNetherland and
China (32, 33) and was reported as themost commonAcinetobac-
ter species causing nosocomial infections in Germany (34). Our
study illustrates the emergence of a multidrug-resistant A. pittii
strain inAustralia. Therefore, accurate identification to the species
level and characterization of the prevalence of A. pittii among the
Acinetobacter species isolated in our region and its antibiotic re-
sistance warrant further investigation.
This work was approved by the Royal Brisbane and Women’s
Hospital Human Research Ethics Committee (HREC/13/QRBW/
391: epidemiology, clinical significance, treatment, and outcome
of infections by carbapenem-resistant Enterobacteriaceae and
Acinetobacter species in Queensland). This project is registered as
BioProject PRJNA255268 and BioSample SAMN03003652.
Nucleotide sequence accession numbers. The GenBank ac-
cession number of blaOXA-421 is KM401566. The GenBank acces-
sion number of the draft genome of A. pittii CR12-42 is
JQNT00000000.
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Chapter 3. Molecular epidemiology of carbapenem-resistant A. 
baumannii in a major hospital in Bangkok 
3.1 Synopsis 
Acinetobacter is an important and complex bacterial genus that causes a wide range of nosocomial 
infections [91]. A high prevalence of carbapenem-resistant Acinetobacter baumannii (CRAB) is 
observed worldwide including Asia [5, 6], which is a concerning threat in the healthcare system. 
Multiple outbreaks of CRAB have been reported from China, India, South Korea, Taiwan, Singapore 
and Thailand [86, 92-96]. 
This Chapter is a study of 300 isolates of A. calcoaceticus – A. baumannii complex from a 2200-bed 
tertiary care hospital situated in Bangkok, Thailand. We investigated molecular epidemiology and 
carbapenem resistance mechanisms in clinical isolates of Acinetobacter spp. from Siriraj hospital, 
Bangkok, Thailand. In addition, 13 Acinetobacter spp. were selected for sequencing to study genomes 
of Acinetobacter spp. disseminated in this hospital. Through the genome analyses, a unique set of 
antimicrobial resistance and biofilm-related genes was identified. The presence and the stability of 
this particular set of these genes may contribute to its spread and persistence of A. baumannii IC2, 
which is the successful epidemic clone in this hospital 
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SYNOPSIS 20 
Objective: Carbapenem resistance in Acinetobacter spp. is an important problem in Thailand. We 21 
investigated the epidemiology and antimicrobial resistance genes of 300 non-repetitive clinical 22 
isolates of Acinetobacter calcoaceticus-Acinetobacter baumannii (ACB) complex obtained from 23 
Siriraj Hospital in Thailand. 24 
Methods: The species identification was performed by partial rpoB gene sequencing. Isolates were 25 
subjected to PCR-based detection of antimicrobial resistance genes as well as allele-specific PCRs 26 
and repetitive sequence-based PCR (rep-PCR) for clonality assessments. The thirteen representative 27 
isolates were selected for full genome sequencing and analysis. 28 
Results: A. baumannii was the main organism (n= 294, 98%) followed by Acinetobacter 29 
nosocomialis (n=4, 1.3%) and Acinetobacter pittii (n=2, 0.7%). The majority of A. baumannii 30 
isolates (n=236, 80%) belonged to international clone (IC) 2. Of 270 carbapenem-resistant A. 31 
baumannii (CRAB) isolates, all were resistant to ciprofloxacin, 92.2% were resistant to amikacin and 32 
93% were resistant to cefepime. blaOXA-23-like and blaOXA-40-like were found in 99.2% and 1.1% in 33 
CRAB isolates, respectively. The armA gene was present in 89% of aminoglycoside-resistant isolates. 34 
The armA gene was found within Tn1548 and in close proximity to macrolide resistance genes (mphE 35 
and msrE) and csu locus which was responsible for biofilm formation. All IC2 isolates harboured an 36 
identical set of antimicrobial resistance genes; blaOXA-23, blaOXA-66, blaADC, strA, strB and tetB and all 37 
biofilm-related genes. 38 
Conclusion: The presence and the stability of this set of antimicrobial resistance and biofilm-related 39 
genes may contribute to its spread and persistence of A. baumannii IC2, which is the successful 40 
epidemic clone in this hospital. 41 
  42 
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INTRODUCTION  43 
Acinetobacter is an important and complex bacterial genus that causes nosocomial infections, 44 
including ventilator-associated pneumonia, bacteraemia, wound infections, urinary tract infections 45 
and meningitis.1 Acinetobacter baumannii, Acinetobacter nosocomialis, Acinetobacter pittii and 46 
Acinetobacter calcoaceticus are difficult to distinguish and usually misidentified. These four genomic 47 
species are grouped as “A. calcoaceticus-A. baumannii (ACB) complex”. The former species are the 48 
most clinically important species whist A. calcoaceticus is rarely recovered from clinical specimens.2 49 
An emergence of carbapenem-resistant A. baumannii (CRAB) has caused a high burden for the 50 
healthcare system worldwide last decades. There are few drug options to treat CRAB infections, with 51 
the only options being tigecycline and colistin 1. 52 
A high prevalence of carbapenem-resistant Acinetobacter spp. is observed in Asia.3, 4 Multiple 53 
outbreaks of CRAB have been reported from China, India, South Korea, Taiwan, Singapore and 54 
Thailand.5-10 A. baumannii was the primary causative pathogen for nosocomial pneumonia in tertiary 55 
care hospitals in Thailand and most of A. baumannii isolates were multidrug-resistant.11 The 56 
prevalence rate of carbapenem-resistant A. baumannii isolates in Thailand was notably high. The 57 
percentage of A. baumannii which were carbapenem resistant was 2.1% in 2000 rising dramatically 58 
to 46.7% in 2005.12 A multi-centre study in Thailand showed that the prevalence rate of carbapenem-59 
non-susceptible A. baumannii isolates was 76.3% in 2010.13 60 
Siriraj hospital is a 2300-bed tertiary care hospital situated in Bangkok, Thailand. A. baumannii was 61 
one of the main skin flora recovered from hospitalised patients at this hospital.14 In 2012, the 62 
percentage of multidrug-resistant (including resistance to carbapenems) A. baumannii collected from 63 
hospitalised patients at Siriraj hospital was 88.7%.15 Predominance and persistence of carbapenem-64 
resistant A. baumannii in South East Asia including in Thailand has been reported.16 65 
In this context of endemicity, we investigated the molecular epidemiology and carbapenem resistance 66 
mechanisms in clinical isolates of Acinetobacter spp. from Siriraj Hospital, Bangkok, Thailand. In 67 
addition, 13 representative Acinetobacter spp. isolates were selected for full genome sequencing in 68 
order to provide a comparative genome analysis of the antimicrobial resistance mechanisms, 69 
resistance islands and biofilm formation on Acinetobacter spp. strains disseminated in this hospital. 70 
  71 
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MATERIALS AND METHODS  72 
Bacterial isolates, antimicrobial susceptibility testing 73 
A total of 270 non-repetitive clinical carbapenem-resistant A. calcoaceticus-A. baumannii (ACB) 74 
complex isolates were investigated. These isolates were collected from January to July 2010 from 75 
Siriraj Hospital - a 2200-bed University hospital in Bangkok, Thailand. The isolates were initially 76 
identified as ACB complex by using the Vitek2 automated identification system (BioMerieux, USA). 77 
Additionally, 30 isolates of carbapenem-susceptible ACB complex collected at the same period of 78 
time were also included in this study. The detail of the carbapenem susceptibility of the study isolates 79 
is illustrated in Table 1A and 1B. 80 
Species identification was undertaken by using partial rpoB gene sequencing (zone 1) as previously 81 
described.17 Antimicrobial susceptibility test by the disk diffusion method was performed to 82 
determine the susceptibility to amikacin, ciprofloxacin, cefepime, imipenem and meropenem 83 
according to the Clinical and Laboratory Standards Institute (CLSI) guideline.18 84 
Genotypic characterisation of carbapenem resistance and resistance mediated by the 16S rRNA 85 
methyltransferase 86 
Multiplex PCRs were performed on all isolates to characterise for oxacillinase genes (blaOXA-51-like, 87 
blaOXA-23-like, blaOXA-40-like, blaOXA58-like, blaOXA-143-like and blaOXA-235-like)19-21 and metallo-ß-lactamase 88 
genes (blaIMP, blaVIM, and blaNDM) as previously described.22-24 Additionally, a PCR for a region of 89 
ISAba1 upstream to blaOXA-51 was carried out to detect the presence of this insertion element amongst 90 
A. baumannii isolates.25 91 
The resistance to aminoglycoside due to the production of 16S rRNA methyltransferases (armA, 92 
rmtB, rmtC and rmtD) was also determined as previously described.26 All primers used in this study 93 
were listed in Table S1. 94 
Molecular typing 95 
Allele-specific PCRs, designed to amplify ompA, csuE and blaOXA-51, were used to determine 96 
sequence groups (SGs) in all A. baumannii isolates as previously described.27, 28 Clonal analysis was 97 
performed on representative isolates by semi-automated rep-PCR DiversiLabTM (bioMerieux, VIC, 98 
Australia) according to the manufacturer’s instruction. Isolates that clustered together with a 99 
similarity of 92% were considered to belong to the same rep-PCR types.  100 
Whole genome sequence and analysis of Acinetobacter isolates 101 
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A total of 13 ACB isolates were subjected for sequencing to capture a range of genomic species, 102 
hospital locations, dates, genotypes and antimicrobial resistance phenotypes. The whole genome 103 
sequencing was performed using (HiSeq and Miseq) Illumina® paired-end technology (Australian 104 
Genome Research Facility and Diamantina Institute, Brisbane, Australia). The de novo assembly and 105 
sequence analyses were performed using CLC genomic workbench version 7.5 with the minimum 106 
500 bp cut off. The in silico analyses of the genomes were performed by; (i) identification of 107 
antimicrobial resistance genes using ResFinder 2.129, (ii) in silico MLST (Pasteur schemes) using 108 
MLST 1.730, which are available on Centre for Genomic Epidemiology server 109 
(http://cge.cbs.dtu.dk/services/). 110 
The genetic contexts of oxacillinase genes, Acinetobacter derived cephalosporinase (blaADC), 16S 111 
rRNA methyltransferase gene and other antimicrobial resistance genes were determined in silico. In 112 
addition, antimicrobial resistance mechanism caused by modification of target genes, such as 113 
mutations in the gyrA and parC and biofilm related genes were identified. The draft genomes were 114 
annotated using Rapid Annotations using Subsystems Technology (RAST).31  115 
In A. baumannii, at least four genes, i.e. bap gene, csu locus, bfmRS and pga locus have been 116 
recognised to be associated with biofilm formation.32, 33 Therefore, these four genes and/or operons 117 
were also determined and compared. The draft genomes were submitted to GenBank under BioProject 118 
PRJNA255268.The draft genome GenBank accession numbers are JRQT00000000, JPKX00000000, 119 
JRQS00000000, JRTX00000000, JRTY00000000, JRQU00000000, JRQV00000000, 120 
JRQX00000000, JRQY00000000, JRTZ00000000, JRQW00000000, JRQZ00000000 and 121 
JRUA00000000. 122 
 123 
RESULTS 124 
Identification of Acinetobacter spp. isolates 125 
A total of 300 isolates previously identified as carbapenem-resistant members of ACB complex by 126 
Vitex2 identification system were further distinguished to species level using gyrB multiplex and the 127 
sequence of partial rpoB gene. Of the 300 clinical isolates, A. baumannii, A. nosocomialis and A. pittii 128 
were 294 (98%), 4 (1.3%), and 2 (0.7%), respectively. Most isolates were collected from sputum 129 
(n=232 or 77%), urine (n=23 or 7.7%), blood (n=16 or 5.3%) or wounds (n=12 or 4%) (Table 1A). 130 
Of 270 carbapenem-resistant isolates, all were resistant to ciprofloxacin, 249 (92.2%) were resistant 131 
to amikacin and 252 (93%) were resistant to cefepime. In comparison, the resistance rate of 30 132 
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carbapenem-susceptible isolates to ciprofloxacin, amikacin and cefepime were 16.7%, 6.7% and 133 
3.3%, respectively.  134 
Resistance determinants of Acinetobacter spp. 135 
The gene blaOXA-51-like was amplified (353 bp) in 291 (99%) A. baumannii isolates using previously 136 
described method.21 The blaOXA-51-like was amplified with a larger product size (~1.5kb) in three 137 
isolates (T209, T222, T227). Of note, these three isolates had distinct colony morphology with 138 
pigment production on LB and MH medium. These isolates were confirmed as A. baumannii by gyrB 139 
amplification. The sequence of 1.5 kb of OXA-51-like PCR products showed that blaOXA-78 (a variant 140 
of blaOXA-51) was interrupted by ISAba19 in all three isolates.  141 
All A. baumannii isolates were negative for ISAba1, the common insertion element upstream to 142 
blaOXA-51-like. Amongst carbapenem-resistant A. baumannii (n=269), 99.2% harboured blaOXA-23-like. 143 
Three A. baumannii isolates harboured blaOXA-40-like with two isolates (T185 and T188) having both 144 
blaOXA-23-like and blaOXA-40-like genes. The blaOXA-58-like gene was found in two A. baumannii isolates. 145 
However, these two isolates were phenotypically susceptible to carbapenems (Table 2).  146 
One carbapenem-resistant A. pittii isolate harboured blaOXA-23-like. All isolates were negative for 147 
blaOXA-143-like, blaOXA-235-like, and MBL genes tested (blaIMP, blaVIM and blaNDM). 16S rRNA 148 
methyltransferase gene, armA, was present in 89% (223/250) of aminoglycoside-resistant isolates. 149 
Amongst carbapenem-resistant A. baumannii isolates (n=269), 248 isolates were also resistant to 150 
amikacin, broad spectrum aminoglycoside with 223 isolates harbouring armA (Table 2). None of the 151 
study isolates was positive for other 16s rRNA methyltransferase genes tested; rmtB, rmtC or rmtD. 152 
Clonal analysis of the Acinetobacter spp. 153 
Of the 294 A. baumannii, the majority of isolates (n=236, 80%) belonged to previously identified SG 154 
1, which corresponds to international clone (IC) 2. Seventeen isolates belonged to SG 4. The 155 
remaining isolates belonged to SG 5 (n=15) or SG 7 (n=5). Twenty-one isolates gave an unrecognised 156 
pattern compared to previously described SGs and were diverse by DiversiLabTM. All isolates of SG 157 
1 and 4 were carbapenem-resistant A. baumannii. 158 
Rep-PCR DiversiLabTM was undertaken on 115 A. baumannii, four A. nosocomialis and two A. pittii 159 
isolates. The dendrogram results showed that 79 (65%) isolates were clustered in the largest group 160 
(>92% similarity), group A (Fig S1). The banding patterns of this cluster were similar to those 161 
identified as international clone 2 (IC2).34 Interestingly, all group A isolates consisted of the isolates 162 
only from SG 1 and 4 and were carbapenem-resistant. Eight different groups and six singletons were 163 
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identified amongst carbapenem-susceptible A. baumannii isolates (n=25). Three isolates of A. 164 
nosocomialis were clustered together (>92% similarity) while two A. pittii isolates were not clonally 165 
related.  166 
In silico analysis of Acinetobacter draft genome 167 
The draft genome results and antimicrobial resistance genes of 13 Acinetobacter isolates which 168 
comprised of A. baumannii (n=11), A. nosocomialis (n=1) and A. pittii (n=1) are shown in Table 3. 169 
The size of the genome ranged from 3,680,364 to 4,362,838 bp. It is important to note that the smallest 170 
genome size was the A. baumannii with the fewest antimicrobial resistance genes. In contrast, A. pittii 171 
with the most number of antimicrobial resistance genes detected had the largest genome size. The 172 
difference of the genome size between these two strains was 682,474 bp. The results of in silico 173 
MLST of these isolates using Pasteur scheme was showed in Table 3. All A. baumannii rep-PCR 174 
group A isolates belonged ST2 except one isolate (T271) that belonged to ST215. A. nosocomialis 175 
and A. pittii isolates were ST279 and a novel ST655, respectively.  176 
Carbapenem resistance mechanisms 177 
In silico analysis of genome sequences of representative 11 A. baumannii isolates indicated that 178 
blaOXA-51-like in these isolates were blaOXA-66 (n=9), blaOXA-68 (n=1) and blaOXA-120 (n=1) (Table 3). 179 
The location of blaOXA-51-like was in between phosphinothricin N-acetyltransferase and fxsA genes, 180 
which is the usual chromosomal location of the blaOXA-51-like gene.35 The A. baumannii with blaOXA-66 181 
were all ST2, and blaOXA-68 and blaOXA-120 belonged to ST215 and a novel ST653 (Table 3). ISAba1 182 
was not detected adjacent to blaOXA-51-like in all isolates. 183 
The genetic environments surrounding blaOXA-23 in A. baumannii and A. pittii isolates were similar. 184 
The blaOXA-23 in both species was bracketed by ISAba1 and was carried by Tn2006 (GenBank 185 
accession no. JN129846).36 The blaOXA-40-like in both A. baumannii isolates was blaOXA-72 and was 186 
flanked by XerC/XerD recombination sites, which were presumed to be responsible for mobilisation 187 
of blaOXA-40-like.37-40  188 
Resistance island and other antimicrobial resistance mechanisms 189 
The backbone of resistance AbaR4 was integrated into specific genomic site, comM (ATPase gene), 190 
which was identified in all isolates belonged to rep-PCR group A. AbaR4 is a common resistance 191 
island of international clone 2 isolates comprising the uspA (universal stress protein A), sup (sulphate 192 
permease), tet(B) (tetracycline resistance), strB (aminoglycoside resistance) and strA 193 
(aminoglycoside resistance) including Tn2006 that carries blaOXA-23.36 The 16S rRNA 194 
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methyltransferase gene, armA in A. baumannii isolates was bracketed by transposase genes, tnpU and 195 
tnpD (Tn1548). The macrolide resistance genes, mphE and msrE, were found in close proximity to 196 
armA in all five armA-harboring isolates. Truncated IS26 was also found downstream of mphE and 197 
msrE (Figure 1). 198 
Acinetobacter derived cephalosporinase, blaADC, was present in all rep-PCR group A isolates. Two 199 
A. baumannii which showed carbapenem susceptibility lacked all the above antimicrobial resistance 200 
genes including blaADC. ISAba1 was detected upstream to chromosomal blaADC in all CRAB isolates. 201 
More than half of group A isolates harboured blaTEM-1 (6/9, 67%). The carbapenem-resistant A. pittii 202 
isolate (T167) harboured several resistance genes including blaOXA-23, blaOXA-10, blaVEB-7, aadA1, 203 
aadB, aphA6, mphE, msrE, sul1, sul2, floR, cmlA1, aar-2 and dfrA10. (Table 3). 204 
Sequences of quinolone resistance-determining region of the gyrA and parC genes revealed a change 205 
of Ser83 to Leu in gyrA and Ser80 to Leu in parC of almost all isolates. There was a Ser80 to Trp in 206 
the parC gene of A. baumannii T214.  207 
Biofilm-related genes in Acinetobacter spp. 208 
Given the likely importance of biofilm formation to the success of A. baumannii in hospitals, biofilm 209 
formation associated genes, bap, csu locus, bfmRS and the pga locus, were identified (Table 4). The 210 
bfmR and bfmS genes and their promoter regions were present in all isolates. All four genes were 211 
detected in genomes of all A. baumannii ST2. The remaining isolates lacked either one or two of 212 
these genes (except bfmRS). The csu locus was located in close proximity with armA (in isolates 213 
harbouring armA). 214 
 215 
DISCUSSION 216 
A high prevalence of CRAB has been observed in Asia including Thailand.13 In 2002, a study from 217 
Siriraj hospital showed that the percentage of A. baumannii collected from hospitalised patients which 218 
were MDR was more than 50% and this increased to 88.7% in 2012.15 A subset of the total isolates 219 
collected at Siriraj hospital from January to July in 2010 was used in this study and included 270 220 
carbapenem-resistant and 30 carbapenem-susceptible ACB complex. A. baumannii was the main 221 
organism (98%) followed by A. nosocomialis and A. pittii which is similar to reports from other 222 
countries.41 Interestingly, all A. nosocomialis isolates was carbapenem-susceptible and recovered 223 
from sputum. Further, ISAba1 was not present in A. nosocomialis genome in the present study. This 224 
suggests that A. nosocomialis amongst our isolates may possess less ability to acquire antimicrobial 225 
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resistance determinants. A. nosocomialis also lacked several putative virulence related genes and had 226 
a lower mortality in clinical studies.42, 43 However, a previous study showed that carbapenem 227 
resistance in A. nosocomialis was the consequence of an acquisition of blaOXA-23-like associated with 228 
ISAba1. 229 
Oxacillinase genes have been responsible for the carbapenem resistance mechanisms in A. baumannii. 230 
It has been reported that specific variants of OXA genes only present in certain geographical areas.16 231 
Similar to the worldwide situation of dominance of OXA-23 causing carbapenem resistance 232 
mechanisms in A. baumannii, blaOXA-23-like was also the main resistance determinant responsible for 233 
carbapenem resistance in A. baumannii in our hospital. Only three isolates of carbapenem-resistant 234 
A. baumannii harboured blaOXA-40-like were identified here. In contrast to the carbapenem-resistance 235 
phenotype observed amongst blaOXA-23-like and blaOXA-40-like-positive isolates, two blaOXA-58-like-236 
harbouring A. baumannii isolates remained susceptible to carbapenems (Table 2). It has been reported 237 
previously that blaOXA-58-like-harbouring Acinetobacter spp. showed variable susceptibilities to 238 
carbapenems.44 This might be caused by the lack of a strong promoter upstream of blaOXA-58-like in 239 
these isolates. Our study showed the first description of blaOXA-58 from Thailand. A high prevalence 240 
of Acinetobacter spp. harbouring blaOXA-58 was observed in Singapore, Taiwan and European 241 
countries.16, 45-48 242 
The presence of blaOXA-51-like in all A. baumannii isolates emphasised that it is the naturally occurring 243 
gene found in A. baumannii. However, three A. baumannii isolates harbouring blaOXA-78, a blaOXA-51-244 
like, were interrupted by ISAba19 resulting in a larger product size observed in multiplex PCR. This 245 
event was previously reported by Zander et al. in A. baumannii from Turkey and South Africa.49 One 246 
of the limitations of this study, these three isolates were not whole genome sequenced, therefore the 247 
genetic context of the blaOXA-78 cannot be analysed here. Thus, detection of intrinsic blaOXA-51-like 248 
alone may not be accurate enough to identify A. baumannii. Additional methods such as gyrB 249 
multiplex PCR or sequencing methods based on the partial rpoB gene and the 16S-23S rRNA gene 250 
spacer region can be utilised for species identification.17, 50-52  251 
blaVEB-type has been reported in A. baumannii.53 However, there was only one report of blaVEB-3 in A. 252 
pittii which was from Taiwan.54 A. pittii T167 harboured blaVEB-7 which was firstly recovered from 253 
A. baumannii (GenBank accession number FJ825622). The blaVEB-7 in A. pittii T167 isolate was 254 
located in ~7kb class 1 integron structure containing blaVEB-7-addB-arr-2-cmlA-blaOXA-10-aadA1 gene 255 
cassette array (Figure 2). This structure was a part of Tn6061 originally identified in Pseudomonas 256 
aeruginosa and was also found in AbaR1, the largest resistance island (~86 Kb) in A. baumannii AYE 257 
strain.55 258 
43 
 259 
The coexisting rate of armA amongst all CRAB isolates and CRAB that belonged to IC2 (by rep-PCR 260 
pattern) was high, 82.8% and 87.3%, respectively. The genetic surrounding of armA was associated 261 
with Tn1548 and similar to genomes of A. baumannii TYTH-1 (GenBank accession no. CP003856) 262 
and MDR-TJ (GenBank accession no. CP003500) isolated in Taiwan and China, respectively.56, 57 263 
This structure was also found in plasmids from A. baumannii MDR-ZJ06 (GenBank accession no. 264 
NC_017172)58 and from many Enterobacteriaceae, such as pNDM-HK of Escherichia coli (accession 265 
no. HQ451074) from Hong Kong59 (Figure 1). 266 
A. baumannii isolates harbouring armA possessed identical set of antimicrobial resistance genes i.e. 267 
blaOXA-23, blaOXA-66, blaADC, blaTEM-1, strA, strB, aphA1, mphE, msrE, sul2 and tetB. This set of 268 
antimicrobial resistance genes represented phenotypic characteristics of the majority of CRAB at 269 
Siriraj Hospital. In addition, the possession of four genes for biofilm formation were strongly 270 
associated with the ST2 regardless the slight variability of the antimicrobial resistance gene 271 
composition. Phenotypic of the biofilm formation of the isolates with different composition of biofilm 272 
forming genes requires further investigation. 273 
Clonal spreads of CRAB have been reported previously in Thailand using different typing methods.10, 274 
60-62 Although SG typing showed that SG1 was the main sequence group of our isolates (80%), others 275 
SGs were also identified including SG4 (6%), SG5 (5%) and SG7 (2%). These SGs were also 276 
recovered from European countries; SG4 was found in the Netherlands, Turkey and Portugal, SG5 in 277 
Austria and Denmark and SG7 in Estonia.27 Rep-PCR results showed that the majority of tested A. 278 
baumannii isolates (65%) belonged to IC2 and were resistant to carbapenem. The clonal spread of 279 
CRAB IC2 has also been reported from Asia-Pacific nations such as Australia, China, Japan and 280 
Singapore.5, 63-65 In contrast, there was no predominant clone amongst carbapenem-susceptible A. 281 
baumannii isolates. This suggests that an acquisition of carbapenem resistance may be one of the 282 
adaptive attributes that cause a persistence of IC2. It is important to note that among the same rep-283 
PCR group of our isolates included different STs or SGs. This suggested the drawbacks of 284 
semiautomated rep-PCR including limited discrimination of rep-PCR compared to MLST and the 285 
lack of manufacturer instructions on similarity cut-off values for classifying closely related rep-PCR 286 
profiles as identical genotypes.66 However, MLST is primary useful for population genetics studies 287 
while rep-PCR has the advantage of being less time-consuming than MLST allowing for the 288 
investigation of large numbers of isolates.34, 66 289 
Whole genome analysis of A. baumannii ST2 isolates (which clustered in IC2) indicated that all 290 
isolates harboured blaOXA-23, blaOXA-66, blaADC, strA, strB and tetB. All genes associated with biofilm 291 
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formation were also present in ST2 isolates. Hence, the stability of these genes within the isolates 292 
belonging to IC2 may help the emergence and spread of this clone, which is the most successful 293 
epidemic clone in this hospital. The genome sequence of carbapenem-resistant A. pittii isolate showed 294 
that this isolate harboured different set of multiple antimicrobial resistance genes that were not 295 
detected amongst A. baumannii IC2 isolates. Class one integron structure was also detected, which 296 
facilitates further acquisition of antimicrobial, detergent and heavy metal resistance determinants in 297 
this A. pittii isolate. Continuous surveillance of Acinetobacter spp. and identification of their 298 
antimicrobial resistance mechanisms as well as screening scheme for colonisation amongst patients 299 
and environment in the hospital may be required for early detection and prevention of inter- and intra-300 
species transfer of CRAB. 301 
In conclusion, we demonstrated the homogenous spread of OXA-23-producing A. baumannii that 302 
belonged to IC2 at Siriraj hospital. Carbapenem-resistant A. nosocomialis and A. pittii was 303 
uncommon. The blaOXA-40-like and blaOXA-58-like carrying A. baumannii strains were also rare.  304 
The genome sequences revealed the genotypic characteristics of carbapenem resistance and other 305 
multiple resistance as well as capability to form strong biofilm A. baumannii isolates within epidemic 306 
clone, IC2. Appropriate empirical antimicrobial treatment and infection prevention programs are 307 
pivotal to help preventing the further spread of this clone. 308 
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Tables and Figures 
Table 1A. Specimen types 
 
Specimen 
Number of isolates 
A. baumannii (294) A. nosocomialis (4) A. pittii (2) 
Total (300) 
CSa CRb CSa CRb CSa CRb 
BAL  1 - -  - 1 
Body fluid - 5 - - - - 5 
Blood culture - 15 - - 1 - 16 
CSF - 1 - - - - 1 
Nasopharyngeal 
aspirate 
- 1 - - - - 1 
Sputum 22 206 4 - - - 232 
Tissue biopsy - 5 - - - - 5 
Urine 2 20 - - - 1 23 
Wounds 
(swab/pus) 
1 11 - - - - 12 
Others - 4 - - - - 4 
a CS; carbapenem-susceptible, b CR; carbapenem-resistant. 
Table 1B. The location of patients when the specimens were collected. 
Location 
Number of isolates 
A. baumannii (294) A. nosocomialis (4) A. pittii (2) Total (300) 
 CSa CRb CSa CRb CSa CRb  
Medicine wards 2 127 1 - 1 1 132 
ICUs 8 68 3 - - - 79 
Surgery wards 7 17 - - - - 24 
OPD 3 18 - - - - 21 
Orthopaedic wards - 8 - - - - 8 
Paediatric wards 1 3 - - - - 4 
Others 2 30 - - - - 32 
a CS; Carbapenem-susceptible, b CR; carbapenem-resistant. 
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Table 2. Oxacillinases and 16S rRNA methyltransferase genes detected by PCR in Acinetobacter 
spp. 
Antimicrobial 
resistant 
genes 
A. baumannii (n=294) A. pittii (n=2) A. nosocomialis 
(n=4) 
Carbapenem 
susceptible 
(n=25) 
Carbapenem 
resistance 
(n=269) 
Carbapenem 
susceptible 
(n=1) 
Carbapenem 
resistance 
(n=1) 
Carbapenem 
susceptible 
(n=4) 
blaOXA-51-like 22 (88%) + 
3a 
267 (99.2%) 0 0 0 
blaOXA-23-like 0 267 (99.2%) 0 1 0 
blaOXA-40-like 0 3 (1.1%) 0 0 0 
blaOXA-58-like 2 (8%) 0 0 0 0 
armA 0 223 (82.8%) 0 0 0 
a Three isolates gave ~1.5kb product size. 
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Table 3. Selected genetic characteristics of Acinetobacter draft genomes 
Isolate 
ID 
Species Specimen Location 
C
R 
SG 
rep-
PCR 
MLST 
in silico 
IS 
Aba1 
Intrinsic 
blaOXA 
Acquired 
blaOXA 
16s rRNA 
methylase 
gene 
Other resistance genes 
Mutation in 
Total bases 
(bp) 
gyrA parC 
T7a A. baumannii CSF ICU + SG1 A ST2 + blaOXA-66 blaOXA-23 armA 
blaADC, blaTEM-1, strA, 
strB, aphA1, mphE, 
msrE, sul2, tetB 
S83L S80L 3,938,556 
T25b A. baumannii Wound swab Surgery + SG1 A ST2 + blaOXA-66 blaOXA-23 armA 
blaADC, blaTEM-1, strA, 
strB, aphA1, mphE, 
msrE, sul2, tetB 
S83L S80L 3,862,654 
T87b A. baumannii Blood culture ICU + SG1 A ST2 + blaOXA-66 blaOXA-23 ArmA 
blaADC, blaTEM-1, strA, 
strB, aphA1, mphE, 
msrE, sul2, tetB 
S83L S80L  3,877,500 
T122a A. baumannii Blood culture Medicine + SG1 A ST2 + blaOXA-66 blaOXA-23 ArmA 
blaADC, blaTEM-1, strA, 
strB, aphA1, mphE, 
msrE, sul2, tetB 
S83L S80L 3,938,051 
T173a A. baumannii 
Nasopharyngeal 
aspirate 
Paediatri
c 
+ SG1 A ST2 + blaOXA-66 blaOXA-23 ArmA 
blaADC, blaTEM-1, strA, 
strB, aphA1, mphE, 
msrE, sul2, tetB 
S83L S80L 3,936,842 
T185b A. baumannii Blood culture Surgery + SG1 A ST2 + blaOXA-66 
blaOXA-23, 
blaOXA-72 
- 
blaADC, strA, strB, 
aac(6’)ii, sul2, tetB 
S83L - 3,988,299 
T188b A. baumannii Sputum OPD + SG1 A ST2 + blaOXA-66 
blaOXA-23, 
blaOXA-72 
- 
blaADC, strA, strB, 
aac(6’)ii, sul2, tetB 
S83L - 3,984,620 
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T258b A. baumannii Sputum Medicine + SG1 A ST2 + blaOXA-66 blaOXA-23 - 
blaADC, strA, strB, 
aac(6’)ii, sul2, tetB 
S83L S80L 3,950,019 
T271b A. baumannii Urine OPD + SG4 A ST215 + blaOXA-66 blaOXA-23 - 
blaADC, blaTEM-1, strA, 
strB, aac(3’)ic, aadA1, 
mphE, msrE,sul1, sul2, 
tetB 
S83L S80L 3,868,725 
T214b A. baumannii Sputum ICU - SG5 E ST10 - blaOXA-68  - -  - S83L S80W 3,799,245 
T229b A. baumannii Sputum 
Paediatri
c 
- UN I ST653 - blaOXA-120  - -  - - - 3,680,364 
T167b A. pittii Urine Medicine + NA 
Single-
ton 
ST655 +  - 
blaOXA-10, 
blaOXA-23 
 
blaVEB-7, aadA1, aadB, 
aphA6, mphE, msrE, 
sul1, sul2, floR, cmlA1, 
aar-2, dfrA10 
S83L S80L 
4,362,838 
 
T228 
A. 
nosocomialis 
Sputum ICU - NA M ST279 
- 
 - - -   
- - 
3,797,192 
a genome sequencing by using Ilumina MiSeq, b genome sequencing by Ilumina HiSeq., UN; unidentified, NA; not applicable.  
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Table 4. The presence of genes associated with biofilm formation identified by whole genome 
sequencing. 
Isolate ID Species MLSTa bap gene csu locus bfmRS pga locus 
T7 A. baumannii ST2 + + + + 
T25 A. baumannii ST2 + + + + 
T87 A. baumannii ST2 + + + + 
T122 A. baumannii ST2 + + + + 
T173 A. baumannii ST2 + + + + 
T185 A. baumannii ST2 + + + + 
T188 A. baumannii ST2 + + + + 
T258 A. baumannii ST2 + + + + 
T271 A. baumannii ST215 - - + + 
T214 A. baumannii ST10 + - + + 
T229 A. baumannii ST653 - + + - 
T167 A. pittii ST655 - - + + 
T228 A. nosocomialis ST279 + + + + 
aIn silico MLST using Pasteur MLST scheme. 
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Figure 1. Genetic surrounding of Tn1548 containing armA 
Genetic surrounding of armA present in A) plasmid of Escherichia coli pNDM-HK from Hong Kong 
(HQ451074), B) Acinetobacter baumannii AC12 from Malaysia (CP007549) and C) A. baumannii 
T7 from Thailand in this study. Orientations of genes are indicated by arrows and the names are as 
given in or below the boxes. Yellow boxes represent armA, pink boxes represent macrolide resistance 
genes, blue boxes represent transposases/ IS elemments and white boxes represent others. Genes for 
csu operon are highlighted in purple and for paraquat inducible proteins are highlighted in green. The 
transposons are indicated within the dash line. 
 
 
Figure 2. Genetic surrounding of blaVEB-7 in A. pittii isolate 
A) Tn6061 from Pseudomonas aeruginosa BM4531 (GU475047). B) The 7kb-contig containing 
antimicrobial resistance array in class 1 integron structure in A. pittii T167. Open arrows indicate 
coding sequences and direction of transcription. Colours are used to indicate ORF categories, red; 
antimicrobial resistance genes, orange; transposition module, yellow; integrase genes, grey; ISCR 
and white; other ORFs. 
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Supplementary data 
Table S1. Primers used in this study 
Primer Target Sequence (5' to 3') Reference 
Ac696F 
rpoB Zone 1 
TAYCGYAAAGAYTTGAAAGAAG 17 
Ac1093R CMACACCYTTGTTMCCRTGA 17 
OXA-51_F 
blaOXA-51-like 
TAATGCTTTGATCGGCCTTG 21 
OXA-51_R TGGATTGCACTTCATCTTGG 21 
OXA-23_F 
blaOXA-23-like 
GATCGGATTGGAGAACCAGA 21 
OXA-23_R ATTTCTGACCGCATTTCCAT 21 
OXA-24_F 
blaOXA-40/24-like 
GGTTAGTTGGCCCCCTTAAA 21 
OXA-24_R AGTTGAGCGAAAAGGGGATT 21 
OXA-58_F 
blaOXA-58-like 
AAGTATTGGGGCTTGTGCTG 21 
OXA-58_F CCCCTCTGCGCTCTACATAC 21 
OXA-143-F 
blaOXA-143-like 
TGGCACTTTCAGCAGTTCCT 20 
OXA-143-R TAATCTTGAGGGGGCCAACC 20 
OXA-235_F 
blaOXA-235-like 
TTGTTGCCTTTACTTAGTTGC 19 
OXA-235_R CAAAATTTTAAGACGGATCG 19 
IMP-F 
blaIMP 
CTACCGCAGCAGAGTCTTTGC 22 
IMP-R GAACAACCAGTTTTGCCTTACC 22 
VIM-F 
blaVIM 
GATGGTGTTTGGTCGCATA 23 
VIM-R CGAATGCGCAGCACCAG 23 
NDM-F 
blaNDM 
GCAGGTTGATCTCCTGCTTG 24 
NDM-R ACGGTTTGGCGATCTGGT 24 
ISAba1-F upstream of blaOXA-51 CACGAATGCAGAAGTTG 25 
armA-F 
armA 
ATTCTGCCTATCCTAATTGG 26 
armA-R ACCTATACTTTATCGTCGTC 26 
rmtB-F 
rmtB 
GCTTTCTGCGGGCGATGTAA 26 
rmtB-R ATGCAATGCCGCGCTCGTAT 26 
rmtC-F 
rmtC 
CGAAGAAGTAACAGCCAAAG 26 
rmtC-R ATCCCAACATCTCTCCCACT 26 
rmtD-F 
rmtD 
CGGCACGCGATTGGGAAGC 26 
rmtD-R CGGAAACGATGCGACGAT 26 
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Figure S1. rep-PCR (DiversiLab) dendrogram of 121 Acinetobacter spp. isolates and their 
specimen types, species and sequence groups. Grey line represents 92% cut off similarity. 
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Chapter 4. Genome of A. baumannii: a comparative analysis of isolates 
from four Asian countries 
4.1 Synopsis 
The clinical significance of carbapenem-resistant A. baumannii (CRAB) infections is widely 
recognised. However, there is limited understanding of the resistance to non-β-lactam antimicrobials 
and virulence of CRAB and carbapenem-susceptible A. baumannii (CSAB). Molecular approach has 
been implemented widely in the characterisation of A. baumannii in previous studies [29, 97-99]. 
However, the data are only available in countries with adequate research resources. To better 
understand the detail characteristics of the genome of A. baumannii, a total of 21 Acinetobacter spp. 
strains comprising 17 CRAB and 4 CSAB representative isolates from Thailand, Singapore, Malaysia 
and Japan were genome sequenced. Extensive molecular characterisation for carbapenem resistance 
mechanisms and molecular epidemiology had been performed on 340 study isolates prior to this 
isolate selection [100, 101]. 
In this study, the genome analysis has provided additional insights on the variability of the genomes 
of the successful clone of A. baumannii IC2 strains in particular the absence and presence of 
pathogenicity and resistance islands. In addition, the detailed genome analysis has provided insights 
of the capability of certain strains of A. baumannii to persist in the hospital environment. The potential 
challenges of the human humoral response in the infections by A. baumannii and in the development 
of vaccines are also evident. This clinical understanding was gained through genome analysis of the 
biofilm forming locus/operon and characterisation of lipooligosaccharides, respectively.  
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ABSTRACT 24 
Acinetobacter baumannii is an important cause of nosocomial infections due to its ability to acquire 25 
multiple antimicrobial resistance genes and to persist in hospital settings. The international clone (IC) 26 
2 is a major clonal lineage of A. baumannii worldwide. We utilized the whole-genome sequencing 27 
approach to explore the diversity and genetic characteristics of 21 isolates of A. baumannii collected 28 
from major hospitals in Thailand, Singapore, Malaysia and Japan between 2009 and 2010. The 29 
majority of isolates were resistant to carbapenems and identified as IC2. The genetic contexts of 30 
intrinsic (blaOXA-51-like and blaADC) and important acquired-type resistance genes (blaOXA-23, blaIMP-4, 31 
blaTEM-1 and armA) were elucidated.  32 
AbaR4 resistance island was identified in the majority of the CRAB isolates (16 of 21 isolates) with 33 
the AbaR4-(I) as the dominant variant (12 of 16). Within this AbaR4, a Tn2006 containing blaOXA-23 34 
that conferring carbapenem resistance was located. Resistance genes to non-β-lactam antimicrobials 35 
were also located inside the AbaR4-(I), i.e. strA, strB, tetA(B), tetR(B) and sul2. AbGRI2-1 which 36 
contained blaTEM-1, aacC1, aadA1 and sul1 was identified in a non-IC2 isolate. AbaR3-type island 37 
was found in an IC1 isolate. Eleven isolates possessed aphA1b, an aminoglycoside resistance gene 38 
that was located in Tn6020. The resistance to broad spectrum aminoglycoside by armA was located 39 
within Tn1548 and in close proximity with mphE and msrE, macrolide resistance. The class 1 integron 40 
containing blaIMP-4 in one A. baumannii was identical to previously described in A. pittii and 41 
Enterobacteriaceae. 42 
The comparative genome analysis revealed variations in the loci for the surface polysaccharide 43 
synthesis, K locus and OC locus, a core virulence factor. OCL1 was the dominant type of OC locus 44 
in IC2. The regions for type VI secretion system (T6SS) and initial adhesion and biofilm formation, 45 
csu operon in non-IC2 isolates were disrupted. AbaR4-(I) in combination with Tn1548 had provided 46 
IC2 with resistance to nearly all antimicrobials available clinically. AbaR4-(I) resistance island, 47 
OCL1, T6SS and biofilm formation genes had contributed to the wide dissemination of A. baumannii 48 
IC2 within the Asia-Pacific region.  49 
   50 
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INTRODUCTION 51 
Nosocomial infections caused by multidrug-resistant Acinetobacter baumannii have been recognised 52 
as a serious global problem [1]. The epidemic spread of international clonal lineages has been 53 
observed worldwide [2]. Amongst several clonal lineages, international clone (IC) 2 is the most 54 
predominant clone that is widely spread within hospitals in many countries, particularly in Asia-55 
Pacific region where a high prevalence of antimicrobial resistance including resistance to 56 
carbapenems was already noted [2, 3]. The increase in carbapenem-resistant A. baumannii (CRAB) 57 
is mainly related to mobile genetic elements (such as transposons, insertion sequence (IS) elements 58 
and plasmids) which disseminate acquired antimicrobial resistance determinants [4]. In addition to 59 
the high propensity to develop and/or acquire resistance to multiple classes of antimicrobials, A. 60 
baumannii is known to be able to survive for a long period of time in hospital environment, which 61 
may lead to long-term persistence [5, 6]. 62 
In addition to the acquired antimicrobial resistance common in A. baumannii, genomic studies have 63 
demonstrated a high level of diversity within A. baumannii genomes even in the strains that are 64 
closely related. Frequently observed characteristics included variations in, (i) antimicrobial resistance 65 
islands (AbaR) such as AbaR4 (common in IC2), AbaR3 (common in ICI) and AbGRI, (ii) regions 66 
responsible for surface polysaccharide synthesis i.e. locus for capsule (K locus) and locus for outer 67 
core of lipid A moiety (OC locus), (iii) region for type VI secretion system (T6SS) and (iv) region 68 
for initial adhesion (csu operon). Our previous study indicated that genes associated with biofilm 69 
formation may be involved in the success of IC2 A. baumannii from Thailand [7]. These identified 70 
additional regions included pga locus and the bap gene. 71 
Although the A. baumannii IC2 is acknowledged as a successful clonal lineage worldwide 72 
(particularly in Asia), the comprehensive genetic features related to hospital “adaptiveness” of this 73 
clone remain unclear. Our study aims to evaluate the genetic diversification and relationship amongst 74 
the genomes of IC2 isolates collected from different countries in Asia-Pacific and to determine their 75 
characteristics that may have contributed to the success of this clonal lineage within this geographical 76 
region by utilising a comparative genome approach. 77 
  78 
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MATERIALS AND METHODS 79 
Bacterial isolates and their phenotypic and genotypic characterisation.  80 
Acinetobacter spp. clinical isolates were collected during 2009-2010 from four tertiary-care hospitals 81 
in Thailand (n=300), Singapore (n=25), Malaysia (n=9) and Japan (n=6) from our previous studies 82 
[7, 8]. (Table S1). From this collection of isolates, 21 A. baumannii isolates were genome sequenced 83 
to capture a range of countries, antimicrobial resistance phenotypes, genotypes and clonal lineages 84 
(Table 2) comprising isolates form Thailand (n=11), Singapore (n=5), Japan (n=3) and Malaysia 85 
(n=2). These included 17 CRAB from all countries and four CSAB isolates from Thailand (n=2) and 86 
Japan (n=2). 87 
Additional complete and draft A. baumannii genomes available on NCBI database were included in 88 
this study for genome content comparison and phylogenetic tree construction. These genomes and 89 
their GenBank accession number are ACICU (CP000863), AB0057 (CP001182), AYE (CU459141), 90 
ATCC17978 (CP000521), ATCC19606 (JMRY00000000) and MDR-ZJ06 (CP001937). 91 
DNA preparation and whole-genome sequencing, assembly and annotation 92 
Genomic DNA was extracted by using the UltraClean® Microbial DNA Isolation Kit (MO BIO 93 
Laboratories) according to manufacturer’s instructions. Whole-genome sequencing was performed 94 
using Illumina HiSeq and MiSeq paired-end technology. Sequence data was assembled using CLC 95 
genomic workbench version 7.5 (CLC Bio, Aarhus, Denmark). Genome annotation was carried out 96 
by using an automated annotation system RAST (http://rast.nmpdr.org/) [9] 97 
Genome analysis 98 
MLST and antimicrobial resistance genes were determined via submission to the MLST finder 1.7 99 
database [10] and ResFinder 2.1 database [11], respectively available from 100 
http://www.genomicepidemiology.org/. Contigs with the key carbapenemases and other β-lactamases 101 
were also manually annotated. The IS elements were identified using the IS Finder database 102 
(https://www-is.biotoul.fr/) [12]. The SNP analysis was performed through a web tool available at 103 
https://cge.cbs.dtu.dk/services/CSIPhylogeny/ to avoid the systematic biases caused by data 104 
generated by different platforms [13]. The phylogenetic trees were visualized and adjusted by using 105 
FigTree v1.4.2 available at http://tree.bio.ed.ac.uk/software/figtree/. 106 
Nucleotide sequence accession numbers 107 
62 
The draft genomes obtained in this study were deposited in the GenBank database under BioProject 108 
PRJNA255268. The GenBank accession numbers are JPKX00000000, JRTX00000000 - 109 
JRTZ00000000, JRQS00000000 - JRQY00000000, LAIL00000000 - LAIO00000000, 110 
LAIY00000000 - LAIZ00000000 and LAKO00000000 - LAKR00000000  111 
 112 
RESULTS 113 
Phenotypic and genotypic characterisations 114 
The 21 representative A. baumannii isolates comprised of 17 CRAB and 4 carbapenem-susceptible 115 
A. baumannii (CSAB) isolates. The antimicrobial susceptibility profiles of the 21 isolates were listed 116 
in Table 1. The 17 CRAB isolates were collected from Thailand (n=7), Singapore (n=4), Malaysia 117 
(n=2) and Japan (n=1). The four CSAB isolates were collected from Thailand (n=2) and Japan (n=2).  118 
Our previous studies have indicated that the majority of the isolates from each country belonged to 119 
international clone 2 (IC2). The in silico MLST showed that most of the strains (n=15) belonged to 120 
sequence type 2 (ST2) using the Pasteur scheme [14] which corresponds to IC2 (Table 2). Of the ST2 121 
isolates, 13 were CRAB while two were CSAB (both isolated in Japan). The core genome 122 
phylogenetic tree and SNP tree including our 21 strains and other six reference strains, where ACICU, 123 
strain of IC2, was utilised as a reference strain, revealed that most of the CRAB isolates were clustered 124 
together with the previously reported widely spread IC2 strain isolated from China MDR-ZJ06 125 
(Figure 1) [15]. Two CSAB isolates from Japan were also a part of the IC2 cluster. One isolate from 126 
Singapore was grouped with IC1 strains, AYE from France and AB0057 from the United States 127 
(Figure 1). 128 
Structure of antimicrobial resistance island 129 
Several antimicrobial resistance islands were identified within our isolates. These included multiple 130 
variants of AbaR4-type, AbaR-3 derived island and recently described AbGRI2 [16-18]. 131 
AbaR4-type resistance islands in 16 isolates were identified truncating the ATPase gene comM while 132 
comM in carbapenem-susceptible isolates from Thailand remained intact (n=2). IC2 isolates (15) 133 
possessed three variants of AbaR4-type including the transposition module (tni), orf4 (hypothetical 134 
protein), sup (sulphate permease) and uspA (universal stress protein) as a backbone (Figure 2A). The 135 
AbaR4-(I) was the predominant type found in 12 isolates. This resistance island was also identified 136 
in a carbapenem-resistant isolate from Japan (J65) with ISAba17 inserted (Figure 2A), which was 137 
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designated as Tn6167 (GenBank accession number JN968483) in A. baumannii from Australia [18]. 138 
The AbaR4-(I) was 34.4 kb in length and carried many resistant genes, i.e. strA, strB, tetA(B), tetR(B), 139 
sul2. The remaining types of AbaR4-type islands lacked a 9.4-kb region containing the tyrosine 140 
recombinase gene int and seven open reading frames with unknown function. 141 
sul2 (sulfonamide resistant dihydropteroate synthase) and glmM (glucosamine mutase) were not 142 
present in both AbaR4-(II) and AbaR4-(III). AbaR4-(III) also lacked a region containing transposition 143 
module adjacent to int region. AbaR4-(V) was found in one non-IC2 isolate from Malaysia. This 144 
AbaR variant did not contain the tetracycline resistance genes, tetA(B) and tetR(B) compared to other 145 
variants detected in IC2 isolates. 146 
Another type of resistance island designated AbGRI2 (GenBank accession number JX869489) was 147 
also identified [17]. AbGRI2-1 was found in a non-IC2 isolate from Thailand. This 16.4 kb resistance 148 
island contained blaTEM-1, a class 1 integron carrying the aacC1-orfP-orfP-orfQ-aadA1 cassette array 149 
and sul1 and multiple copies of IS26. The genetic content of this resistance island was similar to 150 
AbGRI2-1 with the absence of Tn6020 containing aphA1b. 151 
The class 1 integron region containing aacA4-catB8-aadA1 cassette array and sul1, which was similar 152 
to the cassette array in AbGRI2-3 identified in the genome of MDR-ZJ06, was also detected in two 153 
isolates (S10 and J2770). However the location of the class 1 integron of these two isolates was 154 
different from MDR-ZJ06. 155 
A CRAB isolate from Singapore, S36 was grouped together with reference genomes of IC1. The right 156 
side of AbaR3-type island, the original genomic island structure of A. baumannii of IC1 lineage [16], 157 
was detected the genome of S36. This consisted of a Tn6019-like transposase inserting and truncating 158 
comM, Tn6018 and a part of multiple antimicrobial resistance region (MARR) containing resX 159 
(partial invertase/resolvase) region, sul1, the class 1 integron region carrying aacC1-orfP-orfQ-aadA1 160 
gene cassette array and tnpA26 transposase of IS26. The sequence analysis showed that one copy of 161 
orfP was absent from this cassette array compared to that originally found in AbaR3. The left side of 162 
the AbaR3-type was unable to be identifed including the remaining part of the truncated comM in this 163 
isolate (Figure 2B).  164 
Genetic context of acquired antimicrobial resistance genes 165 
Regarding to carbapenem resistance, the blaOXA-23 was found in all CRAB isolates expect one isolate 166 
that harboured blaIMP-4. The blaOXA-23 gene in all isolates was found in a transposon Tn2006 composed 167 
of blaOXA-23, APTase gene, DEAE helicase gene and yeeA, flanked by two copies of ISAba1. In most 168 
of isolates, Tn2006 was located in a genomic resistance island AbaR. The location for Tn2006 169 
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inserting into AbaR-4 was showed in Figure 2.Class A β-lactamase gene blaTEM-1 was detected in nine 170 
isolates and was located in a transposon derived from Tn1 containing a truncated tnpR. Another class 171 
A β-lactamase gene, blaPER-1 was found in an isolate from Malaysia. The blaPER-1 gene was associated 172 
with Tn5393d which also carried aphA6b conferring aminoglycoside resistance in this isolate. 173 
Another transposon known as Tn6020 (flanked by two copies of IS26) was identified in eleven 174 
isolates carrying the aminoglycoside resistant gene, aphA1b.  175 
The metallo-β-lactamase gene, blaIMP-4 in S11 was located in a class 1 integron carrying the blaIMP-4-176 
qacG2-aacA4-catB3 cassette array. The 16S rRNA methyltransferase gene, armA was located within 177 
Tn1548 in ten isolates, flanked by transposase genes, tnpU and tnpD. The macrolide resistance 178 
conferring genes, mphE and msrE, were found in close proximity to armA in all armA-harboring 179 
isolates. Truncated IS26 was also found downstream of mphE and msrE. 180 
Intrinsic chromosomal resistance genes 181 
Variations of the naturally occurring oxacillinase gene blaOXA-51-like were observed in different A. 182 
baumannii isolates (Figure 3A). The blaOXA-66 gene was found in all IC2 isolates (n=15) including 183 
T271 which did not belong to IC2 according to MLST and phylogenetic tree analyses. However, 184 
T271 was grouped together with IC2 isolates by rep-PCR, indicating that this may be related to IC2. 185 
The IC1 isolate possessed blaOXA-69. blaOXA-51, blaOXA-65, blaOXA-68 and blaOXA-120 were identified 186 
amongst isolates that were neither IC1 nor IC2. In all A. baumannii isolates, blaOXA-51-like was not 187 
associated with ISAba1; however, located between fxsA and phosphinothricin N-acetyltransferase-188 
encoding genes.  189 
The variants of Acinetobacter-derived cephalosporinase encoding gene blaADC were identified in all 190 
isolates. The blaADC-30 gene was identified in five isolates and the sequence of 10 isolates showed 191 
99% identity (1 SNP) to blaADC-30. One isolate contained blaADC-56. The remaining blaADC sequences 192 
showed 99% similarity to blaADC-11 (n=2), blaADC-53 (n=1), blaADC-54 (n=1) and blaADC-64 (n=1). The 193 
presence of ISAba1 upstream of blaADC was observered in most of isolates (n=16) which were all IC2 194 
isolates and the IC2-related isolate, T271. The location of blaADC was between GTP cyclohydrolase 195 
and putative outer membrane protein encoding genes.  196 
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Chromosomal gene losses: Type VI secretion system (T6SS) 197 
The comparative genome analysis demonstrated that there were multiple events of chromosomal gene 198 
loss that may due to IS-mediated deletions (Figure 3). The large chromosomal region (49 kb) 199 
responsible for a type VI secretion system known as T6SS was absent in one carbapenem-susceptible 200 
isolate (T229) and one carbapenem-resistant isolate (M2). 29.5 kb of this region was absent in one 201 
carbapenem-resistance isolate form Singapore (S11), which possibly mediated by ISAba5 next to the 202 
deletion. The variation in T6SS region was observed in another susceptible isolate (T214) as well as 203 
an IC1 isolate (S36), while this region in all IC2 isolates was conserved. 204 
Region for biofilm formation: csu operon 205 
The regions of biofilm associated genes were investigated. The region harbouring genes responsible 206 
for chaperon-usher secretion system, CsuA/BABCDE known for pili assembly and biofilm formation 207 
was absent in two isolates. The presence of IS elements; ISAba1, ISAba12 and ISAba125 adjacent to 208 
the csu operon observe in seven isolates including three isolate from Japan. However, in two isolates 209 
from Japan, insertion by IS element did not cause a deletion in the csu region. In The IS-mediated 210 
deletion (IS26) of entire region was also found in reference genome MDR-ZJ06. In the ACICU 211 
genome, ISAba125 was inserted between csuA and csuA/B. There was no variation in a two-212 
component system BfmRS that regulated the csu operons amongst sequences of all isolates and 213 
reference strains. The gene encoding a complex biofilm-associated protein (Bap) was absent in three 214 
isolates (T229, T271 and S11) as well as in two reference strains, ATCC 17978 and ATTCC 19606. 215 
The pga locus encoding protein which synthesises surface polysaccharide and related to the strong 216 
biofilm phenotype was partially deleted by ISAba13 in one susceptible isolate T229. 217 
Variation in the loci for surface polysaccharides synthesis 218 
Variation in both OC and K loci was observed amongst genomes of 21 isolates. The OC locus is 219 
known for synthesis of the outer core of lipid A-core moiety and was previously explored [19, 20]. 220 
OCL1 type was the most predominant amongst these isolates. All IC2 isolates possessed the OCL1 221 
while variation in this locus was identified in non-IC2 isolates; OCL1 (n=1), OCL5 (n=1), OCL6 222 
(n=1) and OCL7 (n=1). In one carbapenem-susceptible isolate (T229), its OC locus was different 223 
from other previously reported loci. The genes encoding glycosyltransferase of new OCL shared the 224 
best blast matched with those in OCL7. However, the genes encoding nucleotide-sugar biosynthesis 225 
showed higher similarity to OCL6 (Figure 4). The structure of all OCL detected in this study was 226 
shown in Figure 4. 227 
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The locus for capsule biosynthesis, K locus, showed greater variation in comparison to OC loci across 228 
all isolates including isolates of IC2. The content and arrangement of the K locus, varied in different 229 
isolates. Four isolates have the KL3 which was identical to K locus in ATCC17978 with an ISAba1 230 
inserting at the same position in two isolates. KL2 which previously identified in ACICU strain found 231 
in three isolates, of which one isolate had ISAba1 insertion. Two isolates possessed KL7 which was 232 
similar to K locus in A. baumannii TCDC-AB0715. One isolate belonged to IC1 had KL1 which was 233 
the K locus of AYE strain. The remaining variations of K locus were demonstrated in Figure 4. 234 
 235 
DISCUSSION 236 
Here we conducted whole-genome sequencing and a comparative genome analysis of 21 A. 237 
baumannii collected from different countries in Asia where IC2 is reported as a predominant clone. 238 
These strains included 17 CRAB and 4 CSAB from Thailand, Singapore, Japan and Malaysia with 239 
various genotypic and phenotypic characteristics. The majority of isolates belonged to IC2. 240 
Additionally, an isolate of IC1 (second common of clonal linage within this region), and isolates that 241 
not clonally related to IC2 or IC1 were also investigated. We sought a better understanding of the 242 
genomic diversity within IC2 and amongst other clonal lineages within the Asian region. 243 
Antimicrobial resistance: islands and mechanisms 244 
Resistance island 245 
AbaR4-type resistance islands are known to be characteristic of the IC2 isolate. Here, we identified 246 
6 variants of AbaR4 and found that AbaR4-(I) was the predominant variant in IC2 isolates across all 247 
countries. AbaR4-(III) was the only variant observed in the non-IC2 strain from Malaysia. This 248 
AbaR-4-(III) type lacked a region containing tetracycline resistance genes which correlates with the 249 
observed tetracycline susceptible phenotype. The acquisition of Tn2006 carrying blaOXA-23, was the 250 
main mechanism observed conferring carbapenem resistance. Tn2006 is frequently found in AbaR-4 251 
of IC2 isolates; however we identified Tn2006 in our non-IC1 isolates. Additionally, two IC2 isolates 252 
from Japan harboured the AbaR4-(I) island without Tn2006. Tn2007 and Tn2008 which had been 253 
reported in USA and Europe were not found amongst our study isolates [21]. This suggests that 254 
AbaR4-(I) variant regardless the presence of Tn2006 was the characteristics of A. baumannii IC2 in 255 
this region.  256 
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ISAba1: association with intrinsic β-lactamases 257 
The recombination and mutation events were usually identified in the intrinsic blaOXA51-like and blaADC 258 
genes [22]. IS element ISAba1 was also recognised acting as a promoter region associated with the 259 
expression of these genes [23, 24]. However, the blaOXA-51-like gene in all IC2 isolates was blaOXA-66 260 
without the presence of ISAba1 upstream. This may suggest that all carbapenem resistance in our IC2 261 
isolates was related to acquired-type OXAs while OXA-66 alone is not enough to confer carbapenem 262 
resistance, observed in two carbapenem-susceptible IC2 isolates harbouring blaOXA-66 from Japan. 263 
Most of blaADC amongst IC2 isolates was blaADC-30 and its variant. ISAba1 was found upstream of 264 
blaADC variants in IC2 isolates while other variants, blaADC-11, blaADC-53, blaADC-54 and blaADC-64 of 265 
non-IC2 isolates were not associated with ISAba1. The cephalosporin resistance phenotypes in 266 
studied isolates were correlated to the presence of ISAba1 upstream of blaADC.  267 
Other resistance mechanisms 268 
Regarding the antimicrobial susceptibility of ampicillin-sulbactam, the correlation between the 269 
presence of blaTEM-1 and ampicillin-sulbactam resistance phenotype was observed. Our findings 270 
supported the notion that TEM-1 may represent a clinically relevant mechanism of sulbactam 271 
resistance in A. baumannii [25]. Even though the metallo-β-lactamase encoding gene, blaIMP-4 was 272 
found in only one isolate from Singapore, the order of gene cassette array carried by class 1 integron 273 
(blaIMP-4-qacG-aacA4-catB3) was identical to those previously identified in various 274 
Enterobacteriaceae and Acinetobacter spp. in Singapore, China, the Philippines and Australia [26, 275 
27]. The frequent presence of this resistance gene array in a broad host range may suggest the 276 
importance of blaIMP-4 array for carbapenem resistance in the Asia-Pacific regions. 277 
Variations in regions for pathogenicity and persistence 278 
The regions responsible for surface polysaccharide synthesis showed variation across all isolates and 279 
within IC2 isolates. The K locus amongst IC isolates was highly variable with 7 variations detected. 280 
Interestingly, four isolates of IC2 had a similar K locus to A. baumannii ATCC17978 strain that was 281 
not a strain of IC2. On the contrary, the OC locus is less variable with the predominant type OCL1 282 
identified in all IC2 isolates and IC2 reference strains, ACICU and MDR-ZJ06. It is known that 283 
surface polysaccharide is highly immunogenic and is an important virulence factor. Thus, the 284 
interaction with host immune system affecting this region may explain a unique form of OC locus 285 
observed amongst our IC2 isolates. Moreover, such variations observed of the K locus may impact 286 
in the difficulties to generate human immune response to A. baumannii.  287 
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Another conserved region in IC2 isolates is the T6SS region, present in all IC2 isolates. The entire 288 
region was absent in three non-IC2 isolates which may cause by IS-mediated deletion. The role of 289 
T6SS in A. baumannii is possibly involved in inter-bacterial interactions and competition with other 290 
bacteria species [28, 29]. The homology observed in this region amongst IC2 isolates may imply that 291 
this region is pivotal for A. baumannii IC2 to predominate and persist in environment.  292 
A similar incidence was observed in the adherence and biofilm associated region, csu region. The csu 293 
region was present in most of IC2 isolates while complete or partial deletions of this region were 294 
detected in six non-IC2 isolates. This suggests that the csu region might responsible for A. baumannii 295 
persistence, particularly for the IC2 clonal lineage. The minor variations in csu operon were found in 296 
three IC2 isolates collected from Japan. This may explain the different situation in Japan, where the 297 
prevalence of carbapenem-resistant A. baumannii is still low in spite of the heavy use of carbapenems 298 
[30]. However, only three isolates collected from Japan were investigated in this study. Further 299 
investigation and more studied isolates may be required for additional understanding of A. baumannii 300 
IC2 in Japan. 301 
In summary, despite a high genomic diversity amongst A. baumannii genomes, the unique genetic 302 
contexts of our IC2 Asian isolates were observed in the present study comprising (i) intrinsic β-303 
lactamase genes; blaOXA-66, and blaADC-30-like associated with ISAba1 upstream, (ii) resistance island 304 
AbaR4-(I), (iii) the OC locus type OCL1 and (iv) intact TS66 and csu operon regions. Although our 305 
approach is a snapshot paradigm to explore population and genetic structure of A. baumannii from 306 
different geographic locations, we have identified the areas of interest which may need further 307 
investigation to elucidate factors leading to the success of this clone. 308 
 309 
CONCLUSION 310 
To our knowledge, this is the first comparative genomic study to include isolates from multiple 311 
countries from Asia. The analysis of 21 A. baumannii genome sequences revealed a large diversity 312 
amongst our isolates. In addition to variable antimicrobial resistance genes and mobile elements, we 313 
identified characteristics found in IC2 isolates including the locus involved in surface polysaccharide 314 
synthesis and the chromosomal regions associated with bacterial interactions and biofilm formation. 315 
Taken together, these characteristics in combination with antimicrobial resistance genes may have 316 
contributed to the success and persistence of this international clone in the Asia-Pacific region. 317 
 318 
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Table 1. Disk susceptibility testing of Acinetobacter spp. 
  
Isolate 
ID 
Country of origin CRAB Antimicrobial susceptibility by disc diffusion testing1 
MEM IPM CTX CAZ FEP SAM TZP TIM AM CIP TE SXT 
T7 Thailand + R R R R R R R R R R R R 
T25 Thailand + R R R R R R R R R R R R 
T87 Thailand + R R R R R R R R R R R R 
T122 Thailand + R R R R R R R R R R R R 
T173 Thailand + R R R R R R R R R R R R 
T185 Thailand + R R R R R S R R R R R R 
T188 Thailand + R R R R R S R R R R R R 
T214 Thailand - S S I S S S S I S R S S 
T229 Thailand - S S S S S S S S S S S S 
T258 Thailand + R R R R R S R R R R R R 
T271 Thailand + R R R R I I R R S R R R 
J65 Japan + R R R R R S R R S R I R 
J133 Japan - S S R R R S S S S R R R 
J2770 Japan - S S R R S S I S R R R S 
M1 Malaysia + R R R R R R R R R R R R 
M2 Malaysia + R R R R R R R R R R I R 
S10 Singapore + R R R R R R R R R R R R 
S11 Singapore + R R R R R S S R S R S I 
S19 Singapore + R R R R R S R R R R R R 
71 
S36 Singapore + R R R R R S R R R R S I 
S46 Singapore + R R R R R I R R R R R R 
Note: CRAB = carbapenem-resistant Acinetobacter baumannii, 1Interpreted using CLSI 2014, MEM = meropenem, IPM = imipenem, CTX = 
cefotaxime, CAZ = ceftazidime, FEP = cefepime, SAM = ampicillin-sulbactam, TZP = piperacillin-tazobactam, TIM = ticarcillin-clavulatnate,  
AM = amikacin, CIP = ciprofloxacin, TE = tetracycline, SXT = trimethoprim-sulphamethoxazole.  
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Table 2. Selected phenotypic and genetic characteristics of Acinetobacter baumannii draft genomes 
 
Isolate 
ID 
Country of 
origin 
Specimen CRAB 
rep-
PCR 
MLST in silico β-lactamases 
16s rRNA 
methylase 
Other resistance genes 
Mutation in 
Pasteur PubMLST 
Intrinsic 
OXA 
Acquired 
OXA 
MBL ADC Class A gyrA parC 
T7 Thailand CSF + 
A ST2 ST208 OXA-66 OXA-23 
- 
ADC-30* TEM-1 ArmA 
strA, strB, aphA1b, mphE, msrE, 
sul2, tet(B) 
S83L S80L 
T25 Thailand Wound swab + 
A ST2 ST195 OXA-66 OXA-23 
- 
ADC-30* TEM-1 ArmA 
strA, strB, aphA1b, mphE, msrE, 
sul2, tet(B) 
S83L S80L 
T87 Thailand Blood culture + 
A ST2 ST457 OXA-66 OXA-23 
- 
ADC-30* TEM-1 ArmA 
strA, strB, aphA1b, mphE, msrE, 
sul2, tet(B) 
S83L S80L 
T122 Thailand Blood culture + 
A ST2 ST436 OXA-66 OXA-23 
- 
ADC-30* TEM-1 ArmA 
strA, strB, aphA1b, mphE, msrE, 
sul2, tet(B) 
S83L S80L 
T173 Thailand 
Nasopharyngea
l aspirate 
+ 
A ST2 ST195 OXA-66 OXA-23 
- 
ADC-30* TEM-1 ArmA 
strA, strB, aphA1b, mphE, msrE, 
sul2, tet(B) 
S83L S80L 
T185 Thailand Blood culture + 
A ST2 NEW-1 OXA-66 
OXA-23, 
OXA-72 
- 
ADC-30* - - strA, strB, aac(6’)ii, sul2, tet(B) S83L - 
T188 Thailand Sputum + 
A ST2 NEW-1 OXA-66 
OXA-23, 
OXA-72 
- 
ADC-30* - - strA, strB, aac(6’)ii, sul2, tet(B) S83L - 
T214 Thailand Sputum + 
A ST2 ST368 OXA-66 OXA-23 
- 
ADC-30* - - strA, strB, aac(6’)ii, sul2, tet(B) S83L S80L 
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T229 Thailand Urine + 
A ST653 NEW-2 OXA-66 OXA-23 
- 
ADC-30* TEM-1 - 
strA, strB, aacC1, aadA1, mphE, 
msrE,sul1, sul2, tet(B) 
S83L S80L 
T258 Thailand Sputum - 
E ST10 ST585 OXA-68  - 
- 
ADC-53 - -  - S83L S80W 
T271 Thailand Sputum - 
F ST215 NEW-3 OXA-120   - 
- 
ADC-64 - -  - - - 
J65 Japan Clinical + 
A ST2 ST208 OXA-66 OXA-23 
- 
ADC-30 - - strA, strB, sul2, tet(B) S83L S80L 
J133 Japan Blood culture - 
A ST2 ST208 OXA-66 - 
- 
ADC-56 - - strA, strB, sul2, tet(B) S83L S80L 
J2770 Japan Clinical - 
A ST2 ST473 OXA-66 - 
- 
ADC-30 - ArmA 
strA, strB,aphA1b, aacA4, aadA1, 
mphE, msrE, sul1, tet(B), catB8 
S83L S80L 
M1 Malaysia Clinical + 
A ST2 ST195 OXA-66 OXA-23 
- 
ADC-30* TEM-1 ArmA 
strA, strB,aphA1b, mphE, msrE, 
sul2, tet(B) 
S83L S80L 
M2 Malaysia Clinical + 
C ST16 ST355 OXA-51 OXA-23 
- 
ADC-11* PER-1 - 
strA, strB,aphA6, aphB6, mphE, 
msrE, sul2, tet39 
S83L S80L 
S10 Singapore Clinical + 
A ST2 NEW-4 OXA-66 OXA-23 
- 
ADC-30 TEM-1 ArmA 
strA, strB,aphA1b, aacA1, aadA1, 
mphE, msrE, sul1, tet(B), catB8 
S83L S80L 
S11 Singapore Clinical + 
D ST654 NEW-5 OXA-65 - IMP-4 ADC-54* - - 
aphA1b, aphA6, aacA4, aac(3’)-  
iid, mphE, msrE, sul1, catB3 
- - 
S19 Singapore Clinical + 
A ST2 ST218 OXA-66 OXA-23 
- 
ADC-30 - ArmA 
strA, strB,aphA1b, aacA4, aadA1, 
mphE, msrE, sul1, tetB, catB8,  
S83L S80L 
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S36 Singapore Clinical + 
B ST1 ST491 OXA-69 OXA-23 - ADC-11* - - aphA6, aacC1, aadA1, sul1 S83L S80L 
S46 Singapore Clinical + 
A ST2 ST219 OXA-66 OXA-23 
- 
ADC-30 - ArmA 
strA, strB,aphA1b, accA4, aadA1, 
sul1, tet(B), catB8 
S83L S80L 
*99% similarity variant 
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Figure 1. Phylogenetic tree of 21 A. baumannii isolates and 6 reference strains. 
The phylogenetic tree was constructed based on the basis of SNPs and was rooted with A. baumannii 
ACICU. Circles were colour coded by the country of origin with reference genomes coded in grey, 
where yellow indicates Thailand, blue indicates Japan, purple indicates Malaysia and red indicates 
Singapore. * represents carbapenem-susceptible isolate.  
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Figure 2. Structure of resistance island found in this study. 
The colour bars represent region that was homologous to the backbone. A) AbaR4-type variants. The 
downward arrows represent Tn2006 insertion sites. The Upward arrow represents the position of 
ISAba17 interruption in Tn6167. B) AbaR3-type island. Arrows indicate the position of IS26 
presented. 
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Figure 3. Distribution of variations in each region from comparative genome analysis. 
The phylogenetic tree from Figure 1 was placed at the top to correlate isolates with their genome 
features. Blue and pink shades generally represent the most common type of variation in IC2 and IC1 
respectively. Different colours indicate other variations unique to an individual isolate. Blank 
indicates that a region was not present. A) Intrinsic β-lactamase alleles. Pink colors represent blaOXA-
66 for blaOXA-51-like allele and blaADC-30-like in blaADC allele. Black dot indicates frameshift mutation of 
blaADC in ACICU. B) AbaR type interrupted comM. Pink shades represent AbaR-4 type with the 
dominant AbaR4-(I). Blue shades represent AbaR3-type. C) Chromosomal region loss. Pink color 
represents the presence of T6SS and csu region. Other colors represent different types of variants 
unique to the isolate. D) Surface polysaccharide. For OC locus, pink color represents OCL1, blue 
represents OCL3. In K locus, pink shades represent KL2 and KL2-like. 
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Figure 4. A schematic representation of all OC locus variants identified within this study. 
The linear comparison figure of OC loci was generated by using Easyfig 2.1 available from 
http://easyfig.sourceforge.net/. Arrows represent genes and their direction of transcription. The color 
scheme represents the predicted function of gene products – cyan; flanking, orange; 
glycosyltransferase (gtrOC), purple; nucleotide-sugar synthesis, red; acyl-transferase and blue; 
others. 
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Table S1. Genome sequence information used in 21 Acinetobacter baumannii isolates 
Isolate ID Country 
of origin 
Source Illumina 
Total 
length 
No. of 
Contigs 
N50 
Average 
contig 
length 
%GC 
content 
No. of 
CDs 
No. of 
RNAs 
Accession no. 
T7 
Thailand CSF MiSeq 3,938,552 71 113,955 55,473 38.8 3,742 66 JRQT00000000 
T25 
Thailand Wound HiSeq 3,862,654 80 141,246 48,283 38.9 3,648 66 JPKX00000000 
T87 
Thailand Blood culture HiSeq 3,877,500 77 148,892 50,357 38.9 3,689 67 JRQS00000000 
T122 
Thailand Blood culture MiSeq 3,938,051 83 109,995 47,446 38.9 3,772 61 JRTX00000000 
T173 
Thailand 
Nasopharygeal 
aspirate 
MiSeq 3,936,792 68 119,860 57,894 39 3,744 63 JRTY00000000 
T185 
Thailand Blood culture HiSeq 3,987,745 102 141,629 39,096 38.9 3,843 67 JRQU00000000 
T188 
Thailand Sputum HiSeq 3,985,383 108 130,770 36,895 38.9 3,806 66 JRQV00000000 
T258 
Thailand Sputum HiSeq 3,799,157 38 205,362 99,978 38.9 3,577 66 JRTZ00000000 
T271 
Thailand Sputum HiSeq 3,679,512 125 74,692 29,436 39 3,507 67 JRQW0000000 
T214 
Thailand Sputum HiSeq 3,949,699 102 96,802 38,723 39.1 3,787 67 JRQX00000000 
T229 
Thailand Urine HiSeq 3,868,725 89 105,643 43,469 39 3,658 66 JRQY00000000 
J65 Japan Unknown HiSeq 3,897,454 62 113,238 62,862 39 3,699 68 LAKO00000000 
J133 Japan Blood culture MiSeq 3,887,746 114 102,009 34,103 39 3,696 65 LAKQ00000000 
J2770 Japan Unknown MiSeq 3,944,409 103 102,056 38,295 39 3,736 63 LAKR00000000 
M1 Malaysia Unknown MiSeq 3,869,793 89 106,127 43,481 39 3,651 65 LAIL00000000 
M2 Malaysia Unknown HiSeq 4,132,915 122 101,807 33,876 38.9 3,984 69 LAKP00000000 
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S10 Singapore Unknown MiSeq 4,073,148 88 110,786 46,286 38.8 3,895 67 LAIM00000000 
S11 Singapore Unknown HiSeq 4,125,959 206 47,424 20,029 39.1 4,026 68 LAIY00000000 
S19 Singapore Unknown MiSeq 4,054,129 64 154,245 63,346 38.9 3,882 65 LAIN00000000 
S36 Singapore Unknown MiSeq 4,022,630 64 191,442 62,854 38.9 3,844 67 LAIO00000000 
S46 Singapore Unknown MiSeq 4,043,025 70 133,482 57,758 38.9 3,875 63 LAIZ00000000 
 
 83 
Chapter 5. Discussion 
5.1 Outline of findings 
The detection of species specific intrinsic oxacillinases genes of Acinetobacter spp. was addressed in 
Chapter 2 [102]. Here, a total of six intrinsic blaOXAs of non-baumannii Acinetobacter species were 
determined by the multiplex PCR. Further, the blaOXA genes and its IS element associated with OXA 
of Acinetobacter non-baumannii were characterised. This chapter also included a case of unique A. 
pittii isolated from Australia containing multiple carbapenemases and two other beta-lactamases 
[103].  
The central focus of this thesis is the molecular epidemiology and genome of A. baumannii as 
described in Chapter 3 and 4. Three hundred Acinetobacter spp. isolates were included in the 
molecular epidemiology. Twenty-four Acinetobacter spp. isolates were genome sequenced and 
analysed in these two chapters.  
A major finding of this thesis is that OXA-23 carbapenemase and the complete set of biofilm-
producing locus or operon are the two significant contributing factors to the dominance of A. 
baumannii IC2 in a university hospital in Bangkok, Thailand (Chapter 3). The comparison of the 
genome data of A. baumannii and non-baumannii shows significantly higher number of antimicrobial 
resistance genes present amongst carbapenem-resistant isolates in comparison to the carbapenem-
susceptible Acinetobacter spp. The detailed analysis of the resistance islands and pathogenicity 
islands shows that the cluster of antimicrobial resistance genes are generally concentrated in IC2 
(Chapter 4). Detailed findings for each chapter of this thesis are described in the following three main 
sub-headings. 
5.1.1 Detection of species specific oxacillinases genes within Acinetobacter and characterisation 
of pathogenic non-baumannii Acinetobacter spp.  
To identify species specific intrinsic oxacillinases genes in Acinetobacter species, a multiplex PCR 
was developed. The multiplex PCR is able to aid in differentiation of six Acinetobacter species 
including A. lwoffii/ A. schindleri (blaOXA-134-like), A. johnsonii (blaOXA-211-like), A. calcoaceticus 
(blaOXA-213-like), A. haemolyticus (blaOXA-214-like) and A. bereziniae (blaOXA-228-like). A total of 30 novel 
oxacillinases are described here. The majority of these novel blaOXA variants belonged to the blaOXA 
from A. calcoaceticus, i.e. blaOXA-213-like. A novel finding was the presence of an unusual insertion 
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element, ISAba11 upstream to blaOXA-214 [102]. Regardless of the presence of ISAba11, the isolates 
remained susceptible to carbapenem. 
The study of oxacillinase genes amongst isolates collected worldwide has contributed to the 
understanding of the acquired-types of blaOXA in Acinetobacter spp. other than A. baumannii. Here, 
blaOXA-23, blaOXA-58, blaOXA-40-like and blaOXA-143-like were described. A. pittii was the predominant 
species (67%) harbouring blaOXAs collected from Asia, Europe, South America and North America 
(Appendix A2.4) [104]. 
A unique case of A pittii ST119 harbouring blaIMP-4, blaOXA-421, blaOXA-96 in Australia is included in 
this Chapter 2.2 [103]. The isolate was initially identified carbapenem resistant A. calcoaceticus - A. 
baumannii complex. Conventional PCR identified the blaIMP-4, which is extremely uncommon 
amongst Acinetobacter spp. in Australia. Detailed molecular characterisation followed by whole 
genome sequencing revealed other important features of this isolate, including the presence of three 
other β-lactamase encoding genes, blaOXA-96 (blaOXA-58-like), blaCARB-2 and a novel blaOXA, blaOXA-421. 
This report also shows the first description of the blaOXA-96 in Australia. 
Overall, this chapter has multi-faceted approaches to the understanding of non- baumannii 
Acinetobacter that are often overlooked due to its low prevalence in comparison to the carbapenem-
resistant A. baumannii. 
5.1.2 Predominance of international clone 2 OXA-23-producing Acinetobacter baumannii and 
insights into the genome of Acinetobacter spp.  
Chapter 3 is the tenet of this thesis containing the detailed description of A. baumannii IC2 from 
Thailand using molecular epidemiology and the overview of the genome characteristics. The 
predominance of A. baumannii IC2 is the highlight of this chapter. A. baumannii IC2 was found in 
80% of the 300 study isolates from Thailand. In addition to this study, the molecular characterisation 
of A. baumannii from Turkey (n=65) is described in Appendix 3.3 of this thesis. One hundred percent 
of A. baumannii from Turkey were OXA-23-producers. Further, 97% of the study isolates from 
Turkey were A. baumannii IC2. However, due to the main focus of this manuscript is on OXA-48-
producing Klebsiella pneumoniae, the molecular epidemiology data of A. baumannii was not included 
in this published manuscript [105]. The published article, table of blaOXA characterisation and figure 
of clonal analysis are presented in Appendix 2.1, 3.3 and 3.4, respectively. These two studies showed 
the dominance of A. baumannii IC2 from both institutes in Thailand and Turkey.  
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Resistance to broad-spectrum aminoglycoside conferred by armA, i.e. 16S rRNA methylase was 
commonly identified amongst A. baumannii IC2. A. nosocomialis (1.3%) and A. pittii (0.7%) were 
isolated in much lower prevalence. Limited diversity was observed amongst A. baumannii IC2. A 
total of 13 representative Acinetobacter isolates, comprised of A. baumannii (n=11), A. nosocomialis 
(n=1) and A. pittii (n=1) were whole genome sequenced. Our WGS data from this manuscript are 
publicly available through www.ncbi.nlm.nih.gov with BioProject PRJNA255268 (Chapter 4 and 
Table S1). 
Within this study, the carbapenemase blaOXA-66 was generally associated with A. baumannii IC2. 
Three isolates were detected to have interruption of the blaOXA-78 by ISAba19. Interestingly, these 
isolates were carbapenem susceptible. Other interesting features of the A. baumannii IC2 were the 
backbone of resistance AbaR4 which was integrated into a specific genomic site, comM (ATPase 
gene). AbaR4 was commonly found in IC2, which contained uspA (universal stress protein A), sup 
(sulphate permease), tet(B) (tetracycline resistance), strB (aminoglycoside resistance) and strA 
(aminoglycoside resistance) including Tn2006 that carries blaOXA-23 [16]. The armA was located in 
the Tn1548 which was outside the AbaR4 and in close proximity with two macrolide resistance genes, 
mphE and msrE. The set of antimicrobial resistance genes, i.e. blaOXA-23, blaOXA-66, blaADC, blaTEM-1, 
strA, strB, aphA1, mphE, msrE, sul2 and tetB represented the typical characteristics of CRAB at 
Siriraj Hospital, Bangkok. 
Another important finding of A. baumannii were the biofilm-related genes. All the key biofilm-related 
genes in Acinetobacter spp, i.e. bap, csu locus, bfmRS and the pga locus were identified in the eight 
ST2 strains (IC2) of the 13 isolates being genome sequenced. In contrast, the Acinetobacter non-IC2 
generally had one or two of the biofilm-related genes absent in comparison. This shows the 
association between biofilm-related genes and the persistence of IC2 in the hospital environment. 
5.1.3 Genomes of Acinetobacter baumannii and non-baumannii Acinetobacter. 
The genome of 21 representative isolates including 17 CRAB and 4 CSAB are described in Chapter 
4. This study was the first comparative whole genome sequence analysis from multiple countries from 
Asia. In general, whole genome sequencing and analysis of CRAB isolates shows the dominance of 
OXA-23-producing A. baumannii IC2. The in silico MLST showed that 13 CRAB isolates and 2 
CSAB belonged to ST2. ST1 was found in one isolate from Singapore.  
The antimicrobial resistance island, AbaR4-type, which was identified within comM (ATPase gene) 
contains multiple antimicrobial resistance genes. In contrast, comM did not contain any antimicrobial 
resistance gene within carbapenem-susceptible isolates from Thailand. The AbaR4 contained genes 
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encoding resistance to aminoglycosides, tetracyclines and sulphonamides. In isolates positive with 
blaTEM-1, blaTEM-1 was located in a Tn1 derived transposon within the second island, AbGRI2 together 
with aacC1 and aadA1, gentamicin and streptomycin resistance genes, respectively. 
The blaOXA-23, which was located in a transposon Tn2006, was the most common carbapenem 
resistance mechanism in CRAB. The composition of Tn2006 was identical to previously described 
Tn2006 comprising of blaOXA-23, APTase gene, DEAE helicase gene and yeeA, flanked by two 
copies of ISAba1 [106]. blaIMP-4 was identified in one isolate from Singapore and located in an 
integron class 1. The composition of integron class 1 containing blaIMP-4-qacG2-aacA4-catB3 was 
identical to the integron class 1 in A. pittii ST119 as described in Chapter 2.3 [103]. 
The comparative genome analysis revealed variations in the loci responsible for the surface 
polysaccharide (K and OC loci) and regions of T6SS and csu operon. The unique genetic features of 
our IC2 Asian isolates were observed in the present study comprising (i) intrinsic β-lactamase genes; 
blaOXA-66, and blaADC-30-like associated with ISAba1 upstream, (ii) resistance island AbaR4-(I), (iii) the 
OC locus type OCL1 and (iv) intact TS66 and csu operon regions. 
 
5.2 General discussion and conclusion 
This thesis contains the first comprehensive analysis of the molecular epidemiology and genome of 
A. baumannii from Thailand. In addition, the genome analysis of A. baumannii from three other 
countries were included and compared with the genome of A. baumannii from Thailand. Various 
novel and previously described blaOXA are idetified in this thesis. Although this is a small sample 
size, the correlation between blaOXA-51-like variants showed a close association with the international 
clone designation, which fitted well with previously described studies [107, 108]. The dissemination 
of OXA-23-producing A. baumannii by clonal expansion in Siriraj Hospital is concerning. However, 
the dominance of OXA-23 has been also reported elsewhere, including in Australia [29]. This clonal 
expansion was potentially due to environmental contamination and person-to-person contact [2]. 
The genome analysis of isolates showed that the two evident characteristics present in A. baumannii 
IC2 are antimicrobial resistance genes and the biofilm forming locus or operon. The exception was a 
carbapenem resistant A. baumannii from Japan (J65) which possessed blaOXA-23 without a complete 
set of biofilm forming locus or operon. This may be an early indication of OXA-23 producing IC2’s 
inability to disseminate in Japan. It is interesting that only Tn2006 was found in the 21 study isolates 
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which had been genome sequenced. Tn2007 and Tn2008, which had been reported in USA and 
Europe, were not found amongst our study isolates [97]. 
The antimicrobial susceptibility of 21 isolates showed that the majority of the isolates were 
susceptible to ampicillin-sulbactam. Ampicillin-sulbactam susceptible isolates generally did not 
possess blaTEM-1. However, the high MIC to sulbactam has been associated with possession of blaTEM-
1 [109]. Ampicillin-sulbactam MICs of two carbapenem-resistant and five carbapenem-susceptible 
Acinetobacter spp. were within the susceptible range (Appendix 3.1). Ampicillin-sulbactam 
susceptibility among A. baumannii has also been reported in other countries [110, 111]. Therefore, 
this antimicrobial has been recommended as a treatment option for infections by A. baumannii [112]. 
Ampicillin-sulbactam has been successful in treating patients with carbapenem susceptible A. 
baumannii infections. However, lower success rates were reported, when this antimicrobial agent was 
used to treat carbapenem resistant A. baumannii [113]. 
 
5.3 Future directions 
Studies in this thesis have expanded knowledge in important aspects of carbapenem resistance and 
overall whole genome sequence description of A. baumannii and non-baumannii. The dissemination 
of carbapenemase genes coupled by 16S rRNA methylase genes conferring aminoglycoside 
resistance will likely escalate. Therefore, the threat posed by limited treatment to clinically important 
antimicrobial agents should not be underestimated. Various regimens of combination therapy have 
been proposed for the treatment of CRAB infections [112]. Our findings of typical clonality and 
antimicrobial resistance phenotypes may facilitate justification of empirical combination therapy at 
Siriraj hospital. 
The clonal commonality of OXA-23-producing A. baumannii in this study is possibly a consequence 
of environmental contamination and person-to-person transmission. This emphasises the importance 
of elimination of CRAB colonisation from the patients and hospital environment in order to reduce 
transmission. Disinfectants and antiseptics have been widely used to control colonisation such as 
chlorhexidine and propenol, PVP-iodine and tricolsan [52, 53, 114]. However, the MIC of 
chlorhexidine in A. baumannii increased after the use of chlorhexidine to control colonisation in 
patients [115]. This suggests that apart from active surveillance for antimicrobial resistance, 
continuation of surveillance for chlorhexidine including other disinfectants utilised in infection 
prevention schemes, may require. 
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Extensive analysis of the transmission of A. baumannii in an intensive care unit using a mathematical 
model has previously shown that increasing the nurse-patient ratio and improvement of 
environmental contamination including increasing hand washing rate resulted in the decline of A. 
baumannii colonisation [116]. Additionally, antimicrobial stewardship has significantly decreased 
the rate of antimicrobial resistance rates in A. baumannii without affecting the medical quality [117]. 
Taken together, a possible research area that may help control the dissemination of A. baumannii is 
to establish an effective approach in “source control” in particular to eradicate colonisation of A. 
baumannii from patients and the hospital environment based on current literature and concepts 
elucidated from this thesis. 
To complement the infection control aspect in order to eradicate IC2, the development of effective 
vaccines is also required. Various attempts have been made to develop vaccines for A. baumannii 
over the past few years such as using K1 capsular polysaccharide and other novel vaccine candidates 
[118-120]. However, based on the recent studies to understand the surface of polysaccharides of A. 
baumannii, A. baumannii possessed lipooligosaccharide (LOS) and not lipopolysaccharide (LPS) 
[64]. Polysaccharide is highly immunogenic, in contrast to lipooligosaccharide that is not. This will 
be challenging in the development of potential targets of vaccines against A. baumannii. The genome 
data of this thesis, which is available publicly, may be used in finding potential vaccine candidates. 
Lastly, further understanding the A. baumannii at the proteomic level may also help in the vaccine 
development. 
The epidemiology and molecular epidemiology data of A. baumannii from countries in South East 
Asia is currently limited to Thailand, Singapore, Malaysia, Indonesia and Vietnam [81, 121, 122]. In 
fact, countries in this region and the neighbouring countries, such as Myanmar, the Philippines and 
Papua New Guinea, which have no epidemiological data of A. baumannii, may have similar rates of 
CRAB to Thailand. In some countries, the genus and species identification of A. baumannii is still 
problematic and not implemented yet in clinical diagnostics. Therefore, an extensive surveillance and 
screening using molecular methods in wider regions of South East Asia should be proposed, utilising 
methods such as Multiplex PCR developed in this thesis which can rapidly detect and identify 
Acinetobacter spp. in this region. Overall, there are multiple aspects of A. baumannii the warrant 
further investigation to overcome the problems by A. baumannii in greater details.  
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APPENDICES 
Table A1. Molecular and characterisation of Acinetobacter study isolates from Thailand
isolate AM ATM CIP FEP IPM MEM Remark Date Source Ward OXA-51 OXA-23 OXA-40 OXA-58ISAba1/OXA-51 SG Species ArmA
T1 R 9 R R R R Jan-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T2 R 12 R R R R Jan-10 Pleural fluidICU 1 1 0 0 0 1 A. baumannii 1
T3 R 12 R R R R Jan-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T4 R 10 R R R R Jan-10 Sputum OPD 1 1 0 0 0 1 A. baumannii 1
T5 R 11 R R R R Jan-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T6 R 18 R I R R Jan-10 Sputum ICU 1 1 0 0 0 4 A. baumannii 1
T7 R 11 R R R R Jan-10 CSF ICU 1 1 0 0 0 1 A. baumannii 1
T8 R 9 R R R R Jan-10 Hemoculture OPD 1 1 0 0 0 1 A. baumannii 1
T9 R 11 R R R R Jan-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T10 R 7 R R R R Jan-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T11 R 12 R R R R Feb-10 Sputum Surgery 1 1 0 0 0 1 A. baumannii 1
T12 R 10 R R R R Feb-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T13 R 18 R I R R Feb-10 Sputum ICU 1 1 0 0 0 4 A. baumannii 1
T14 R 16 R I R R Feb-10 Sputum Medicine 1 1 0 0 0 4 A. baumannii 1
T15 R 10 R R R R Feb-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T16 R 11 R R R R Feb-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T17 R 10 R R R R Feb-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T18 R 13 R R R R Feb-10 Peritoneal dialysisICU 1 1 0 0 0 1 A. baumannii 1
T19 R 7 R R R R Feb-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T20 R 13 R R R R Feb-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T21 R 7 R R R R Feb-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T22 R 11 R R R R Feb-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T23 R 13 R R R R Feb-10 Pus OPD 1 1 0 0 0 1 A. baumannii 1
T24 R 7 R R R R Feb-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T25 R 14 R R R R Feb-10 Swab Surgery 1 1 0 0 0 1 A. baumannii 1
T26 R 7 R R R R Feb-10 Sputum Surgery 1 1 0 0 0 1 A. baumannii 1
T27 R 14 R R R R Feb-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T28 R 13 R R R R Feb-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T29 R 16 R R R R Feb-10 Urine Medicine 1 1 0 0 0 4 A. baumannii 1
T30 R 13 R R R R Feb-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T31 R 12 R R R R Feb-10 Urine Orthopedic 1 1 0 0 0 1 A. baumannii 1
T32 R 11 R R R R Feb-10 Sputum Surgery 1 1 0 0 0 1 A. baumannii 1
T33 R 10 R R R R Feb-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T34 R 8 R R R R Feb-10 Urine Medicine 1 1 0 0 0 1 A. baumannii 1
T35 R 7 R R R R Feb-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T36 R 8 R R R R Feb-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T37 R 7 R R R R Feb-10 Sputum Surgery 1 1 0 0 0 1 A. baumannii 1
T38 R 15 R R R R Feb-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T39 R 12 R R R R Feb-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T40 R 11 R R R R Feb-10 Urine Medicine 1 1 0 0 0 1 A. baumannii 1
T41 R 16 R I R R Feb-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 0
T42 R 11 R R R R Feb-10 Urine Medicine 1 1 0 0 0 1 A. baumannii 1
T43 R 12 R R R R Feb-10 Sputum RCU 1 1 0 0 0 1 A. baumannii 1
T44 R 7 R R I R Feb-10 Urine Surgery 1 1 0 0 0 5 A. baumannii 1
T45 R 8 R R R R Feb-10 Lavage ER 1 1 0 0 0 1 A. baumannii 1
T46 R 13 R R R R Feb-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T47 R 11 R R R R Feb-10 Tissue biopsy84/3 1 1 0 0 0 1 A. baumannii 1
T48 R 7 R R R R Feb-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T49 R 10 R R R R Feb-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T50 R 11 R R R R Feb-10 Sputum Surgery 1 1 0 0 0 1 A. baumannii 1
T51 R 9 R R R R Feb-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T52 R 10 R R R R Feb-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T53 R 13 R R R R Feb-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 0
T54 R 10 R R R R Mar-10 Urine Surgery 1 1 0 0 0 1 A. baumannii 1
T55 R 7 R R R R Mar-10 Urine Medicine 1 1 0 0 0 5 A. baumannii 1
T56 R 12 R R R R Mar-10 Sputum MV 2 ] 1 1 0 0 0 1 A. baumannii 1
T57 R 9 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T58 R 9 R R R R Mar-10 Sputum CCU 1 1 0 0 0 1 A. baumannii 1
T59 R 7 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T60 R 7 R R R R Mar-10 Hemoculture Medicine 1 1 0 0 0 1 A. baumannii 1
T61 R 13 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 0
T62 R 12 R R R R Mar-10 Pus Surgery 1 1 0 0 0 1 A. baumannii 1
T63 S R I R R Mar-10 Sputum Medicine 1 1 0 0 0 4 A. baumannii 1
T64 R 10 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T65 R 7 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 0
T66 R 7 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 0
T67 R 15 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 0
T68 R 10 R R R R Mar-10 Hemoculture Bone Marrow 1 1 0 0 0 1 A. baumannii 1
T69 R 9 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T70 R 7 R R R R Mar-10 Urine Medicine 1 1 0 0 0 1 A. baumannii 1
T71 R 7 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T72 S 20 R S R R Mar-10 Sputum ICU 1 1 0 0 0 4 A. baumannii 0
T73 R 15 R R R R Mar-10 Others Medicine 1 1 0 0 0 1 A. baumannii 0
T74 R 7 R R R R Mar-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T75 R 12 R I R R Mar-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T76 R 8 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T77 R 15 R R R R Mar-10 Swab Medicine 1 1 0 0 0 1 A. baumannii 1
T78 R 10 R R R R Mar-10 Hemoculture ICU 1 1 0 0 0 1 A. baumannii 1
T79 R 9 R R R R Mar-10 Tip ICU 1 1 0 0 0 1 A. baumannii 1
T80 R 14 R R R R Mar-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T81 R 16 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T82 R 10 R R R R Mar-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T83 R 12 R R R R Mar-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T84 R 7 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T85 R 14 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 0
T86 R 13 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 0
T87 R 9 R R R R Mar-10 Hemoculture ICU 1 1 0 0 0 1 A. baumannii 1
T88 R 16 R I R R Mar-10 Hemoculture Medicine 1 1 0 0 0 1 A. baumannii 1
T89 R 10 R R R R Mar-10 Hemoculture ICU 1 1 0 0 0 1 A. baumannii 1
T90 R 8 R R R R Mar-10 Others ICU 1 1 0 0 0 1 A. baumannii 1
T91 R 12 R R R R Mar-10 Sputum CCU 1 1 0 0 0 1 A. baumannii 1
T92 R 7 R R R R Mar-10 Urine Medicine 1 1 0 0 0 5 A. baumannii 0
T93 R 10 R R R R Mar-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T94 R 9 R R R R Mar-10 Others ICU 1 1 0 0 0 1 A. baumannii 1
T95 R 7 R R R R Mar-10 Sputum Other 1 1 0 0 0 5 A. baumannii 0
T96 R 11 R R R R Mar-10 Sputum RCU 1 1 0 0 0 1 A. baumannii 1
T97 R 10 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T98 R 10 R R R R Mar-10 Urine Medicine 1 1 0 0 0 1 A. baumannii 1
T99 R 7 R R R R Mar-10 Urine Medicine 1 1 0 0 0 5 A. baumannii 0
T100 R 12 R R R R Mar-10 Hemoculture Medicine 1 1 0 0 0 1 A. baumannii 1
T101 R 10 R R R R Mar-10 Sputum Orthopedic 1 1 0 0 0 1 A. baumannii 1
T102 R 9 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T103 R 16 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 0
T104 R 8 R R R R Mar-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T105 R 7 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 0
T106 R 7 R R R R Mar-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T107 R 7 R R R R Mar-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T108 R 16 R R R R Mar-10 Swab Medicine 1 1 0 0 0 1 A. baumannii 1
T109 R 10 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T110 R 10 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T111 R 12 R R R R Mar-10 Sputum RCU 1 1 0 0 0 1 A. baumannii 1
T112 R 11 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T113 R 7 R R R R Mar-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T114 R 8 R R R R Mar-10 Swab ICU 1 1 0 0 0 1 A. baumannii 1
T115 R 12 R R R R Mar-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T116 R 12 R R R R Mar-10 Sputum RCU 1 1 0 0 0 1 A. baumannii 1
T117 R 10 R R R R Mar-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T118 R 15 R R R R Mar-10 Urine Medicine 1 1 0 0 0 1 A. baumannii 0
T119 R 10 R R R R Mar-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T120 R 12 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T121 S 16 S S S S Mar-10 Sputum Medicine 1 0 0 0 0 7 A. baumannii 0
T122 R 9 R R R R Mar-10 Hemoculture Bone Marrow 1 1 0 0 0 1 A. baumannii 1
T123 R 7 R R R R Mar-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T124 R 11 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 0
T125 R 12 R R R R Mar-10 Sputum RCU 1 1 0 0 0 1 A. baumannii 1
T126 R 16 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 0
T127 R 12 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T128 R 15 R R R R Mar-10 Urine Medicine 1 1 0 0 0 4 A. baumannii 1
T129 R 12 R R R R Mar-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T130 R 9 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T131 R 10 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T132 R 9 R R R R Mar-10 Tissue biopsyICU 1 1 0 0 0 1 A. baumannii 1
T133 R 12 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T134 R 11 R R R R Mar-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T135 R 7 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T136 R 12 R R R R Mar-10 Sputum Surgery 1 1 0 0 0 1 A. baumannii 1
T137 R 10 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T138 R 8 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T139 R 15 R R R R Mar-10 Sputum OPD1 1 1 0 0 0 1 A. baumannii 1
T140 R 8 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T141 R 8 R R R R Mar-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T142 R 7 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T143 R 11 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T144 R 13 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T145 R 12 R R R R Apr-10 Sputum MV 2 ] 1 1 0 0 0 1 A. baumannii 1
T146 R 15 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 4 A. baumannii 1
T147 R 11 R R R R Apr-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T148 R 13 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T149 S 12 R R R R Apr-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T150 R 12 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T151 R 10 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T152 R 7 R R R R Apr-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T153 R 9 R R R R Apr-10 Swab ICU 1 1 0 0 0 1 A. baumannii 1
T154 R 11 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T155 R 7 R R R R Apr-10 Urine Medicine 1 1 0 0 0 1 A. baumannii 1
T156 R 11 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T157 R 7 R R R R Apr-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T158 S 12 R R R R Apr-10 Sputum ICU 1 1 0 0 0 4 A. baumannii 0
T159 R 7 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T160 R 12 R R R R Apr-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T161 R 13 R R R R Apr-10 Sputum MV 2 ] 1 1 0 0 0 1 A. baumannii 1
T162 R 16 R I R R Apr-10 Sputum ICU 1 1 0 0 0 4 A. baumannii 1
T163 R 13 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T164 R 7 R R R R Apr-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T165 S 11 R R R R Apr-10 Sputum Orthopedic 1 1 0 0 0 4 A. baumannii 0
T166 R 13 R R R R Apr-10 Urine OPD 1 1 0 0 0 1 A. baumannii 1
T167 R 7 R R R R Apr-10 Urine 84/6 0 1 0 0 0 5 A. pittii 0
T168 R 11 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T169 R 7 R R R R Apr-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T170 R 9 R R R R Apr-10 Sputum Orthopedic 1 1 0 0 0 1 A. baumannii 1
T171 R 7 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T172 R 12 R R R R Apr-10 Sputum RCU 1 1 0 0 0 1 A. baumannii 1
T173 R 9 R R R R Apr-10 Aspirate Pediatric 1 1 0 0 0 1 A. baumannii 1
T174 R 10 R I R R Apr-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T175 R 10 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T176 R 15 R R R R Apr-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T177 R 9 R R R R Apr-10 Sputum OPD 1 1 0 0 0 1 A. baumannii 1
T178 R 7 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T179 S 11 R R R R Apr-10 Urine Orthopedic 1 1 0 0 0 4 A. baumannii 0
T180 R 7 R R R R Apr-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T181 R 12 R R R R Apr-10 Sputum MV 2 ] 1 1 0 0 0 1 A. baumannii 1
T182 R 16 R I R R Apr-10 Sputum Surgery 1 1 0 0 0 1 A. baumannii 1
T183 R 10 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T184 R 11 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T185 R 14 R R R R Apr-10 Hemoculture Surgery 1 1 1 0 0 1 A. baumannii 0
T186 R 8 R R R R Apr-10 Hemoculture Medicine 1 1 0 0 0 1 A. baumannii 1
T187 R 7 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T188 R 15 R R R R Apr-10 Sputum OPD 1 0 1 0 0 1 A. baumannii 0
T189 R 12 R R R R Apr-10 Sputum OPD 1 0 1 0 0 1 A. baumannii 0
T190 R 10 R R R R Apr-10 Sputum OPD 1 1 0 0 0 1 A. baumannii 1
T191 R 9 R R R R Apr-10 Hemoculture OPD 1 1 0 0 0 1 A. baumannii 1
T192 R 10 R R R R Apr-10 Swab Medicine 1 1 0 0 0 1 A. baumannii 1
T193 R 7 R R R R Apr-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T194 R 10 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T195 R 11 R R R R Apr-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T196 R 11 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T197 R 9 R R R R Apr-10 Sputum RCU 1 1 0 0 0 1 A. baumannii 1
T198 R 7 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T199 R 7 R R R R Apr-10 Sputum ICU 1 1 0 0 0 1 A. baumannii 1
T200 R 8 R R R R Apr-10 Sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T201 S 16 S S S S May-10 sputum ICU 0 0 0 0 0 all- A. nosocomialis 0
T202 S 18 S S S S May-10 Urine Surgery 1 0 0 0 0 12 (1kb)A. baumannii 0
T203 S 13 S S S S May-10 sputum Surgery 1 0 0 0 0 9 A. baumannii 0
T204 S 10 R S S S May-10 sputum OPD 1 0 0 0 0 5 A. baumannii 0
T205 S 15 S S S S May-10 sputum ICU 0 0 0 0 0 all- A. nosocomialis 0
T206 S 14 S S S S May-10 sputum ICU 1 0 0 0 0 9 A. baumannii 0
T207 S 14 S S S S Jun-10 sputum ICU 1 0 0 1 0 9 A. baumannii 0
T208 S 16 R S S S Jun-10 sputum Medicine 1 0 0 0 0 5 A. baumannii 0
T209 R 14 S S S S psuedo-like Jun-10 sputum ICU >1kb 0 0 1 0 7 A. baumannii 0
T210 S 15 S S S S Jun-10 sputum Medicine 0 0 0 0 0 all- A. nosocomialis 0
T211 S 16 S S S S Jun-10 Urine PV2 1 0 0 0 0 5 A. baumannii 0
T212 S 10 S S S S Jun-10 sputum ICU 1 0 0 0 0 5 A. baumannii 0
T213 S 16 S S S S Jun-10 pus N/A 1 0 0 0 0 5 A. baumannii 0
T214 S 11 R S S S Jun-10 sputum ICU 1 0 0 0 0 5 A. baumannii 0
T215 S 22 S S S S Jun-10 sputum Surgery 1 0 0 0 0 12 (1kb)A. baumannii 0
T216 S 18 S S S S Jun-10 sputum ICU 1 0 0 0 0 12 (1kb)A. baumannii 0
T217 S 19 S S S S Jun-10 Hemoculture Social 0 0 0 0 0 all- A. pittii 0
T218 S 15 S S S S Jun-10 sputum Surgery 1 0 0 0 0 10 A. baumannii 0
T219 S 18 S S S S Jun-10 sputum Surgery 1 0 0 0 0 12 A. baumannii 0
T220 S 16 S S S S Jun-10 sputum ICU 1 0 0 0 0 5 A. baumannii 0
T221 S 16 S S S S Jun-10 sputum Medicine 1 0 0 0 0 12 A. baumannii 0
T222 S 15 S S S S psuedo-like Jul-10 sputum ICU >1kb 0 0 0 0 7 A. baumannii 0
T223 R 10 R R R R Jul-10 sputum N/A 1 ? 0 0 0 1 A. baumannii 0
T224 S 15 S S S S Jul10 sputum OPD 1 0 0 0 0 12 A. baumannii 0
T225 S 13 S S S S Jul-10 sputum OPD 1 0 0 0 0 5 A. baumannii 0
T226 S 14 S S S S Jul-10 sputum CK2 1 0 0 0 0 7 A. baumannii 0
T227 S 13 S S S S psuedo-like Jul-10 sputum Surgery >1kb 0 0 0 0 7 A. baumannii 0
T228 S 13 S S S S Jul-10 sputum ICU 0 0 0 0 0 all- A. nosocomialis 0
T229 S 18 S S S S Jul-10 sputum Pediatric 1 0 0 0 0 12 A. baumannii 0
T230 S 10 R S S S Jul-10 sputum Surgery 1 0 0 0 0 5 A. baumannii 0
T231 R 8 R S R R Jun-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T232 S 11 R R R R Jun-10 sputum ICU 1 1 0 0 0 1 A. baumannii 0
T233 R 8 R R R R Jun-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T234 R 14 R R R R Jun-10 Urine OPD 1 1 0 0 0 1 A. baumannii 1
T235 R 10 R R R R Jun-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T236 S 17 R I R R Jun-10 sputum Medicine 1 1 0 0 0 8 A. baumannii 0
T237 R 16 R R R R Jun-10 sputum ICU 1 1 0 0 0 1 A. baumannii 1
T238 R 12 R R R R Jun-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T239 I 6 R R R R Jun-10 Swab OPD 1 1 0 0 0 inconclusiveA. baumannii 0
T240 S 14 I I I R Jun-10 sputum Medicine 1 1 0 0 0 12 A. baumannii 0
T241 S 15 R I R R Jun-10 Hemoculture ICU 1 1 0 0 0 12 A. baumannii 0
T242 R 9 R R R R Jun-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T243 R 10 R R R R Jun-10 tissue biopsyICU 1 1 0 0 0 1 A. baumannii 1
T244 R 13 R R R R Jun-10 sputum OPD 1 1 0 0 0 1 A. baumannii 1
T245 R 10 R R R R Jun-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T246 R 12 R R R R Jun-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T247 S 12 R R R R Jun-10 sputum Surgery 1 1 0 0 0 12 A. baumannii 0
T248 R 12 R R R R Jun-10 sputum ICU 1 1 0 0 0 1 A. baumannii 1
T249 R 17 R R R R Jun-10 Pus OPD 1 1 0 0 0 4 A. baumannii 1
T250 R 13 R R R R Jun-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T251 R 11 R R R R Jun-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T252 R 11 R R R R Jun-10 sputum ICU 1 1 0 0 0 1 A. baumannii 1
T253 R 12 R R R R Jun-10 Hemoculture Pediatric 1 1 0 0 0 1 A. baumannii 1
T254 R 12 R R R R Jun-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T255 R 13 R R R R Jun-10 sputum Surgery 1 1 0 0 0 1 A. baumannii 1
T256 R 13 R R R R Jun-10 sputum CK2 1 1 0 0 0 1 A. baumannii 1
T257 R 12 R R R R Jun-10 sputum Orthopedic 1 1 0 0 0 1 A. baumannii 1
T258 R 14 R R R R Jun-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T259 R 14 R R R R Jun-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T260 R 13 R R R R Jun-10 sputum Pediatric 1 1 0 0 0 8 A. baumannii 1
T261 R R Jun-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T262 R 13 R R R R Jun-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T263 R 13 R R R R Jul-10 tissue biopsyOPD 1 1 0 0 0 1 A. baumannii 1
T264 R 12 R R R R Jul-10 sputum ICU 1 1 0 0 0 1 A. baumannii 1
T265 R 11 R R R R Jul-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T266 R 12 R R R R Jul-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T267 S 13 R R R R Jul-10 swab OPD 1 1 0 0 0 4 A. baumannii 0
T268 R 12 R R R R Jul-10 sputum OPD 1 1 0 0 0 1 A. baumannii 1
T269 R 13 R R R R Jul-10 tissue biopsyMedicine 1 1 0 0 0 1 A. baumannii 1
T270 R 13 R R R R Jul-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T271 S 17 R I R R mucoid Jul-10 urine CK1 1 1 0 0 0 4 A. baumannii 0
T272 R 7 R R R R Jul-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T273 R 9 R R R R Jul-10 Urine ICU 1 1 0 0 0 1 A. baumannii 1
T274 R 12 R R R R Jul-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T275 S 12 R R R R Jul-10 sputum Medicine 1 1 0 0 0 12 A. baumannii 0
T276 R 12 R R R R Jul-10 sputum ICU 1 1 0 0 0 1 A. baumannii 1
T277 R 12 R R R R Jul-10 sputum RCR 1 1 0 0 0 1 A. baumannii 1
T278 R 13 R R R R Jul-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T279 R 15 R R R R Jul-10 sputum Surgery 1 1 0 0 0 4 A. baumannii 1
T280 R 9 R R R R Jul-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T281 R 13 R R R R Jul-10 sputum ICU 1 1 0 0 0 1 A. baumannii 1
T282 R 6 R R R R Jul-10 sputum OPD 1 1 0 0 0 1 A. baumannii 1
T283 S 16 R I I R Jul-10 sputum Pediatric (RCU)1 1 0 0 0 1 A. baumannii 0
T284 R 6 R R R R Jul-10 drain Medicine 1 1 0 0 0 5 A. baumannii 0
T285 R 7 R R R R Jul-10 sputum Orthopedic 1 1 0 0 ? inconclusiveA. baumannii 0
T286 R 14 R R R R Jul-10 sputum Surgery 1 1 0 0 0 1 A. baumannii 1
T287 R 10 R R R R Jul-10 sputum ICU 1 1 0 0 0 1 A. baumannii 1
T288 R 6 R R R R Jul-10 sputum ICU 1 1 0 0 ? inconclusiveA. baumannii 1
T289 S 7 R R R R Jul-10 sputum ICU 1 1 0 0 0 1 A. baumannii 0
T290 S 13 R R R R Jul-10 Body fluid Surgery 1 1 0 0 0 1 A. baumannii 0
T291 R 13 R R R R Jul-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T292 R 20 R S R R Jul-10 sputum Medicine 1 1 0 0 0 4 A. baumannii 1
T293 S 14 R R R R Jul-10 Ascitic fluidICU 1 1 0 0 0 1 A. baumannii 0
T294 S 12 R R R R Jul-10 sputum Orthopedic 1 1 0 0 0 1 A. baumannii 0
T295 R 12 R R R R Jul-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 0
T296 S 11 R R R R Jul-10 Hemoculture OPD 1 1 0 0 0 1 A. baumannii 1
T297 R 9 R R R R Jul-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 1
T298 R 12 R R R R Jul-10 sputum Surgery 1 1 0 0 0 1 A. baumannii 1
T299 R 17 R R R R Jul-10 sputum ICU 1 1 0 0 0 8 A. baumannii 1
T300 R 15 R I R R Jul-10 sputum Medicine 1 1 0 0 0 1 A. baumannii 0
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Abstract The purpose of this study was to evaluate a new
chromogenic medium, chromID OXA-48, for the isolation of
carbapenemase-producing Enterobacteriaceae (CPE) directly
from rectal swabs. chromID CARBA and chromID OXA-48
are two chromogenic media that have been commercialized
for the isolation of CPE directly from clinical samples. Both
media were evaluated alongside a broth enrichment method
recommended by the CDC for isolation of CPE, with rectal
swabs from 302 unique hospitalized patients at the Hacettepe
University Hospital, Ankara, Turkey. A total of 33 patients
(11 %) were found to be colonized with CPE using a combi-
nation of all methods, and all CPE produced OXA-48
carbapenemase. Klebsiella pneumoniae was by far the most
dominant species of CPE and was isolated from 31 patients.
Culture on chromID OXA-48 offered the highest sensitivity
(75.8 %) for detection of CPE compared with the other two
methods (sensitivity for both other methods was 57.6 %) and
also offered the highest specificity (99.3 %). However, a
combination of methods (either chromID OXA-48 plus
CDC method or chromID OXA-48 plus chromID CARBA)
was necessary to achieve an acceptable sensitivity (90.9 %).
For isolation of CPE, in a setting where OXA-48
carbapenemase is the dominant type of carbapenemase,
chromID OXA-48 is a highly useful medium but using a
combination of methods is optimal for adequate detection.
The combined use of two chromogenic media offered accept-
able sensitivity (90.9 %) and the highest specificity (98.5 %)
and also allowed for isolation of CPE within 18–20 h.
Introduction
There is a pressing need to define robust standardized screen-
ing methods for the effective detection of carbapenemase-
producing Enterobacteriaceae (CPE) in order to control their
spread [1]. To address this need, the Centers for Disease
Control (CDC) recommended a straightforward broth enrich-
ment method that could be used in almost any clinical labo-
ratory [2]. Other methods include direct culture onto chromo-
genic agars such as CHROMagar KPC (CHROMagar) [3],
chromID CARBA (bioMérieux) [4] or Brilliance CRE
(Oxoid) [5] or the use of direct molecular methods such as
PCR [6]. Several studies have highlighted the potential diffi-
culty in isolating Enterobacteriaceae with OXA-48-like
carbapenemase as such isolates often have low carbapenem
MICs and may be inhibited by some selective media that
contain carbapenems [5, 7, 8]. In this study we sought to
compare three methods for their ability to recover CPE from
rectal swabs taken from 302 hospitalized patients attending
the Hacettepe University Hospital in Ankara, Turkey. These
three methods comprised: enrichment culture using 5 ml TSB
plus 10-μg ertapenem as recommended by CDC [2], direct
culture on an established chromogenic agar designed for
detection of CPE (chromID CARBA) and finally, direct cul-
ture on a recently commercialized chromogenic agar
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specifically designed for isolation of CPE that produce OXA-
48 carbapenemase (chromID OXA-48).
Materials and methods
Patient samples
Rectal swabs were taken for routine screening for CPE from
302 unique patients hospitalized on eight different wards at
the Hacettepe University Hospital, Ankara, Turkey between
March and April 2013.
Culture of rectal swabs
chromID CARBA (reference 43861) and chromID OXA-48
agar (reference 414011) were provided by bioMérieux, La
Balme-les-Grottes, France. All other materials were obtained
from Oxoid, Basingstoke, UK unless stated otherwise. The
material on each rectal swab was suspended in 0.5 ml of
0.85% saline to generate a homogeneous suspension of faecal
material. Aliquots of this suspension (50 μl) were used to
inoculate chromID CARBA, chromID OXA-48 and 5 ml
trypticase soy broth (TSB) containing a 10-μg ertapenem disc.
The inoculum on the two chromogenic agars was spread to
obtain isolated colonies and all media were incubated at 37 °C
for 18–20 h. After incubation, the broth was mixed and a
10-μl aliquot was inoculated onto MacConkey agar, which
was then incubated for 18–20 h at 37 °C. Coloured colonies
on either chromogenic medium and lactose fermenting colo-
nies on MacConkey agar were regarded as presumptive iso-
lates of CPE in accordance with manufacturer’s instructions or
CDC guidelines, respectively.
Bacterial identification
To gain some insight into the selectivity of the media, all
recovered isolates were identified irrespective of colony col-
our. Enterobacteriaceae were initially identified using API
20E (bioMérieux) and all isolates were identified by
MALDI-TOF mass spectrometry (Bruker, Coventry, UK).
Phenotypic and genotypic investigation of carbapenemases
All isolates of Enterobacteriaceae recovered on any of the
three media were screened for possible carbapenemase pro-
duction in accordance with UK national guidelines [9] using
the Rosco KPC, MBL & OXA48 confirm ID kit
(Bioconnections, Knypersley, UK) in accordance with manu-
facturer’s instructions.
Al l isola tes showing phenotypic evidence of
carbapenemase production were investigated using PCR for
the five most common carbapenemase genes found in
Enterobacteriaceae (i.e. those encoding for OXA-48, KPC,
VIM, IMP and NDM-1) [10]. PCR amplification and se-
quencing of the blaOXA-48 gene was performed on eight rep-
resentative isolates of Klebsiella pneumoniae. The primers
were forward primer (5′- GTGGCATCGATTATCGGAAT -
3′) and reverse primer (5′- CTTCTTTTGTGATGGCTTGG -
3′), which gave an amplicon of 736 bp [11]. The PCR products
were sequenced by Macrogen Inc (Seoul, South Korea) using
a BigDye Terminator v3.1 cycle sequencing kit with an
Applied Biosystems 3730 XL sequencer. Nucleotide se-
quences were compared using BLAST (http://blast.ncbi.nlm.
nih.gov/Blast.cgi).
Susceptibility testing
For all isolates confirmed as CPE using PCR, susceptibility
testing was performed against 18 antimicrobials by broth
microdilution using commercially-prepared Sensititre trays
(Trek Diagnostic Systems, East Grinstead, UK; Product:
GNX2F) and results were interpreted using EUCAST
breakpoints [12]. Fosfomycin susceptibility was determined
by the EUCAST standardized disc diffusion method [12].
These isolates were also screened for production of
extended-spectrum ß-lactamase (ESBL) and AmpC using
the Rosco ESBL/AmpC Screen kit (Bioconnections,
Knypersley, UK).
Clonal analysis of carbapenemase-producing K. pneumoniae
All isolates of carbapenemase-producingK. pneumoniaewere
analysed for their clonal relationship using semi-automated
rep-PCR (Diversilab; bioMérieux, Oakleigh, Australia). DNA
preparation and PCR amplification and analysis were per-
formed as described previously [13].
Re-inoculation of CPE on to the test media
All confirmed isolates of CPE were re-inoculated (in pure
culture) onto all three media (i.e. TSB plus ertapenem and
both chromogenic agars). This was performed using an inoc-
ulum of approximately 100 CFU (obtained via serial dilutions
in 0.85 % saline) and processed as described above. The re-
inoculation of isolates was performed in duplicate on separate
occasions.
Statistical analysis
Differences between the efficiencies of the two chromogenic
media for isolat ion of carbapenemase-producing
Enterobacteriaceae were compared using McNemar’s test
with the continuity correction applied. The dendrogram
representing clonal analysis of isolates was generated using
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Pearson’s correlation with cut-off similarities of 95 % for
isolates assigned to the same clone.
Results
Comparison of culture methods for detection of patients
colonized with CPE
A total of 33 patients (11 %) were found to be colonized with
CPE out of 302 distinct patients who were screened. All
isolates of CPE were confirmed as harboring OXA-48
carbapenemase as confirmed by both phenotypic testing and
PCR. No other carbapenemases were detected in the isolates
of Enterobacteriaceae. Table 1 shows the sensitivity of each
method (and combinations of the three methods) for detection
of colonized patients.
Among the OXA-48 producers, Klebsiella pneumoniae
was by far the most dominant species and was isolated from
31 patients. One patient was colonized with Escherichia coli
only, one patient was colonized with Enterobacter cloacae
only and one patient was colonized with both K. pneumoniae
and E. coli (all with OXA-48 carbapenemase). E. coli pro-
duced red colonies on both chromogenic media whereas
K. pneumoniae and E. cloacae formed blue colonies on
chromID OXA-48 and green colonies on chromID CARBA.
Culture on chromID OXA-48 was more sensitive than any
other single method for isolation of CPE, although this was
not statistically significant (P=0.2) and still only allowed
detection of 75.8 % of colonized patients. However, using a
combination of chromID OXA-48 with either of the other two
methods allowed for the detection of 90.9 % of colonized
patients (Table 1).
Table 2 documents the growth of other isolates that were
recovered on the three media. Other than CPE, the most
common other species recovered on all three media was
Acinetobacter baumannii with 65 isolates recovered from 65
patients. All isolates of A. baumannii formed colorless colo-
nies on both chromogenic agars or were non-lactose
fermenting on MacConkey agar and were therefore distinct
from isolates of CPE.
Susceptibility of OXA-48 producing K. pneumoniae
On examination of the isolates from different media, it was
apparent that different colony variants of K. pneumoniaewere
present within some samples suggesting that individual pa-
tients might be colonized with more than one strain of
K. pneumoniae. Such variation related to colony size and
particularly variations in colour due to the strength of chro-
mogenic reactions. This was supported by antimicrobial sus-
ceptibility testing, which revealed the presence of
K. pneumoniae isolates with different susceptibility patterns
within a single patient sample. In total, 49 isolates that were
phenotypically distinct (on the basis of their antibiogram)
were recovered from the 31 patients colonized with this spe-
cies. In accordance with EUCAST criteria, all 49 isolates of
K. pneumoniae were non-susceptible to co-trimoxazole, pi-
peracillin-tazobactam, ticarcillin-clavulanate and ertapenem.
Susceptibility to other agents was as follows: imipenem
(59 %), meropenem (55 %), doripenem (47 %), cefepime
(33 %), cefotaxime (16 %), aztreonam (29 %), ceftazidime
(29 %), tigecycline (100 %), amikacin (98 %), gentamicin
(53 %), tobramycin (8 %), colistin (47 %), levofloxacin
(31 %) and ciprofloxacin (2 %). In accordance with criteria
proposed by Barry et al. [14], 96 % of isolates of
K. pneumoniae were susceptible to fosfomycin. Fifty-three
percent of isolates co-produced ESBL and a further 16 %
co-produced ESBL and AmpC ß-lactamase. A more detailed
analysis of carbapenem susceptibility is provided in Table 3.
Re-inoculation of OXA-48 producers onto test media
All three media were re-challenged with a low inoculum
(100 CFU) of all recovered isolates of CPE (n=52). These
included one E. cloacae isolate, two E. coli isolates and 49
isolates of K. pneumoniae. All isolates of CPE grew (and
produced expected coloration) on chromID OXA-48 whereas
only 31 % were detected using chromID CARBA and 69 %
were recovered following subculture of TSB plus ertapenem.
There was a clear correlation between a low carbapenem
minimum inhibitory concentration (MIC) and failure to grow
on these media. For example, isolates that failed to grow in
Table 1 Total number of colo-
nized patients detected by each
method and by combinations of
methods
PPV positive predictive value,
NPV negative predictive value
Method n Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Total 33
CDC method 19 57.6 95.2 59.4 94.8
chromID OXA-48 25 75.8 99.3 92.6 97.1
chromID Carba 19 57.6 98.9 86.4 95
chromID OXA-48 plus CDC method 30 90.9 94.8 68.2 98.8
chromID OXA-48 plus chromID Carba 30 90.9 98.5 88.2 98.9
chromID Carba plus CDC method 25 75.8 94.4 62.5 96.9
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TSB plus ertapenem typically had an ertapenem MIC of 2–
4 mg/L whereas most of the isolates that were able to grow
showed MICs of >4 mg/L. Similarly, growth on chromID
CARBA at low inocula was only achieved by isolates with a
meropenem MIC of at least 4 mg/L whereas meropenem sus-
ceptible isolates (MIC≤2 mg/L) were all inhibited when inoc-
ula of 100 CFU were re-inoculated onto chromID CARBA.
Clonal analysis of OXA-48-producing K. pneumoniae
and sequencing of blaOXA-48
All 49 isolates of K. pneumoniae were subjected to typing
using rep-PCR and the results are shown in Fig. 1. The results
indicate the presence of at least four clonal types of
K. pneumoniae detected within patients at this hospital. The
blaOXA-48 gene was sequenced for eight isolates, comprising
two isolates from each of four distinct clusters. The gene
sequences of these representative isolates showed 100 % ho-
mology to the published sequence for blaOXA-48 (GenBank
accession number: AY236073).
Discussion
Previous studies have established that OXA-48 is the most
frequently encountered carbapenemase in Enterobacteriaceae
in Turkey [15]. K. pneumoniae is reported to be the dominant
host species and outbreaks of OXA-48 producing
K. pneumoniae have been documented [16]. There is no
accepted ‘gold standard’ method for the detection of CPE
from clinical specimens. Molecular methods are available
[6] but they fail to provide any information regarding the host
species or its susceptibility. Wilkinson et al. [5] examined the
sensitivity and specificity of the CDC broth method with a
collection of 130 CPE and 70 Enterobacteriaceae with either
ESBL or AmpC ß-lactamases. They reported that ertapenem
offered a superior sensitivity to meropenem as a selective
agent but, even with ertapenem, 22 % of CPE were inhibited
at an inoculum level of 100 CFU/ml. In this study we have
shown that the CDC broth method failed to recover CPE from
42.4% of colonized patients. Moreover the positive predictive
value of the method was also limited (59.4 %) as many of the
Enterobacteriaceae that were recovered using the broth meth-
od did not turn out to harbor carbapenemases (see Tables 1
and 2).
Chromogenic culture media are useful as screening tools
for the isolation of antimicrobial-resistant bacteria including
CPE. CHROMagar KPC (also available as pre-poured plates
under the ‘Colorex’ brand) was the first commercially avail-
able medium designed for selective isolation of CPE. In early
studies in Greece [17] and Israel [18], CHROMagar KPC was
shown to have good performance when compared with
MacConkey-based media supplemented with carbapenems.
Table 2 Non-CPE isolated from
302 non-duplicate specimens
using three culture methods
a In accordance with manufac-
turer’s instructions and the CDC
protocol, false positive colonies
only include colored colonies on
the two chromogenic media or
lactose fermenters on
MacConkey agar
Isolates All CDC
method
chromID
OXA-48
chromID
Carba
Acinetobacter baumannii 65 25 47 50
Enterobacter aerogenes 1 1 0 0
Enterobacter cloacae 1 1 0 0
Escherichia coli 6 5 2 1
Klebsiella pneumoniae 11 9 1 1
Klebsiella oxytoca 3 2 1 0
Pseudomonas aeruginosa 5 2 1 3
Stenotrophomonas maltophilia 1 0 0 1
Total 45 52 56
Total false positivesa 18 4 2
Table 3 Carbapenem susceptibility data for Klebsiella pneumoniae isolates (n=49) with OXA-48 carbapenemase
Carbapenem S / I / Ra %S %I %R MIC50
(mg/L)
MIC90
(mg/L)
MIC range
(mg/L)
Doripenem ≤1 / 2 / >2 47 20 33 2 >2 0.25 – >2
Ertapenem ≤0.5 / 1 / >1 0 2 98 >4 >4 1 – >4
Imipenem ≤2 / 4–8 / >8 59 12 29 2 >8 ≤1 – >8
Meropenem ≤2 / 4–8 / >8 55 10 35 2 >8 ≤1 – >8
a Susceptible (S), Intermediate (I) and Resistant (R) as defined using EUCAST criteria
522 Eur J Clin Microbiol Infect Dis (2015) 34:519–525
Fig. 1 Rep-PCR analysis of 49
phenotypic variants of OXA-48-
producing K. pneumoniae
Eur J Clin Microbiol Infect Dis (2015) 34:519–525 523
Subsequent studies showed that CPE with low carbapenem
MICs (e.g. some strains with blaNDM-1) may not grow on this
medium, particularly at low inocula [19, 20]. chromID
CARBA showed a superior performance to Colorex KPC
for the isolation of CPE with NDM-1 enzyme in a study in
Pakistan [20] and was superior to the CDC broth method in a
report fromGreece [4]. chromID CARBAwas also superior to
BrillianceCRE in two further studies in Pakistan, although the
authors speculated that the selectivity of Brilliance CRE may
have been compromised during transportation of the medium
from Europe to Pakistan [21, 22]. For all of these media, a
potential weakness is their limited ability to support the
growth of Enterobacteriaceae with OXA-48 carbapenemase
as such isolates commonly have lowMICs to carbapenems [5,
7]. To address this issue, Nordmann et al. developed
‘SUPERCARBA’ medium, a non-chromogenic (Drigalski-
based) agar medium containing a low concentration of
ertapenem (0.25 mg/L), designed to accommodate the isola-
tion of CPE with OXA-48 carbapenemase [23]. The medium
has a limited shelf life of 7–10 days [7] and to our knowledge
is not yet commercially available. Girlich et al. [24] evaluated
SUPERCARBA for the isolation of OXA-48 producers from
77 patients hospitalized in Morocco and reported an identical
sensitivity to Brilliance CRE but a higher specificity for
SUPERCARBA (98.5 % vs. 86.6 %). We have noted only
one previous report of the performance of chromID OXA-48
and the study involved inoculation of a large collection of
CPE (and other bacteria) at various inocula onto chromID
CARBA, SUPERCARBA and chromID OXA-48 [25].
Rectal swabs and/or stool samples (n=130) from non-
colonized patients were also tested to evaluate specificity.
The authors concluded that chromID OXA-48 was as sensi-
t ive for detect ion of OXA-48 producers as the
SUPERCARBA medium, but with a higher specificity [25].
To our knowledge this is the first report that has evaluated
chromID OXA-48 with a patient population that has coloni-
zation with CPE. Although chromID CARBA has proven to
be highly effective in other studies, we have demonstrated its
limited efficacy in a setting where OXA-48 is the dominant
carbapenemase type. These findings are not unexpected and
this limitation is stated in the manufacturer’s product informa-
tion. As noted by Girlich et al., chromID CARBA shows a
weak sensitivity for detection of OXA-48 producers, but is “a
powerful tool for detection of all other classes of CPE” [25].
Our study provides evidence that chromID OXA-48 is a
highly useful medium for detection of OXA-48 producing
Enterobacteriaceae from colonized patients and is superior to
the CDC broth-based method. Twenty-five out of 33 patients
(75.8 %) were detected using this medium alone and it was
subsequently demonstrated that all CPE (recovered by any of
the three methods) were able to grow on this medium using a
low inoculum (100 CFU). This suggests that failure to isolate
CPE on chromID OXA-48 was probably attributable to either
a very low amount of CPE in the sample or overgrowth by
other bacteria. When used with chromID CARBA, this com-
bination of media potentially offers a highly effective solution
for detection of Enterobacteriaceae with any commonly en-
countered carbapenemase.
One potential disadvantage of the use of chromogenic
media is the increased cost to the laboratory, as they are
invariably more expensive than conventional media. In May
2014, the UK list price (without tax) for materials only for the
CDC method was £1.33 (1.7 EUR / 2.23 USD) whereas the
combined cost for purchase of both chromID CARBA and
chromID OXA-48 was £3.16 (3.9 EUR / 5.3 USD).
Alternatively, the manufacturer has recently commercialized
chromID CARBA SMART, which includes both media in a
single Petri dish in the form of a bi-plate (£2.44 / 3.0 EUR / 4.1
USD). The increased cost will need to be weighed against the
increased labour time for subculture of enrichment broths in
the CDC method (and the subsequent delay in isolating CPE)
and, most importantly, the relative overall effectiveness of the
methods.
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Sir,
The prevalence of New Delhi metallo-b-lactamase-1 (NDM-1),
encoded by the blaNDM-1 gene, has been increasing among various
Gram-negative bacteria.1 blaNDM-1 has been shown to reside in
various plasmid incompatibility (Inc) types.1 Recently, a new Inc
type, IncN2, has been identified in Escherichia coli and Klebsiella
pneumoniae and proposed to acquire the blaNDM-1-carrying region
by transposition.2,3 In Thailand, NDM-1 producers have become an
emerging issue,4 and yet the characteristics of the blaNDM-1-carrying
plasmid have not been elucidated. Here we report the genetic study
of plasmids harbouring blaNDM-1 from domestic isolates.
We examined three clinical isolates, one E. coli (ECS01) and two
K. pneumoniae (KPS01 and KPS03), which were obtained from
urine samples of independent Thai patients at two unrelated hos-
pitals during June to August 2012 (IRB approval no. Si 454/2009).
No previous hospitalization, antimicrobial exposure or healthcare-
related history was documented for any patient. MIC values were
determined using Etest (bioMe´rieux, France). According to the
CLSI guideline,5 all isolates were resistant to all tested b-lactam
agents, including cefoxitin, ceftazidime, imipenem, meropenem,
doripenem and piperacillin/tazobactam, as well as ciprofloxacin
with high MIC values (Table 1). Both K. pneumoniae isolates were
resistant to gentamicin, but only KPS03 was resistant to amikacin.
E. coli ECS01 remained susceptible to both gentamicin and amika-
cin. Multilocus sequence typing was performed to assign sequence
type (ST) using primers and amplification conditions as recom-
mended for E. coli (http://mlst.ucc.ie) and K. pneumoniae (http://
www.pasteur.fr/mlst). E. coli ECS01 belonged to ST131 and K. pneu-
moniae KPS01 and KPS03 were ST11 and ST15, respectively.
blaNDM-1 was identified on a plasmid, extracted by alkaline lysis
from these isolates by PCR sequencing according to the protocol
reported previously.5 The Inc type of blaNDM-1-carrying plasmids
was determined by multiplex PCR-based replicon typing using pri-
mers and conditions as previously published.6 Forward and reverse
primers to target the IncN2 variants were designed as N2-F:
5′-TAGCCTTCGGACAGGGTGAG-3′ and N2-R: 5′-ACGTTCGCCTGGA
TTTCATC-3′, respectively. All blaNDM-1-carrying plasmids were
matched with the IncN2-type plasmid. The blaNDM-1-carrying plas-
mids were determined for their transferability by electroporation
using E. coli TOP10 (Invitrogen, USA) as described elsewhere. The
NDM transformants generated from ECS01, KPS01 and KPS03 par-
ents were designated as ECS01-NDM, KPS01-NDM and KPS03-NDM,
respectively. The blaNDM-1-carrying plasmids from each strain were
designated as pNDM-ECS01, pNDM-KPS01 and pNDM-KPS03,
respectively. Southern blotting hybridization using a specific
blaNDM-1 probe illustrated that a blaNDM-1-carrying plasmid, approxi-
mately 40 kb in size, was presented in both parents and transfor-
mants (data not shown). Transformants showed decreased
susceptibility to all tested b-lactam agents, including carbape-
nems, but remained susceptible to gentamicin and amikacin
(Table 1).
To further characterize the genetic structure of the blaNDM-1-
carrying plasmid, pNDM-ECS01 was selected for whole DNA
sequencing using the Nextera DNA library kit (Illumina, USA)
according to the manufacturer’s directions, and data were gener-
ated on MiSeq (Illumina). Annotation and sequence analysis were
performed using CLC Genomics Workbench (version 6.5.1). The
plasmid was 41 190 bp and consisted of 50.8% GC content.
Fifty-six open reading frames were predicted encoding 40 coding
sequences for known proteins, 3 truncated proteins and 13 hypo-
thetical proteins (see Table S1, available as Supplementary data at
JAC Online). Our plasmid was most closely related to the
41187 bp identical plasmids pTR3 and pTR4 (GenBank numbers
JQ349086 and JQ349085, respectively), which were recently
reported as IncN2-type blaNDM-1-carrying plasmids in K. pneumo-
niae ST1 and ST273 from two patients in Singapore,3 except for
three nucleotide insertions, C, A and T, at positions 1152, 9230
and 41119, respectively, relative to the start of repA gene. In add-
ition, pNDM-ECS01 was also closely related to the 35947 bp
p271A, another IncN2-type blaNDM-1-carrying plasmid identified
in an E. coli ST101 isolate from Australia.7 A 5243 bp region at
the position 3492–8734 on pNDM-ECS01 was absent in p271A.
This region contained the conserved upstream repeat-controlled
# The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
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regulon normally found in IncN plasmid and was related to bac-
terial conjugation efficiency. The remaining pNDM-ECS01 shared
99.98% homology to p271A. The complete DNA sequence of
pNDM-ECS01 was deposited to GenBank database (KJ413946).
NDM-1 producers have gained serious attention due to their
high-level resistance to carbapenems. Genetic studies have
shown that blaNDM-1 is commonly located on a plasmid that
could be easily disseminated via horizontal transfer. We report
here the characterization of IncN2-type blaNDM-1-carrying plas-
mids from clinical isolates in Thailand. Unlike the previous reports,
this study first demonstrated the acquisition of IncN2-type
plasmid-containing blaNDM-1 in highly virulent E. coli ST131 and
outbreak-related drug-resistant K. pneumoniae ST11 and ST15
clones.8 – 10 The first IncN2-type blaNDM-1-carrying plasmid from
a patient in Australia had a link to the Indian subcontinent since
he was transferred from a hospital in Bangladesh.7 Our cases and
cases in Singapore had no link to the Indian subcontinent and
indeed had no history of traveling abroad. This suggests the
potential for international multiclone spread of blaNDM-1 gene in
this plasmid backbone. This should be an alert for continuous
multinational surveillance of blaNDM-1-carrying isolates to appro-
priately control these highly resistant bacteria.
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Sir,
Inhaled tobramycin is used to treat chronic lung infections caused
by Pseudomonas aeruginosa in cystic fibrosis. The advantages of
inhalation over parenteral administration are direct endobronchial
delivery and minimal systemic toxicity. Tobramycin inhalation is
considered safe and effective.1 Serum levels in cystic fibrosis
patients after inhalation are generally low (,1 mg/L),2,3 without
evidence for drug accumulation in serum.2 Therefore, routine
monitoring of systemic tobramycin levels after inhalation is not
indicated.
We report elevated serum tobramycin concentrations in a child
with renal failure receiving inhaled tobramycin.
An 11-year-old child was admitted to a paediatric intensive
care unit for an out-of-hospital cardiac arrest. Resuscitation
was complicated by bilateral pneumothorax. Extracorporeal
membrane oxygenation was started on admission and continued
for 4 days. Rhabdomyolysis on day 2 caused acute renal failure
with oliguria. Continuous veno-venous haemofiltration (CVVH)
was started on day 6. On day 8, atelectasis of the right superior
lobe was detected. The patient received antimicrobials to success-
fully treat Staphylococcus aureus ventilator-associated pneumo-
nia and systemic Candida albicans infection. In the fourth week
intravenous ciprofloxacin was commenced to treat P. aeruginosa
pneumonia. Because of increased diuresis and severe clotting of
the line, CVVH was discontinued in the fifth week. The subsequent
rise in creatinine decreased spontaneously after 5 days. One day
after CVVH discontinuation, tobramycin for inhalation (TOBIw,
Novartis Pharma, Basel, Switzerland) at 300 mg twice daily was
started, delivered by a vibrating mesh nebulizer (Aeronebw Pro,
Aerogen, Galway, Ireland), because of increased respiratory
distress with oxygen requirement, fever and elevated C-reactive
protein levels. Inhalation was preferred to intravenous infusion
because of renal impairment. Ciprofloxacin was switched to
meropenem because of resistance of P. aeruginosa. In the
sixth week of admission a CT scan showed empyema, for which
thoracoscopic surgery and drainage was performed.
Seven days after starting tobramycin for inhalation the tobra-
mycin serum level (13.8 mg/L 6 h after administration) was
interpreted as a sampling error. The test was repeated after the
weekend on day 10. The concentrations were 17.9 mg/L (trough)
and 17.1 mg/L (1 h after administration). Tobramycin was discon-
tinued on the 11th day. Concentrations after the last dose were
14.1 mg/L (after 1 h) and 13.4 mg/L (after 6 h). Five days after dis-
continuation the levels were ,0.5 mg/L and renal function
improved accordingly (Figure 1). The patient’s respiratory condi-
tion gradually improved and subsequent cultures were negative.
The patient recovered and was discharged to a rehabilitation
centre 3 months after hospital admission. We obtained informed
consent from both patient and parents to publish this report.
Several possible causes for the high tobramycin levels were
considered. Erroneous substitution of inhalation for intravenous
therapy and medication with probable cross-reactivity of the
tobramycin immunoassay were excluded. Skin contamination of
fingerprick blood following nebulization of tobramycin4 was
excluded because only arterial blood was drawn.
A few case reports have described patients with renal dysfunction
receiving tobramycin inhalation with high trough levels of 10.6,5 8.8,6
19.5,7 2.58 and 13.4 mg/L9 and a peak level of 2.1 mg/L.10 They
received 80–300 mg twice daily,5 300 mg twice daily6 – 8,10 or
600 mg twice daily9 for 5–25 days. Four patients were venti-
lated,5,8–10 one had bronchopulmonary dysplasia,5 one was a lung
transplant recipient6 and one had bronchiectasis.7 Two patients
developed vestibular injury6,7 and one got hearing difficulties.9 We
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Predominance of VREfm ST203 subgroup
in Queensland
Sir,
The molecular epidemiology of Enterococcus faecium in an
Australian setting has recently been described for the first
time.1 Johnson et al. described the epidemiology of 85 E.
faecium isolates in blood culture over a 12 year period at a
single institution in Victoria, Australia (Austin Health,
Melbourne).1 This comprised 34 vancomycin resistant E.
faecium (VREfm) and 51 vancomycin susceptible E. faecium
(VSEfm) isolates. They defined 17 different sequence types
(STs) amongst 85 E. faecium isolates using multilocus
sequence typing (MLST) and found three dominant STs
(ST17, ST252 and ST203). Amongst the VREfm isolates, all
but one carried the resistance gene, vanB.1 ST17, the putative
founder of clonal complex 17 (CC17), was stable and predo-
minated in VREfm and VSEfm for the first 10 years of the
12 year study period. From 2007 to 2009, a significant increase
in VREfm bacteraemia was identified.1 The predominant ST
was ST203, accounting for 76% and 81.8% of VREfm bacter-
aemia isolates in 2007 and 2009, respectively. ST203 is a
double-locus variant of ST17 and both STs belong to CC17.
We have investigated 765 VREfm isolates (39 clinical and
726 screening isolates) from hospitalised patients across 26
hospitals in Queensland, collected from January to November
2010. Van genotyping was performed on all isolates. A total of
758 isolates (99.1%) had a vanB genotype while seven isolates
were positive for vanA. Ninety-one vanB VREfm were selected
to study molecular epidemiology using repetitive polymerase
chain reaction (PCR) (DiversiLab; bioMe´rieux, France), com-
prising both clinical (n¼ 39) and screening (n¼ 62) specimens.
Results revealed that the majority of isolates from Queensland
(n¼ 88) were very closely related (>92% similarity).
Fourteen isolates from this major group were further ana-
lysed by high resolution melting (HRM) genotyping as
described.2 Four melting types (MelTs) were identified,
MelT11 (n¼ 1), MelT34 (n¼ 1), MelT121 (n¼ 11) and one
novel MelT. MelT11, MelT34 and MelT121 represent STs
which are clustered in CC17. MelT11 and MelT121 include
various STs from each subgroup founded by ST17 and ST203,
respectively. MelT34 incorporated multiple subgroups of CC17
as well as the singleton ST51 (Table 1). MLST was performed
in all 14 isolates as previously described;3 of these, 12 isolates
were ST203. The results from MLST were correlated with
HRM genotyping except the novel MelT that was identified as
ST203 (Table 1).
In conclusion, our results indicate that 88 of 91 isolates
(97%) were closely related. HRM genotyping and MLST of
representative isolates from this cluster revealed that ST203
was predominant. This suggests that ST203 may be responsible
for VREfm in Queensland. These findings correspond with
what was found by Johnson et al. The same ST causing
outbreaks in two geographically non-contiguous states suggests
that other regions in Australia may be similarly affected. ST203
has also been reported in Korea, Japan China, Germany, Den-
mark, The Netherlands and Serbia (http://efaecium.mlst.net/).
Interestingly, ST203 isolates reported from these countries
almost entirely possessed the vanA gene. On the contrary,
the majority of isolates from Victoria and Queensland pos-
sessed vanB. This highlights that CC17, especially ST203, has a
great ability for hospital adaptation. CC17 has caused outbreaks
in multiple continents including Australia.4 Further study and
surveillance of this subgroup is necessary to understand its
persistence in the hospital environment.
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Table 1 Correlation of MelT with ST
MelT Possible ST* CC
11 17, 63, 103, 180, 187, 234, 267, 295, 307, 308, 357, 460,
475, 480, 538, 543, 554, 578, 584
17
34 49, 51, 177, 232, 341, 547, 548, 556 17
121 203, 365, 412, 478, 483, 577 17
* Generated by Enterococcus faeciumMLSTand MelT key as described by
Tong et al.2 and found at http://menzies.edu.au/node/43174.
Bold type indicates ST identified by MLST.
CC, clonal complex; MelT, melting type; MLST, multilocus sequence
typing; ST, sequence type.
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ternationaA B S T R A C T
The aim of this studywas to identify acquired OXA-type carbapenemases in Acinetobacter spp. other than
Acinetobacter baumannii. Froma total of 453 carbapenem-susceptible and -resistantAcinetobacter isolates
collectedworldwide, 23were positive for blaOXA genes bymultiplex PCR. These isolateswere identified as
Acinetobacter pittii (n =18), Acinetobacter nosocomialis (n =2), Acinetobacter junii (n =1) and Acinetobacter
genomic species 14TU/13BJ (n =2). The blaOXA genes and associated insertion sequence (IS) elementswere
sequenced by primer walking. In 11 of these isolates, sequencing of the PCR products revealed that they
were false-positive for blaOXA. The remaining 12 isolates, originating from Europe, Asia, South America,
North America and South Africa, harboured OXA-23 (n =4), OXA-58 (n = 5), OXA-40-like (n =1) and OXA-
143-like (n = 1); oneA. pittii isolate harbouredbothOXA-23 andOXA-58. IS elementswere associatedwith
blaOXA in 10 isolates. OXAmultiplex PCR showed a high degree of false-positive results (47.8%), indicating
that detection of blaOXA in non-baumannii Acinetobacter spp. should be confirmed using additional
methods.
ã 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.1. Introduction
Carbapenem-hydrolysing class D b-lactamases, also known as
oxacillinases (OXA), are the most commonly reported carbapenem
resistance determinants in Acinetobacter spp., particularly in
Acinetobacter baumannii. In the genus Acinetobacter, various
intrinsic OXA have already been identified, including OXA-23-like
in Acinetobacter radioresistens, OXA-51-like in A. baumannii, OXA-
134-like in Acinetobacter lwoffii, OXA-211-like in Acinetobacter
johnsonii, OXA-213-like inAcinetobacter calcoaceticus, OXA-214-like
in Acinetobacter haemolyticus and OXA-228-like in Acinetobacter
bereziniae [1]. The commonest acquired subclass in A. baumannii is
OXA-23-like, which is the intrinsic OXA of A. radioresistens, and can
beencodedonplasmidsoron the chromosome.OtheracquiredOXA
subclasses, mainly encoded on plasmids in A. baumannii, include
OXA-40-like, OXA-58-like, OXA-143-like and OXA-235-like, but
their natural hosts are currently unknown [2]. Although OXA are
weak carbapenem hydrolysers, they can confer resistance in thex: +49 221 478 32002.
iggins).
l Society of Chemotherapy. All righpresence of additional resistance mechanisms (e.g. altered perme-
ability) and when overexpressed, typically mediated through
promoters provided by insertion sequence (IS) elements (OXA-40
and OXA-143 appear to be exceptions to this) [3]. The association
with ISelementsandfrequentplasmidlocationhighlight thepotential
of blaOXA genes to spread within the genus Acinetobacter via
transposition events and horizontal gene transfer. Several acquired
OXA subclasses have already been detected in variousAcinetobacter
spp. mainly originating from European and Asian countries [4,5].
The aim of this study was to characterise the acquired blaOXA
genes detected by multiplex PCR in Acinetobacter spp.
2. Materials and methods
2.1. Bacterial isolates, blaOXA screening, species identification and
carbapenem susceptibility
A total of 453 clinical Acinetobacter isolates other than A.
baumannii collected from 141 centres in Europe, the Americas,
SoutheastAsia andSouthAfrica aspartof theTigecyclineEvaluation
andSurveillanceTrial (TEST)andtheGermanTigecyclineEvaluation
and Surveillance Trial (G-TEST) studies were screened for the
presenceofblaOXAgenes [6,7].Mostof the isolatesweremembers ofts reserved.
376 E. Zander et al. / International Journal of Antimicrobial Agents 43 (2014) 375–377the A. baumannii group, i.e. they were Acinetobacter nosocomialis or
Acinetobacter pittii. A subset of carbapenem-resistant isolates were
further tested for the presence of OXA-235 [2]. Species identifica-
tion was performed using gyrB PCR and rpoB sequencing as
previously described [8,9]. Clonal relatedness was investigated by
repetitive sequence-based PCR (rep-PCR) (DiversiLab; bioMérieux,
Nürtingen,Germany) [6]. Imipenemandmeropenemsusceptibility
were determined by Etest (bioMérieux).
2.2. Sequencing of blaOXA and associated insertion sequence elements
The blaOXA genes and surrounding areas were amplified and
sequenced by primer walking. blaOXA-143-like was amplified using
primers 50-CATCTCGGTAAACAGTCGAT-30 and 50-TTAATCCCCCT-
CATTGAACT-30. As flanking primers for blaOXA-40-like failed to
amplify the gene, OXA-40-like specific primers (50-ATGAAAAAATT-
TATACTTCC-30 and50-TTAAATGATTCCAAGATTTTC-30)were used for
partial sequencing. To investigate the association of blaOXA-23-like
and blaOXA-58-like with ISAba1 or ISAba3, respectively, PCR sequenc-
ing was performed using previously published primers [10,11]. In
addition, inverse PCR was performed to sequence downstream of
blaOXA-23. Briefly, plasmids were extracted using a QIAprep Spin
Miniprep Kit (QIAGEN, Hilden, Germany) and were digested with
BamHI, EcoRI and EcoRV (New England BioLabs, Frankfurt amMain,
Germany), respectively. Then, 5mL of the heat-inactivated restric-
tion reaction was self-ligated using Quick Ligase (New England
BioLabs), amplified by PCR and sequenced using inverse primers
OXA-23inv_F (50-TTGGGCAATGGATATAAAAC-30) and OXA-23inv_R
(50-TAGAGGCTGGCACATATTCT-30).
2.3. Characterisation of false-positive blaOXA PCR products
A subset of isolates amplified a PCR product for OXA-23-like and
OXA-58-like in the multiplex format but failed to amplify a product
using flanking primers (see Section 2.2) and blaOXA-specific primers
(OXA-23-like, 50-ATGAATAAATATTTTACTTGCTATG-30 and 50-
TTAAATAATATTCAGCTGTT-30; and OXA-58-like, 50-ATGAAATTAT-
TAAAAATATTGAGTT-30 and 50-TTATAAATAATGAAAAACACCC-30).
The results of these isolates were interpreted as false-positive. To
analyse these false-positive results, the multiplex amplicons were
cloned intopCR4-TOPO (Invitrogen, Karlsruhe,Germany) according
to the manufacturer’s instructions and were sequenced with M13
primers.
3. Results and discussion
The number of intrinsic OXA identified in Acinetobacter spp. was
recently expanded on the basis of whole-genome sequencing [12].Table 1
Characterisation of 12 Acinetobacter spp. isolates harbouring blaOXA genes.
Isolate Country of origin Species OXA multiplex PCR
AF281 Ireland A. pittii 23-like
BMBF436 Colombia A. pittii 23-like
S22 Singapore A. pittii 23-like, 58-like
AF496 South Africa A. nosocomialis 23-like
BMBF461 South Korea AGS 14TU/13BJ 23-like
BMBF471 Italy A. pittii 40-like
AF626 Taiwan A. pittii 58-like
AF134 China A. pittii 58-like
AF263 Hong Kong A. pittii 58-like
G2-88b Germany A. junii 58-like
AF614 Taiwan A. nosocomialis 58-like
AF726 USA (Indiana) A. pittii 143-like
IS, insertion sequence; MIC, minimum inhibitory concentration; IPM, imipenem; MEM,These represent a potential reservoir of carbapenem resistance
genes in Acinetobacter spp. if overexpressed, as demonstrated in A.
bereziniae (OXA-229) and A. baumannii (OXA-51-like) [1,6,10].
However, the present study focused on the distribution of acquired
OXA in non-baumannii Acinetobacter spp., which appear to be the
commonest carbapenem resistance determinants in this genus.
Among a total of 453 Acinetobacter isolates, 23 were positive for an
acquired OXA by multiplex PCR. The isolates were identified as A.
pittii (n =18), A. nosocomialis (n =2), Acinetobacter junii (n =1) and
Acinetobacter genomic species 14TU/13BJ (n =2). Of these, 9 isolates
were resistant to both carbapenems tested, 1 was resistant only to
meropenem and the remaining 13 isolates were carbapenem-
susceptible (Tables 1 and 2).
Although isolate pairs BMBF436 and BMBF471, as well as AF263
and AF281, showed 98.8% and 96% similarity, respectively, by rep-
PCR (data not shown), they originated from different countries and
carried different OXA subclasses (Table 1). No epidemiological
relatedness was found between the remaining isolates.
Sequencing confirmed the presence of four acquired OXA
subclasses in 12 of the isolates. OXA-23 was identified in A. pittii
(n =2), A. nosocomialis (n =1) and Acinetobacter genomic species
14TU/13BJ (n =1). OXA-58 was identified in A. pittii (n =3), A.
nosocomialis (n =1) and A. junii (n =1). One A. pittii isolate co-
harboured OXA-23 and OXA-58. Furthermore, two A. pittii isolates
harboured OXA-255 (OXA-143-like) and OXA-72 (OXA-40-like),
respectively. Identification of OXA-72 was based on a partial
sequence (791 of 828bp) (see Section 2.2). By Etest, eight isolates
were resistant to imipenem and meropenem, three isolates were
susceptible to both antimicrobials and one A. junii isolate was
meropenem-resistant but imipenem-susceptible (Table 1).
IS elements were associated with blaOXA in 10 of the 12 isolates
(Table 1). ISAba3 flanked blaOXA-58 in four carbapenem-resistant
Acinetobacter isolates [A. nosocomialis, A. pittii (n =2) and A. junii]
and two carbapenem-susceptible A. pittii isolates (Table 1).
Interestingly, sequencing 200bp upstream from the start codon
of blaOXA-58 (including the putative promoter region) showed no
difference between carbapenem-susceptible and carbapenem-
resistant isolates. Consistent with the current results, ISAba3
associated with blaOXA-58 has also been detected in carbapenem-
susceptible A. bereziniae and A. lwoffii isolates [13]. Carbapenem
resistance in the presence of IS-associated blaOXA-58 might
therefore, require additional strain-dependent mechanisms, for
example, low permeability mediated by altered porin expression.
ISAba1 was present upstream of blaOXA-23 in all OXA-23-positive
carbapenem-resistant isolates, but was absent downstream of the
gene. EcoRV-digested and self-ligated plasmid DNA from A. pittii
isolate S22 amplified an ca. 5 kb amplicon by inverse PCR.
Sequencing of the blaOXA-23 downstream region identified the firstSequencing IS element upstream
of blaOXA
Carbapenem MIC (mg/L)
IPM MEM
OXA-23 ISAba1 >32 >32
OXA-23 ISAba1 >32 >32
OXA-23, OXA-58 ISAba1, ISAba3 >32 >32
OXA-23 ISAba1 >32 >32
OXA-23 ISAba1 >32 >32
OXA-72 – 16 >32
OXA-58 ISAba3 >32 >32
OXA-58 ISAba3 1.5 3
OXA-58 ISAba3 1.5 2
OXA-58 ISAba3 1 16
OXA-58 ISAba3 >32 >32
OXA-255 – 1 0.75
meropenem; AGS, Acinetobacter genomic species.
Table 2
Characterisation of 11 Acinetobacter spp. isolates with false-positive blaOXA PCR results.
Isolate Country of origin Species OXA multiplex PCR Closest similarity of sequenced multiplex PCR amplicons Carbapenem MIC (mg/L)
IPM MEM
G2-30 Germany A. pittii 23-like 90% class C b-lactamase of Acinetobacter oleivorans 0.5 4
BMBF470 Italy A. pittii 23-like ND 0.25 2
G3-72 Germany A. pittii 23-like ND 0.5 4
G1-44 Germany A. pittii 23-like ND 0.25 2
AF874 USA (Utah) A. pittii 58-like Hypothetical proteins (cloning revealed threedifferent sizes
of inserts thatwere all sequenced and identified as different
hypothetical proteins)
0.5 1
G3-6 Germany A. pittii 58-like ND 0.25 4
G3-11 Germany A. pittii 58-like ND 0.25 2
G1-56 Germany A. pittii 58-like ND 0.25 4
AF1 USA (Florida) A. pittii 58-like ND 0.5 2
AF257 Honduras A. pittii 58-like ND 0.75 4
BMBF460 South Korea AGS 14TU/13BJ 23-like, 58-like 74% urea carboxylase of Serratia proteamaculans (70%
carboxylase of A. baumannii)
>32 24
MIC, minimum inhibitory concentration; IPM, imipenem; MEM, meropenem; ND, not determined; AGS, Acinetobacter genomic species.
E. Zander et al. / International Journal of Antimicrobial Agents 43 (2014) 375–377 377193 nucleotides of an ATPase gene that has recently been detected
downstreamof blaOXA-23, e.g. as part of transposonTn6206, in the A.
baumannii BJAB0715 genome [14]. Sequences downstream of the
blaOXA-23 genes in the remaining isolates showed 100% similarity to
S22.
Although positive by multiplex PCR for an acquired blaOXA, 11
mostly carbapenem-susceptible isolates did not amplify blaOXA
using other gene-specific primers in a singleplex PCR (see
Section 2.3). This included 10 A. pittii isolates that were false-
positive for OXA-23-like (n =4) or OXA-58-like (n =6) and one
carbapenem-resistant Acinetobacter genomic species 14TU/13BJ
isolate (BMBF460) that was false-positive for both genes (Table 2).
Three isolates (BMBF460, G2-30 and AF874) representing species
with an amplicon corresponding to each of the different OXA
subclasses were selected for further investigation. Sequencing of
clonedmultiplex amplicons confirmed that the acquiredblaOXAwas
not present. BLAST search revealed the presence of three different
hypothetical proteins inA. pittii isolateAF874, a putative novel class
C b-lactamase in A. pittii isolate G2-30, and a urea carboxylase in
Acinetobacter genomic species 14TU/13BJ isolate BMBF460 (Ta-
ble 2). The mechanism of carbapenem resistance in BMBF460
remains to be determined. The presence of acquired blaOXA in
Acinetobacter spp. other than A. baumannii has been reported
previously by multiplex PCR, however they are not always
confirmed by sequencing [10,15]. The high rate of false-positive
blaOXA detected in this study (47.8%; 11/23 isolates) strongly
suggests that confirmation of multiplex PCR results in non-
baumannii Acinetobacter species is required by sequencing.
In summary, among 453 Acinetobacter isolates other than A.
baumannii, acquired blaOXA genes were identified in 12 Acineto-
bacter isolates mainly obtained from Europe and Asia, which
correlates with previous reports. The first detection of acquired
OXA in Acinetobacter spp. from South Africa and North America
highlights their worldwide spread. In addition, this is the first
reportofOXA-23 inAcinetobactergenomic species14TU/13BJ andof
the coexistence of OXA-23 and OXA-58 in A. pittii. However, 11
isolates tested false-positive for blaOXA using the established
multiplex PCR. The high degree of false-positive results by OXA
multiplex PCR in non-baumannii Acinetobacter spp. indicates that
the results should be confirmed by additional methods, e.g.
sequencing of the complete gene.
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Appendix 3. Other data relevant to the thesis 
A3.1 Minimum inhibitory concentration of representative Acinetobacter spp. 
 ry Minimum inhibitory concentration (µg/mL) 
 
Species Country of 
origin 
Erta- 
penem 
Mero- 
penem 
Ampi- 
cillin/ 
Pipera- 
cillin/ 
Cefe- 
pime 
Ticarcillin/ 
Clavulanic 
Genta- 
micin 
Ami- 
kacin 
Cipro- 
floxacin 
Cefta- 
zidime 
   Sulbac- 
tam 
Tazo- 
bactam 
 acid     
A. pittii Thailand >32 >32 4 >256 >256 >256 >256 >256 >32 >256 
T167 
A. nosocomialis 
 
Thailand 
 
3 
 
0.38 
 
1 
 
0.016 
 
3 
 
0.016 
 
0.75 
 
2 
 
0.094 
 
3 
T228 
A. baumannii 
 
Singapore 
 
>32 
 
12 
 
4 
 
>256 
 
32 
 
256 
 
24 
 
>256 
 
>32 
 
>256 
S36 
A. baumannii 
 
Thailand 
 
4 
 
0.5 
 
1.5 
 
0.016 
 
3 
 
12 
 
1 
 
3 
 
>32 
 
8 
T214 
A. baumannii 
 
Thailand 
 
1 
 
0.19 
 
0.75 
 
0.016 
 
0.75 
 
0.016 
 
0.5 
 
2 
 
0.125 
 
1.5 
T229 
A. baumannii 
 
Japan 
 
1.5 
 
0.5 
 
0.75 
 
0.016 
 
>256 
 
8 
 
2 
 
3 
 
>32 
 
>256 
J133 
A. baumannii 
 
Japan 
 
4 
 
0.75 
 
1.5 
 
0.032 
 
16 
 
0.032 
 
>256 
 
>256 
 
>32 
 
192 
J2770            
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A3.2 Alignment of the OXA-51-like variants  
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A3.3 Molecular characterisation of Acinetobacter baumannii from Turkey 
 
ID 
DVL 
Cluster 
OXA-51 OXA-23 OXA-40 OXA-58 OXA-143 OXA-235 gyrB multiplex 
52 1 ABA 3 1 1 0 0 0 0 A. baumannii 
53 2 ABA 3 1 1 0 0 0 0 A. baumannii 
54 3 ABA 3 1 1 0 0 0 0 A. baumannii 
55 14 ABA 3 1 1 0 0 0 0 A. baumannii 
56 16 ABA 3 1 1 0 0 0 0 A. baumannii 
57 23 ABA 3 1 1 0 0 0 0 A. baumannii 
58 33 ABA 3 1 1 0 0 0 0 A. baumannii 
59  34 ABA 3 1 1 0 0 0 0 A. baumannii 
60  37 ABA 3 1 1 0 0 0 0 A. baumannii 
61  38 ABA 3 1 1 0 0 0 0 A. baumannii 
62  39 ABA 1 1 1 0 0 0 0 A. baumannii 
63  40 ABA 1 1 1 0 0 0 0 A. baumannii 
64  41 ABA 1 1 1 0 0 0 0 A. baumannii 
65  42 ABA 1 1 1 0 0 0 0 A. baumannii 
66 43 ABA 1 1 1 0 0 0 0 A. baumannii 
67 44 ABA 3 1 1 0 0 0 0 A. baumannii 
68 45 ABA 1 1 1 0 0 0 0 A. baumannii 
69  46 ABA 1 1 1 0 0 0 0 A. baumannii 
70  47 ABA 3 1 1 0 0 0 0 A. baumannii 
71  49 ABA 3 1 1 0 0 0 0 A. baumannii 
72  50 ABA 1 1 1 0 0 0 0 A. baumannii 
73  51 ABA 1 1 1 0 0 0 0 A. baumannii 
74  52 ABA 1 1 1 0 0 0 0 A. baumannii 
75 53 ABA 1 1 1 0 0 0 0 A. baumannii 
76 54 ABA 1 1 1 0 0 0 0 A. baumannii 
77 55 ABA 1 1 1 0 0 0 0 A. baumannii 
78 56 ABA 2 1 1 0 0 0 0 A. baumannii 
79 85 ABA 4 1 1 0 0 0 0 A. baumannii 
80 59 ABA 3 1 1 0 0 0 0 A. baumannii 
81 89 ABA 2 1 1 0 0 0 0 A. baumannii 
82 90 ABA 2 1 1 0 0 0 0 A. baumannii 
83 60 ABA 2 1 1 0 0 0 0 A. baumannii 
84 94 ABA 3 1 1 0 0 0 0 A. baumannii 
85 104 ABA 2 1 1 0 0 0 0 A. baumannii 
86 105 ABA 2 1 1 0 0 0 0 A. baumannii 
87 108 ABA 2 1 1 0 0 0 0 A. baumannii 
88 excluded                 
89 121 ABA 2 1 1 0 0 0 0 A. baumannii 
90 122 ABA 2 1 1 0 0 0 0 A. baumannii 
91 125 ABA 2 1 1 0 0 0 0 A. baumannii 
92 171 ABA 2 1 1 0 0 0 0 A. baumannii 
93 172 ABA 4 1 1 0 0 0 0 A. baumannii 
94 174 ABA 3 1 1 0 0 0 0 A. baumannii 
95 164 ABA 2 1 1 0 0 0 0 A. baumannii 
96 165 ABA 2 1 1 0 0 0 0 A. baumannii 
97 178 ABA 2 1 1 0 0 0 0 A. baumannii 
98 166 ABA 3 1 1 0 0 0 0 A. baumannii 
99 180 ABA 2 1 1 0 0 0 0 A. baumannii 
100 181 ABA 2 1 1 0 0 0 0 A. baumannii 
101 182 ABA 2 1 1 0 0 0 0 A. baumannii 
102 208 ABA 2 1 1 0 0 0 0 A. baumannii 
103 209 ABA 2 1 1 0 0 0 0 A. baumannii 
104 206 ABA 2 1 1 0 0 0 0 
not confirmed as 
A. baumannii 
105 201 ABA 2 1 1 0 0 0 0 A. baumannii 
106 205 ABA 2 1 1 0 0 0 0 A. baumannii 
107 227 ABA 3 1 1 0 0 0 0 A. baumannii 
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108 229 ABA 3 1 1 0 0 0 0 A. baumannii 
109 233 ABA 3 1 1 0 0 0 0 A. baumannii 
110 236 ABA 3 1 1 0 0 0 0 A. baumannii 
111 239 ABA 3 1 1 0 0 0 0 A. baumannii 
112 240 ABA 3 1 1 0 0 0 0 A. baumannii 
113 273 ABA 3 1 1 0 0 0 0 A. baumannii 
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A3.4 Dendrogram of 61 Acinetobacter baumannii isolates from Turkey 
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A3.5 List of primers used to solve the ambiguity of the order of scaffolds of Acinetobacter spp. 
genome and other primers for molecular characterisation 
Primer name Primer sequences  Purpose 
T87_1F AGTAATTTCACCCGGTTTAGGG 
Closing genome gaps 
T87_1R TTGGAAATACTGGGTTTCTTCG 
T87_2F GCGATAGTGAACGGATTGAG 
T87_2R GCTCGGACACCTGAATTAGC 
T87_3F TGCTTCCAGATGTATGCTCTTC 
T87_3R GGAGAAACTGTCCGAGGTTATG 
T87_4F AGGTGGAGCTGACTTCATCC 
T87_4R GTATCCTTGCCGATCACGAC 
T87_5F TCAACGCCTGCAATAATGG 
T87_5R TCATGAGCTTTGGCACAGG 
T87_6F ATGCTGAACCGTACAACCAG 
T87_6R GGTGTAGTCGCTTGTGTGTTG 
T87_walk_F GTTCGCCGGATAAGTAATTTGC 
T87_walk_R ATGGTTGCATTCGGTAAGCAC 
J65gap2_1 CCGAGCATCCGTATGAGACT 
J65Gap2_2 TGTCCGAGGTTATGTTGACG 
Sup_F CCCCATATCACCGACAGTTC 
Sup_R TGAAATGGGTTCTCCTCTGG 
DOWNOXA_1 CGTTCCTCTAACTTTCCTG 
DOWNOXA_2 TGTCCTGATACTCATCCTGTC 
UPOXA_1 CACCAGCAACTATCACTGC 
UPOXA_2 GAATAACCAGCACACCTGAG 
Ac696F TAYCGYAAAGAYTTGAAAGAAG 
rpoB 
Ac1093R CMACACCYTTGTTMCCRTGA 
Ac1055F GTGATAARATGGCBGGTCGT 
Ac1598R CGBGCRTGCATYTTGTCRT 
 122 
Sp2F GTTCCTGATCCGAAATTCTCG 
Multiplex PCR for 
gyrB 
Sp4F CACGCCGTAAGAGTGCATTA 
Sp4R AACGGAGCTTGTCAGGGTTA 
D14 GACAACAGTTATAAGGTTTCAGGTG 
D19 CCGCTATCTGTATCCGCAGTA 
D16 GATAACAGCTATAAAGTTTCAGGTGGT 
D8 CAAAAACGTACAGTTGTACCACTGC 
G1_csuEF CTTTAGCAAACATGACCTACC 
SG typing 
G1_csuER TACACCCGGGTTAATCGT 
G1_ompAF GATGGCGTAAATCGTGGTA 
G1_OXA66F GCGCTTCAAAATCTGATGTA 
G1_OXA66R GCGTATATTTTGTTTCCATTC 
G1and2_ompAR CAACTTTAGCGATTTCTGG 
G2_csuEF GGCGAACATGACCTATTT 
G2_csuER CTTCATGGCTCGTTGGTT 
G2_ompAF GACCTTTCTTATCACAACGA 
G2_OXA69F CATCAAGGTCAAACTCAA 
G2_OXA69R TAGCCTTTTTTCCCCATC 
AB_70F_RPOD ACGACTGACCCGGTACGCATGTAYAT
GMGNGARATGGGNACNGT 
MLST 
AB_70FS ACGACTGACCCGGTACGCATGTA 
AB_70R_RPOD ATAGAAATAACCAGACGTAAGTTNGC
YTCNACCATYTCYTTYTT 
AB_70RS ATAGAAATAACCAGACGTAAGTT 
AB_CPN_3F2 ACTGTACTTGCTCAAGC 
AB_CPN_R2 TTCAGCGATGATAAGAAGTGG 
AB_GDH_SEC_F ACCACATGCTTTGTTATG 
AB_GDH_SEC_R GTTGGCGTATGTTGTGC 
AB_GDHB_1F GCTACTTTTATGCAACAGAGCC 
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AB_GDHB_775R GTTGAGTTGGCGTATGTTGTGC 
AB_gltA_Citrato_F1 AATTTACAGTGGCACATTAGGTCCC 
AB_gltA_Citrato_R12 GCAGAGATACCAGCAGAGATACACG 
AB_GPI_F1 AATACCGTGGTGCTACGGG 
AB_GPI_R1 AACTTGATTTTCAGGAGC 
AB_GYR_M13_F CAGGAAACAGCTATGACC 
AB_GYR_UP1ER CAGGAAACAGCTATGACCAYGSNGGN
GGNAARTTYRA 
AB_gyrB_APRU_F TGTAAAACGACGGCCAGTGCNGGRTC
YTTYTCYTGRCA 
AB_gyrB_M13_-21 TGTAAAACGACGGCCAGT 
AB_REC_RA1 CCTGAATCTTCYGGTAAAAC 
AB_REC_RA2 GTTTCTGGGCTGCCAAACATTAC 
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A3.6 Figure demonstrates STs available from MLST database (Oxford scheme) from Asia and Oceania. 
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A3.7 Table of epidemiology studies used in Chapter 1 
Australia 
No.  Isolates  Year Hospital Typing 
Method 
Clonality  Result Non-baumannii Resistance gene Reference 
1 177 Acinetobacter spp. 1995-
2000 
WM, 
Sydney 
PFGE 8 pulsotypes 
were identified 
CR isolates appeared in 
1999 (different 
pulsotypes from CS) 
A. pittii 
(pulsotype III) 
A. nosocomialis 
(pulsotype IV) 
OXA-23 in all 
resistant isolates (13) 
and was found in 
different pulsotypes  
Valenzuela 
JK, 2007 
3 Acinetobacter spp.  PW, Sydney  2 pulsotypes     
6 Acinetobacter spp.  RB, 
Brisbane 
 2 pulsotypes     
2 32 MDR AB 2002-
2007 
Sydney REP-PCR, 
genotypes 
2 REP-PCR 
types, 3 clonal 
groups 
REP-PCR can’t 
discriminate 6 isolates 
that have integron  
- OXA-23 in all CR Mak JK, 2009 
3 53 MDR AB 2001-
2003 
RBWH, 
Brisbane 
PFGE, PAR 3 Common 
pulsotypes, 8 
Single  
One major clone: 
majority of AB from 
RBWH since 2000 
  Long YB, 
2009 
4 ~41 patients CRAB 2006 RBWH, 
Brisbane 
PFGE (4) Identical  Successful control: 
cleaning w Virkon 
  Doidge M, 
2010 
5 33 MDR AB (27 CR) 1998-
2008 
RBWH, 
Brisbane 
PFGE, 
DiversiLab, 
MLST 
4 clones 
6 STs  
ST92 (22) predominant 
(2000-2008), ST69 (3), 
73 (2), 125 (2),126 (1), 
127(1) 
 OXA-23 in all CR Runnegar N, 
2010 
6  13 MDR AB (10 from 
#ref 2) 
1997-
2007 
Sydney SBT, recA, 
OXA-51-
like 
IC1 (6), IC2 (7)    Post V,  2010 
7 61 CRAB 2000-
2010 
Sydney, 
Brisbane, 
Canberra,  
SBT, recA, 
OXA-51-
like, REP-
PCR, RAPD 
IC2 Study Aminoglycoside 
resistant in IC2 
 OXA-23 all Nigro SJ, 
2011 
8  90 AB  2001-
2010 
Sydney, 
Brisbane, 
Canberra, 
Melbourne 
SBT, recA, 
OXA-51-
like, MLST 
IC1 (11), IC2 
(52) 
ST109 (3), ST247(1)  OXA-23 (3), OXA-58 
(2) 
Hamidian M, 
2011 
 
China 
No.  Isolates  Year Hospital Typing 
Method 
Clonality  Result Non-baumannii Resistance gene Reference 
1  2000-
2009 
Nationwide   Acinetobacter: 
nosocomial pathogen 
  Yong-Hong 
Xiao, 2011 
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8.8% in 2000 and 
15.5% in 2009 
     IMP/MER resistance 
rate: 2.5/4.1% in 2000 
and 50/52.4% in 2009 
  
     85% is A. baumannii   Ni, 2007 
Sun, 2009a 
 2003-
2008 
   MER: <10% in 2000 
and >50% in 2010 
 OXA-23, 58, 66? Wang, 2010b 
       OXA-23 Zhou, 2007 
  11 teaching 
hospitals 
  Clonal spread in 11 
hospital 
 97.7% OXA-23 
IMP-8 (1) 
OXA-66 (some) 
Wang, 2007 
  16 cities  CC22 closely 
related to IC2 
86.8% CRAB 
45.9% CSAB 
 Almost all OXA-23 Fu, 2010 
2 221 IMP-resistant 
Acinetobacter spp. 
AB (187) 
 
1999-
2005 
11 teaching 
hospitals 
PFGE 15 types 
 
Clone P  
Clone A  
Most prevalent 
GS10/11 (18) 
A. pittii (2) 
A. nosocomialis 
(5) 
OXA-23 (97.7%) 
OXA-58 (7) 
OXA-72 (1) 
IMP-8 (1); nonAB 
OXA-66 (18 
representative 
isolates) 
Wang H, 
2007  
3 37 IMP-resistant AB 2007 Shenyang PFGE, 
MLST 
4 types 2 epidemic clones  
ST92 (18) 
ST75 (17) 
Both are CC92 
 OXA-23 (34) 
OXA-58 (24) 
PER-1 (35) 
AdeABC important 
for high IMP-
resistance 
Zhang, 2010 
4 49 MDRAB 2007 3 military 
hospitals 
DiversiLab 5 major clones 
 
2 major clones were 
widespread in 3 
hospitals CC92?  
 OXA-23 (73.5%) 
OXA-58 (2%) 
ISAba1/OXA-51 
(12.2%) 
 
5  2109 AB 2009-
2010 
18 
provinces 
PFGE Diverse Different plasmid  NDM-1 in 4 isolates Chen, 2011 
6 57 CRAB 
20 CSAB 
2007-
2009 
Chongqing PFGE, 
MLST 
6 pulsotypes 
5 STs 
2 clones in CRAB 
ST75 (49%) 
ST137 (51%) 
Both: CC92 
 OXA-23 (100%) 
 
 
7 174 MDRAB 
86 CRAB 
2009 
(Jan-
June) 
Hunan 17 (1 4 types Clonal spread  OXA-23 (90.7%) 
 
Chen, 2011 
8 46 CRAB 
19 PSAB 
2004-
2009 
Beijing REP-PCR, 
MLST 
8 types 
23 STs 
ST92 (24), ST191 (7), 
ST75 (5), ST118 (2), 
STn17(1) 
All are CC92 
 OXA-23 (80.4%) Huang, 2013 
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9 95 IMP-R AB 2003-
2004 
University 
Hospital 
PFGE 6 clonal patterns  2 predominant pattern A 
(50), B (35) 
 All OXA-23 and 
OXA-66 (51-like) 
Han Zhou, 
2007 
10 76 CRAB, MDRAB 2008-
2011 
ICUs DiversiLab 
(24 hospital 
infections) 
4 groups  2 major groups: 
epidemic status of 
nosocomial infection 
caused by CRAB 
 All OXA-23 Wei Jiang, 
2010 
 
Japan 
No.  Isolates  Year Hospital Typing 
Method 
Clonality  Result Non-baumannii Resistance gene Reference 
1 88 Acinetobacter spp. 
3 CRAB 
*CR rate 1998-2002 
1998-
2002 
22 centres   CR rate 5.9% in 1998 
and 4.8% in 2002 
 IMP-1 Jones RN, 
2004 
2 902 Acinetobacter spp. 2004 100 centres   CR rate 3.2%   Ishii,  
3 201 ABC  2007-
2009 
Nagasaki   CR 1 isolate (patient 
died from pneumonia) 
Mortality rate 24.3% 
   
4 598 Acinetobacter 
27 carb-non-susceptible  
14 AB 
13 non-baumannii 
2007 72 hospitals  
(Nationwide
) 
PFGE, 
MLST 
3 types (2 are 
CC92) 
3 STs 
 
4.5% carb-non-
susceptible 
Acinetobacter spp. 
ST208 (10) , ST219 (3) 
are CC92 
ST222 (1) is CC276  
Found in 
diverse area 
(13) 
A. pittii (3): 
OXA-58 (3), 
IMP-1 (2) 
A. nosocomialis 
(4): IMP-1 (3), 
IMP-2 (2) 
A. calco (4), 
IMP-1 (4) 
A. lwoffii (2): 
OXA-58 (1), 
IMP-1 (2) 
 
ST222 isolate: IMP-1, 
OXA-58 
OXA-23 (6) 
ISAba1/OXA-51 (12) 
Kouyama Y, 
2012 
5 305 Acinetobacter spp. 
55 Carb-non-susceptible 
ACB 
52 AB 
3 A. pittii 
 
18% CNSACB 
2009-
2010 
176 centres MLST 6 STs 
ST92, 106, 74, 79 
are CC92 
ST92 (76.9%) 
ST106 (9.6%) 
ST74 (3.8%) 
ST76 (3.8%) 
ST188 (3.8%) 
ST195 (1.9%): OXA-23 
producing 
 
OXA-66 
(82.7%), OXA-
80 (9.6%), 
OXA-83 
(1.9%), OXA-
51 (1.9%) 
OXA-23 (1.9%) 
ISAba1/OXA-
51 (69%) 
 
A. pittii: IMP-19 (1) Endo S, 2012 
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6 48 Acinetobacter spp. 
with MBL genes  
2001-
2006 
5 hospitals PFGE, 
MLST 
(Pasteur) 
A. pittii ST119 (w 
IMP-19) is 
predominant  
A. baumannii (1): 
ST120 (not related to 
IC1,2 or 3) 
A. pittii (25): 
ST119 (18), ST63, 64, 
93, 121 
A. nosocomialis (5): 
ST68, 71  
A. bereziniae (9) 
Unclassified (3) 
Others (5) 
A. baumannii 
IMP-19 
 
 
 
 
 
A. pittii 
IMP-19 (23) 
IMP-1 (1) 
IMP-11 (1) 
OXA-58 (2) 
 
A. nosocomialis  
IMP-19 (4) 
 
A. bereziniae 
IMP-19 (9) 
Ichiyama S, 
2013 
7 1 A. baumannii  
Transferred from India to 
Japan 
2011 Indian 
hospital 
Jikei Uni 
Hospital, 
Tokyo 
MLST ST222 (missing in 
pubmlst) 
Not CC92  OXA-51 (no ISAba1) 
OXA-23 
NDM-1 
Nakazawa Y, 
2013 
 
Hong Kong 
No.  Isolates  Year Hospital Typing 
Method 
Clonality  Result Non-baumannii Resistance gene Reference 
1 60 clinical  
80% A. baumannii 
1990-
1994 
Queen 
Mary 
AP-PCR Unrelated strains 7.4% of all bacteria 
5.8% resistance to IMP 
(stable) 
  Siau, 1996 
2 18 Acinetobacter spp. 
bacteremia 
1995 Queen 
Mary 
AP-PCR  16 A. baumannii 
2. A. lwoffii 
 All susceptible to IMP Siau, 1999 
3 45 MDR AB 
24 CRAB 
2005-
2006 
5 hospitals PFGE, 
MLST 
2 types 
2 STs 
ST26 (24) in CRAB 
(non-CC92) 
ST22 (19) CSAB 
 OXA-23 all CRAB Ho, 2010 
 
India/Pakistan 
No.  Isolates  Year Hospital Typing 
Method 
Clonality  Result Non-baumannii Resistance gene Reference 
1 20 Acinetobacter spp. 
17 A. baumannii (11 
CRAB) 
1 A. pittii 
1 A. nosocomialis 
1 unidentified 
2008 2 hospitals PFGE Not related 3 groups: >85% have 
same OXA-51-like  
Interhospital spread  
 OXA-23 all CR 
OXA-66, 68, 69, 98, 
99, 114, 65 variant, 
100 
Evans BA, 
2010 
2 132 A. baumannii 2010-
2011 
Panjab, 
India 
  42 (31.8%) CR 
4 PDR: tiger and 
colistin 
  Mahajan G, 
2011 
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3 88 A. baumannii 2011-
2012 
Tertiary 
hospital, 
India 
  10 (11%) IMP 
resistance 
12 () MEM resistance 
  Ghakraborty 
B, 2011 
4 94 patients  
20% community-acquired 
Acinetobacter infection 
2009 Tertiary 
hospital, 
northern 
India 
  70% MDR 
70% crude mortality 
rate 
76% CRAB (MER) 
13% colistin R 
  Mathai AS, 
2011 
5 4180 samples from ICU 
4.5% Acinetobacter spp. 
2010-
2011 
(2 yrs) 
Kolkata, 
India 
  5.2% IMP-R 
9.8% MEM-R 
74% ACB 
14.2% A. lwoffii 
7.8% A. 
haemolyticus 
3.8% A. junii 
 Rit K, 2012 
6 23 A. baumannii 2011 2 
hospitals, 
Delhi, 
India 
MLST  ST ST110 (2) 
ST188 (3) 
ST146 (2) 
ST69 (2) 
ST103 (1) 
ST108 (1) 
ST194 (1) 
 
 
Novol ST 
ST368 (1) 
ST387 (1) 
ST388 (1) 
ST389 (1) 
ST390 (3) 
ST391 (3) 
1-10-10-6-1-4-
14 
 Rynga D, 
2013 
7 140 Acinetobacter spp. 2010-
2011 
Tertiary 
hospital, 
North 
India 
  20% MEM-R (28)  IMP-1 (8) 
IMP-2 (0) 
VIM-1 (2) 
VIM-2 (1) 
Efflux (4) 
Sinha N, 2013 
8 55 IMP-R A. baumannii 2007 
(4 mo) 
Tertiary 
hospital, 
South 
India 
RAPD 6 clusters 2 major cluster (17, 13)  IMP-1 (42%) 
No VIM-2 
Karthika RU, 
2009 
9 74 A. baumannii 2011 
(5 mo) 
University 
Hospital, 
Varanasi 
ERIC-PCR 3 NDM: different 
patterns 
30 MBL activity: 
 
 3 NDM 
5 VIM 
Mishra S, 
2013 
10 30 IMP-R AB 2008-
2009 
Tertiary 
hospital, 
Delhi 
  All susc to colistin 
Using real-time PCR 
  All IMP-1, VIM-1 
IMP-2 (15) 
VIM-2 (6) 
OXA-23 (14) 
NDM-1 (9/14) 
Niranjan DK, 
2013 
11 156 Acinetobacter spp. 1997-
2006 
ICUs at 
King 
Edward 
Memorial 
Hospital 
  93% were B lactamases 
+ 
11.5% (18) positive: 
ESBL DDST 
 10 PCR for ESBLs 
5 PER-1 
(chromosomal) 
Litake GM, 
2009 
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12 62 Acinetobacter spp. 
(48 AB, 14 non-AB) 
2007-
2008 
(6 mo) 
4 hospitals 
in south 
India 
RAPD-PCR 40 types Nonclonal spread OXA-23 (28.5% 
OXA-24 
(64.3%) 
OXA-58 
(35.7%) 
OXA-23 (47.9%) 
OXA-24 (22.9%) 
OXA-58 (4.2%) 
Karunasagar 
A, 2011 
 
Malaysia 
No.  Isolates  Year Hospital Typing 
Method 
Clonality  Result Non-baumannii Resistance gene Reference 
1 109 Acinetobacter spp. 1987, 
1996-
1998 
UMMC, 
KL 
REP-PCR 4 types 2 major types (92% of 
isolates) were persist 
over a decade in this 
hospital 
 
1987(21) 4.8% 
IMP-R 
1996-1998 (88) 
36.4% IMP-R 
 Misbah S, 
2004 
2 23 nosocomial blood 
stream pathogens 
2003-
2007 
3 ICUs   22% Acinetobacter spp. 
(5)  
  Gopal 
Katherason S, 
2010 
3 185 A. baumannii 
170 (92%) clinical 
15 (8%) environment and 
hands of HCW 
2006-
2009 
Teaching 
hospital 
ICU 
PFGE 8 types (70% 
similarity) 
Clinical isolates 96.5% 
IMP-R, 98.2% MEM-R 
All colistin S 
  
A persistent 
clone of MDR-
AB 
Isolates form 
hands of HCW 
were closely 
related to 
clinical isolates 
suggesting 
transmission 
form HCWS to 
patients by 
hands 
 Boon Hong 
Kong, 2011 
 
Singapore 
No.  Isolates  Year Hospital Typing 
Method 
Clonality  Result Non-baumannii Resistance gene Reference 
1 60 Acinetobacter spp. 1998-
1999 
4 medical 
centres, 
Malaysia 
2 sites, 
Singapore 
  13.3% IMP-R   Biedenbach 
DJ, 1999 
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2 Acinetobacter spp. 
41 ACB IMP-R (53%) 
2004 
(8 
month
) 
Tertiary 
care 
hospital  
PCR-based 
fingerprint 
No dominate 
clone (but no 
screening for 
colonization) 
4 small clonal groups 
for 50% of isolate 
 
52% IMP-R in 2004 
and constant 2002-2006 
  Tan TY, 2007 
3 171 Acinetobacter spp. 
81.3% A. baumannii 
(139) 
2006-
2007 
5 hospitals   A. baumannii 70.5% 
carb-R 
0.7% colistin R 
7.9% tigercycline R 
25% carb-R  Tan TY, 2008 
4      Over all 49.6% of 
Acinetobacter: Carb-R 
in 2007  
  Hsu LY, 2007 
5 1990 MDRAB emerged 
in the burns unit of SGH 
1992: 2 isolates colistin R 
     2 A. pittii and 1 
A. nosocomialis: 
OXA-58, IMP-4 
(from Brown S, 
2005) 
 Koh TH, 
2008 
6 47 patients 
82 strain of A. baumannii 
2001-
2006 
   A. baumannii (33%): 
most common causing 
nosocomial infections  
 
78.7% IMP-R 
  Chin H, 2007 
7 2000 Acinetobacter spp. 2008-
2008 
4 public 
hospitals 
  46.7% Acinetobacter 
IMP-R 
 
50% blood IMP-R 
Possible 
association 
between 
prescription of 
carbapenems 
and IMP-R 
Acinetobacter 
 Hsu LY, 2010 
8 193 ACB 
 
78.7% A. baumannii 
9.3% A. pittii 
11.9% A. nosocomialis 
 
2006 
(1 mo) 
6 hospitals  AFLP 
MLST 
(pasture) 
 IC1: outbreak in 2001 
(OXA-69) 
 
IC2: outbreak in 2001 
and 2006 (OXA-66) 
 
ST25, ST111 unrelated 
to IC1, 2, or 3 
A. baumannii 
72.4% CR 
A. pittii 38.9% 
A. nosocomialis 
34.8% 
 
OXA-23 in A. 
baumannii (108), A. 
noso (8) 
 
ISAba1/OXA-51 in 
IMP-R AB (12) 
 
OXA-58 in A. 
baumannii (1) 
A. nosocomialis (4) 
A. pittii (8) 
KOH TH, 
2011 
9 114 IMP-R ACB 5 mo 
each 
of  
1996 
2001 
Tertiary 
general 
hospital 
PFGE 16 pulsotypes  
A (36.3% for carb 
producing 
isolates) 
IMP-R 
1996 (7.7%) 
2001 (21.2%) 
3 A. pittii 
OXA-23 (1) 
OXA-58, IMP-4 
(2) 
OXA-23 (37) 
OXA-96 (58-like) (1) 
 
OXA-51-like 
Tse Hsien 
Koh, 2007 
 
Tse Hsien 
Koh, 2007 
132 
 
2 A. 
nosocomialis 
OXA-58, IMP-4 
(2) 
 
-64 (13), -66 (14), -69 
(4), -88 (3), -95, -91, 
93 
 
Korea 
No.  Isolates  Year Hospital Typing 
Method 
Clonality  Result Non-baumannii Resistance gene Reference 
1. 142,107 and 68,391 
6.6% Acinetobacter spp. 
2009 24 
hospitals 
and 2 
Com Labs 
  IMP-R 
1% 1997 
22% 2007 
51% 2009 
  Lee K, 2011 
KONSAR 
group 
2 547 Acinetobacter spp. 
388 AB (272 CNSAB) 
A. nosocomialis (82) 
A. pittii (62) 
A. bereziniae (13) 
A. GS 14TU (2) 
2008 19 
hospitals 
DiversiLab, 
MLST 
57 band patterns 
57 STs 
70% CNSAB 
All CNSAB: 3 band 
patterns (similar to IC2 
by Higgins)  
5 STs of CNSAB 
ST92 (159), 
ST75 (64), 
ST137 (3), 
ST138 (38), are CC92 
ST69 (8) DLV with 
ST92 
 
A. baumannii (1) and A. 
bereziniae (1) low level 
resistance to colistin, A. 
GS 14TU (2): high level 
 
IMP-1 (6) 
VIM-2 (4) 
OXA-23 (1 A. 
pittii) 
OXA-23 (169/272 
CNSAB) 
ISAba1/OXA-51 
(89O 
 
Lee 
Yangsoon, 
2011 
2.1 IMP-non-susceptible 
Acinetobacter spp. 
A. baumannii (44) 
A. pittii (10) 
A. nosocomialis (2) 
2008-
2010 
Uni 
Hospital, 
Daejeon 
Rep-PCR 2 types of AB 
Diverse band 
pattern : A. pittii, 
A. nosocomialis 
 A. pittii  
IMP-1 (10) 
100% 
 
A. nosocomialis 
VIM-2 (2) 
100% 
A. baumannii 
OXA-23 (100%) 
ISAba1/OXA-51 
(88.6%) 
 
Ji Youn Sung, 
2011 
3 36 CRAB 2004-
2006 
17 non-
tertiary 
hospitals 
DiversiLab, 
MLST 
8 rep-PCR 
patterns 
2 STs 
ST69 (17) 47.2% 
ST92 (19) 52.8%) 
These 2 clones: 
nationwide and 
both tertiary and 
non-tertiary 
hospitals  
ISAba1/OXA-51 (25) 
69.4% 
ISAba1/OXA-23 (14) 
38.9% 
Sunok Park, 
2013 
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4 287 Acinetobacter spp. 
from blood stream 
infection 
A. baumannii (44.2%) 
A. nosocomialis (34.1%) 
Acinetobacter close to 
13TU (9.8%) 
A. pittii (5.2%) 
A. calcoaceticus (1%) 
Non-ACB (5.6%) 
 
65 CRAB isolates 
2003-
2010 
one 
hospital 
MLST 9 STs 
CC92: 
ST92 
ST75 
ST138 
ST220 
 
DVL of CC92 
ST69, 70, 71 
 
ST110 
ST20 
 
ST92 (47.8%), 
ST69(15.9%): most 
prevalent clones in 
2003-2007 
 
ST75 (39.7%), ST138 
(25.9%) had increased 
in 2008-2010 
suggesting substitution 
of main clones (still in 
CC92) into more 
resistant clones  
 
IMP/MEM-R 
2003-2007: 
12.9%-20.5%  
2008: 
41.4/41.5% 
 
2008-2012 
polymyxin-R in 
few isolates 
High colistin-R 
in A. 
nosocomialis 
(43.9%) 
 
ST75, ST138 
showed high 
carb-R, ST92 
showed 
moderate 
resistance 
All ST75, 138  (and 
one ST92) had OXA-
23 
 
ST92 (66.7%), ST69 
(66.7%): high 
prevalent of PER 
 
OXA-23 (38) 58.5% 
 
IMP-1 
A. baumannii (3) 
A. pittii (7) 
Young 
Kyoung Park, 
2012 
5 44 of A. baumannii IC2 2003-
2010 
Multiple 
hospitals  
MLST Both CR, CS 
ST92 (19) 
ST75 (7) 
ST138 (5)  
 
ST69 (9) 
ST71 (2) 
ST220 (1) 
Most CRAB in Korea 
have originated from 
the same ancestor with 
a globally disseminated 
clone  (IC2) 
 ST75 AbaR4-type 
with Tn2006 
 
ST138; Tn2006 not in 
AbaR 
Dae Hun 
Kim, 2012 
6 2 Carb-R A. nosocomialis   Korea, 
Thailand 
  Hypothesised that 
AbaR-4 in A. 
nosocomialis have been 
transferred from A. 
baumannii IC2 
 OXA-23 located in 
AbaR4-type 
Dae Hun 
Kim, 2012 
7 29 MDR AB 
22 CRAB 
7 CSAB 
2007-
2011 
Single 
university 
hospital, 
Daejeon 
SBT, rep-
PCR, MLST 
IC2 (27): OXA-66 
 
IC1 (2): OXA-69 
 
2 rep-PCR 
patterns: correlate 
with IC from SBT 
MLST of IC2  
5STs: ST75, 92, 137, 
138, 357 
 
MLST of IC1: ST109 
 AbaR7 found in IC1 
(2) isolates 
 
OXA-23 (11/22) 
 
armA (24/29) 
Ji Youn Sung, 
2012 
8 253 A. baumannii 
(93.7%) 
A. nosocomialis (10) 
A. pittii (5) 
 
2008-
2009 
73 
hospitals, 
10 Asian 
countries 
MLST (108 
isolates 
tested) 
36 STs 76.9% CC92 (83) from 
all 8 countries: 18 STs  
ST92 (19) (IN, MY, 
PH, TW, TH), ST195 
 82.5% CRAB (208) 
 
108 tested: 
ISAba1/OXA-51 6.5 
% (7) 
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> 60% A. baumannii 
causing HAP were 
resistant to all 
antimicrobial agents 
except the polymyxins 
indicting, which indicates 
that the continuing 
increase of highly MDR 
A. baumannii in Asia  ( 
Chung DR, 2011) 
(18) (TH, MY) are 
predominant  
 
CC108: prevalent in 
India (5) 
 
CC119 (3), CC254 (3), 
singleton (11) 
 
OXA-23 94.4% (102) 
OXA-24 6.5% (7) all 
from Taiwan 
 
All CC92 (47 tested) : 
AbaR4-like (AbaR25-
I most prevalent 
(34.8%)) 
9 158 A. baumannii 
 
2011 13 
hospitals: 
Nationwi
de 
   Resistance rate 
(IMP/MEM) 
2006-2007 
20/23.3 
2008 
25.4/28.8 
2011 
55.4/37.5 
 Kyungmin 
Huh, 2013 
10  31 amikacin and cipro-R 
A. baumannii 
30 A. baumannii 
1 A. calcoaceticus 
2010 
(4 mo) 
Single 
hospital 
ERIC-PCR, 
MLST 
4 STs CC118:  
ST191 (28) 
ST208  
 
CC110: 
ST229 
ST207 (1 A. calco) 
 
30/31 OXA-23 
28/31 armA 
All ORDR 
mutations (both 
gyrA, parC) 
 Seung Bok 
Hong, 2013 
11 69 CRAB 
 
5 CRAB (2005) 
2009-
2010 
Single 
hospital, 
Daegu 
PFGE,  
SBT, MLST 
(both 
Pasture, and 
Oxford) 
9 pulsotypes 
ST2 all; Pasture 
 
2 main pulsotypes: 
 
63 SG1 (IC2) isolates: 
MLST Oxford 
ST191 (56)  
ST208 (6) 
ST353(1) 
5 CRAB (2005) 
showed ST353 
suggesting that 
isolates form 
2005 were not 
clonally related 
to 2009-2010 
All OXA-23 
PER (9) 
armA (58/69) 84% 
Mamata 
Gurang, 2013 
12 8 MDR AB 2001-
2012 
(4mo) 
NICU, 
Daejeon 
SBT, MLST, 
rep-PCR 
1 clone 
ST357 (IC2) 
All ST357; have not 
reported in Korea 
before  
All CS but 
resistant to 
amikacin, genta, 
4th gen cep and 
cipro 
All has armA Ji Youn Sung, 
2013 
13 52 IMP-nonsusceptible A. 
baumannii 
2007-
2011 
Universit
y hospital, 
Daejeon 
SBT, MLST 6 STs 
All CC92, IC2 
ST69 (2), ST92 (5), 
ST75 (2), ST137 (16), 
ST138 (25), ST358 (1) 
 OXA-23 (31) 
ISAba1/OXA-51 (23) 
armA (45) 
Hye Hyun 
Cho, 2013 
14 30 XDR 
All IMP-R 
2007 
(4 mo) 
7 tertiary 
hospitals 
PFGE 28 types  Both clonal and non-
clonal dissemination  
No interhospital 
transmission 
 OXA-23 (23) 77% all 
with ISAba1 
ISAba1/OXA-51 (7) 
23% 
Yoon Soo 
Park, 2010 
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15 35 MDR 2007-
2008 
3 Uni 
Hospitals 
Rep-PCR Hospital A, C 
diverse, B has 2 
patterns 
2 predominate clones  OXA-23 (22.9%) 
with high MIC 
ISAba1/OXA-51 
(60%)  
IMP-1 (8.6%)  
Sun Hoe Koo, 
2010 
16 28 IMP-R AB Clinical 
isolates 
7 IMP-R AB 
environmental isolates 
 
2004 2 ICUs, 
Uni 
Hospital 
PFGE One major clone; 
82% of clinical 
and 86% of 
environmental 
  ISAba1/OXA-51 
(93.7%) 
IMP-1 (n=2) (6.3%) 
Chaulagain 
BP, 2012 
17 190 IMP-NS 
Acinetobacter spp. 
92.2% (178) A. 
baumannii 
 
2007 
(3 mo) 
12 
tertiary-
care 
hospitals 
PFGE (140 
isolates of 
OXA-23) 
Sequence 
type group 
(37 rep 
isolates) 
15 types  
37 subtypes 
89% of A. baumannii 
with OXA-23 had 
identical PFGE pattern  
76% was IC2 
11/12 OXA-182 A. 
baumannii had the same 
PFGE pattern 
12 non-
baumannii 
IMP-1 (75%) 
VIM-2 (17%) 
SIM-1 (8%) 
OXA-23 (80%) 
ISAba1/OXA-51 
(12%) 
Novel OXA-182; 
93% to OXA-143 
(7%) 
VIM-2 (1%)  
Chang-Ki 
Kim, 2010 
18 86 A. baumannii 2007-
2010 
A 
hospital, 
Gangwon 
province 
AFLP 
Rep-PCR 
All except one 
(85) showed 
identical AFLP 
profiles and 
similar band 
patterns (rep-
PCR) 
Clonal spread  All OXA-23 
31 TEM 
32 PER-1 
 
armA (81%) 
 
 
Taiwan 
No.  Isolates  Year Hospital Typing 
Method 
Clonality  Result Non-baumannii Resistance gene Reference 
1 614 ACB 
120 (19.5%) MDR ACB 
2006 
(a 
year) 
Hsin-Chu 
general 
hospital 
PFGE 26 types  
36 subtypes 
Many diff MDR clones 
found in this hospital 
  Ming-Feng 
Lin, 2009 
2 167 A. baumannii 
(hospitalised in ICU) 
2005 10 major 
teaching 
hospitals, 
Nationwi
de  
PFGE (25 
XDR 
isolates) 
6 pulsotypes  
 
One or more of 6 
clones were 
present in all of 
the diff major 
Taiwanese 
hospitals 
IMP-R AB  
25% in 2005 
22% in 2000 
 
6% colistin R (2005) 
 
Supporting the endemic 
propensity of A. 
baumannii 
  Shio-Shin 
Jean, 2009 
3. 94 A. baumannii 
73 from patients 
31 from environment 
2006 
(a 
year) 
3 ICUs in 
university
Rep-PCR, 
RAPD 
9 groups of rep-
PCR 
 
All MDR 
Type 1 (79.8%) was the 
most common: major 
  Hui-Lan 
Chang, 2009 
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, 
Taichung 
clone that caused 
outbreak in this hospital 
4 A. baumannii  
1997-1998 (2071) 
1999-2005 (9021) 
1985-
2005 
Tertiary 
hospital, 
northern 
Taiwan 
  1997-1998 
nonsusceptible rate 
(2%) 
 
1999-2005 (4.8%) 
  Wen-Tsung 
Lo, 2011 
5 247 Acb 
47.8% A. baumannii 
32% A. nosocomialis 
8.9% A. pittii 
2007-
2008 
NTUH 
tertiary 
hospital  
PFGE (77 
non-
baumannii) 
No clonal spread 
in non-baumannii 
isolates 
CR 
A. baum 44.3% 
A. noso 5.2% 
A. pittii 0% 
 A. baumannii 
bacteraemia was 
associated with a 
higher mortality rate 
(14, 30 days) 
Yi-Chieh Lee, 
2011 
6 23 MDR AB 2009 
(1 mo) 
5 
hospitals 
PFGE 11 pulsotypes 
 
5 pulsotypes were 
clonally spread among 
the 5 hospitals 
 OXA-23 (57%) 
ISAba1/OXA-51 
(61%) 
Ming-Feng 
Lin, 2011 
7 92 A. baumannii (3.8%) 
From IAIs 
SMART 
2006-
2010 
5 tertiary 
hospitals 
(Northern
) 
  IMP-R 
2006 (70%) 
2007 (80%) 
 
 CRAB  
2006 (70%) 
2007 (81%) 
2008 (58%) 
2009 (16%) 
2010 (25%) 
Yu-Lin Lee, 
2012 
8 56 (3.2) A. baumannii in 
the Asia-Pacific region 
UTI 
SMART 
2009-
2010 
38 
medical 
centres 
form 10 
countries 
  IMP-R  ~64.3% 
 
   Po-Liang Lu, 
2012 
9 43 patients A. junii 
bacteraemia 
2000-
2010 
NTUH    100% Carb S 
35% colistin R 
 Tsai HY, 
2012 
10 42 clinical ACB isolates  
29 environmental  
2009 
(a 
year0 
 PFGE, 
Rep-PCR 
4 pulsotypes 
4 types rep-PCR 
(same results w 
PFGE) 
Type A (90.6%)  MDR 
95.2% clinical 
81.8% 
enviromental 
OXA-23, OXA-51 (in 
MDR isolates) 
Cheng-Mao 
Ho, 2013 
11 134 MDR-AB 2007 3 hospital 
from 
north, 
south and 
east  
PFGE 17, 23, 11 
pulsotypes in each 
hospitals 
High proportion of 
identical strains in 
eastern Taiwan 
Resistance 
Colistin 10.4% 
Rifampicin 
47.8% 
Tigeclycline  
45.5% 
 Kai-Chih 
Chang, 2012 
12 IMP-R isolates ACB 
46 clinical/ 
11 environmental 
2003-
22004 
ICU 
veterans 
general 
hospital 
PFGE 2 pulsotypes in 
both species 
A. baumannii was 
closely related  
A. baumannii 
(42/5) 
A. nosocomialis 
(4/6) 
ISAba3/OXA-58 22 
clinical isolates AB 
All A. nosocomialis 
 
ISAba1/OXA-51 in 
21 clinical AB 
 
Yi-Tzu Lee, 
2012 
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13 13,811 A. baumannii 
infections 
2003-
2008 
121 
hospitals 
Nationwi
de 
  Significant increase in 
CRAB over that by all 
A. baumannii  
14% in 2003 to 46% in 
2008 
The greatest: central 
Taiwan: 4% in 2003 to 
62% in 2008 
 
 Use of anti-
psuedomonal 
carbapenems was 
significantly 
correlated with the 
increase of CRAB 
Chiu-Hsia Su, 
2012 
14 ACB isolates 
TSAR 
2002-
2010 
26 
hospitals 
(all 4 
regions) 
Nationwi
de 
  IMP-R 
2002 (3.4%) 
2010 (58.7%) 
 
Susceptibility to 
polymyxin: 99.8% 
(remain high) 
  Shu-Chen 
Kuo, 2012 
15 667 A. baumannii  1995-
2012 
Single 
hospital: 
north  
PFGE Heterogeneous Susceptibility to carb 
decreased steadily 
88.1% (2001-2003) to 
<25% (2010-2012) 
 
Remain susceptible to 
colistin 
 
Partially susceptible to 
tigecycline (80%)  
 ISAba1/OXA-51 
consistently identified 
(start in 2001) 
 
Tn2006, Tn2008 (first 
appeared 2007) 17.5% 
(2007-2009) to 50% 
(2010-2012) 
ISAba3/OXA-58, 
OXA-72, MBL genes: 
sporadic  
Wen-Wei Ku, 
2013 
16 192 A. baumannii 2009 10 
teaching 
hospitals 
  IMP-susceptibility  
29%  
  Shio-Shin 
Jean, 2013 
17 151 ACB isolates 
88.7% A. baumannii 
8% A. pittii 
3.3% A. nosocomialis 
2006 
(3 mo) 
25 
medical 
centres 
PFGE, 
MLST 
(Pasteur) 
3 majors clones: 
ST2, CC2 
(Pasteur) 
26 isolates: CRAB 
7.7% OXA-23 
7.7% OXA-24 
No IMP, VIM 
One A. 
nosocomialis 
had OXA-51 
1 CR A. pittii 
OXA-58 
 
5 all CS but one had 
OXA-51 
 
18 65 A. baumannii 
 
55.4% IMP-R 
2009 
(6mo) 
2 regional 
hospitals  
Rep-PCR One major clone 
of IMP-R (84%) 
in the four regions 
72% class 1 integrase 
genes 
  Ming-Feng 
Lin, 2013 
19 Bacteraemia  
42% A. baumannii 
47.7% A. nosocomialis 
 
CRAB (71) 
CRNS (64) 
2000-
2008 
Veteran 
generals 
hospital 
PFGE 7, 14 pulsotypes CRAB 
1.4% colistin R 
8.2% tige R 
CRNS 
45.3% colistin 
R 
No tige R 
Significantly higher 
mortality rate with 
CRAB 40.8% vs 
14.1% at 14-day 
Ya-Sung 
Yang, 2013 
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20 136 IMP-R Acinetobacter 
spp. 
2005-
2007 
Regional 
hospital 
PFGE 56 pulsotypes 
 
No predominant 
pulsotype 
 OXA-23 (19%), 
chromosomal with 
ISAba1 
OXA-24 (1%) 
ISAba1/OXA-51 
(10/39) (26%) 
Ming-Feng 
Lin, 2011 
21 83 IMP-R Acinetobacter 
spp. 
2007 3 
hospitals 
PFGE 51 pulsotypes No predominant 
pulsotype 
 OXA-23 (32.5%) 
OXA-72 (6%) 
OXA-51-like were 
OXA-66 
Han-Yueh 
Kuo, 2010 
22 291 A. baumannii 2007 
(4 mo) 
10 
hospitals 
PFGE 2 major clones 
(77.8%) 
142 (49%) IMP-R 
 
 27 (19%) OXA-72: 
predominance in 
southern Taiwan 
(22/38) 
All on 2 plasmid 
types 
Shu-Chen 
Kuo, 2013 
23 19 A. pittii  1999-
2007 
3 
hospitals 
PFGE 16 pulsotypes No clonal relatedness Carb-R 57.9% 
(11) 
All susceptible 
to colistin 
IMP-1 (10) 
IMP-8 (1) 
OXA-58 (11) with 
ISAba3 
Li-Yueh 
Huang, 2010 
24 1,265 A. baumannii 
 
2007-
2009 
Chung 
Shan Med 
Universit
y, central 
Taiwan 
  15.18% MDR  96.35% (185/192) 
OXA-23  
0.52% (1/192) OXA-
24 
Yang SC, 
2010 
25 62 A. baumannii 
(42 IMP-R) 
2009 2 teaching 
hospitals 
PFGE 41 types   IMP-R isolates 
Tn2006 (28) 
Tn2008 (6) 
ISAba1/OXA-51 (8) 
ISAba3/OXA-58 (2) 
IMP-1 (1) 
 
Hao-Yuan 
Lee, 2012 
26 32 XDRAB 2006 
(2 mo) 
4 ICUs in 
Tertiary 
hospital, 
southern 
Taiwan 
PFGE 1 pulsotypes Clonal spread caused  
outbreak 
 All OXA-72 (OXA-
24-like), 
ISAba1/OXA-51 
Wei-Ru Lin, 
2011 
27 92 MEM-R 2005-
2007 
 PFGE 11 pulsotypes  
3 major 
pulsotypes 
76% belonged to one of 
three pulsotypes 
  OXA-72 (59) 
(plasmidic) 
ISAba1/OXA-51 (33) 
OXA-58 (2) 
OXA-23 (1) 
 
Loss of CarO doesn’t 
produce a higher MIC 
Po-Liang Lu, 
2009 
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Thailand 
No.  Isolates  Year Hospital Typing 
Method 
Clonality  Result Non-baumannii Resistance gene Reference 
1 13 CRAB 2006 
(1 mo) 
Regional 
hospital, 
North 
PFGE 8 pulsotypes  2005 IMP-R 57% 
Genetically diverse, 
with some isolates were 
closely related 
 In 2004, OXA-72 
chromosome-encoded 
was identified 
(GenBank 
AY739646) 
 
All OXA23 
IMP (2)  
Both on plasmid 
Niumsup PR, 
2009 
2 200 CRAB 2003, 
2004, 
2006, 
2008 
Siriraj 
Hospital 
PCR-RAPD 
Plasmid 
profiling  
3 RAPD types 
10 plasmid 
profiles  
I (20), II (16), III  (1) 
2 clones with OXA-23 
wide-spread in this 
hospital  
 37 isolates: PCR 
All OXA-23/ISAba1 
 
Thapa B, 
2010 
3 83 A. baumannii 
69% IMP-R 
2005-
2006 
(3 mo) 
Ramathib
odi 
hospital 
PFGE 36 types 
 
3 predominant types 
Inter-intradepartmental 
spread 
 Class 1 integrase: all 
IMP-14 (1) 
Kansakar P, 
2011 
4 115 A. baumannii  
COMPACT II  
Asia-Pacific study 
2010 
(4mo) 
20 
medical 
centres, 4 
countries 
  CNSAB (73%) 
Philippines 25% 
Singapore 90.5% 
Thailand 76.3% 
Vietnam 89.5% 
 
  Kiratisin P, 
2012 
5 72 Acinetobacter 
bacteraemia 
2005-
2008 
2 rural 
provinces 
  44% non-HCA risk 
factors: 
56.3% Acb complex 
43.8% (non-Acb) 
 
56% HCA infections 
79% Acb 
21% non-Acb 
Underline the 
need for 
clinician 
awareness of 
Acinetobacter 
spp. as a 
potential cause 
of CA 
bacteraemia in 
Thailand 
Greater proportion of 
non-HCA infections 
were due to non-Acb 
complex 
Porter KA, 
2013 
6* 2,130 A. baumannii 2003-
2005 
Songklan
agarind  
  Outbreak of IMP-R AB 
in this hospital is asso 
with increasing ATB 
pressure, esp IMP, 
admission to ICR, RCU 
 Not significant 
difference in mortality 
rate between IMP-R 
AB and IMP-S AB 
Jamulitrat S, 
2007 
7* NARST 
 
2000-
2005 
33 
hospitals  
  CRAB 
2000 (2.1%) 
  Apisarnthanar
ak A, 2009 
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Nationwi
de 
2005 (46.7%) 
Emergence of PDR AB 
8* Acinetobacter 
8,699 (in 2000) 
14,071 (in 2005) 
NARST  
2000-
2005 
28 
hospitals  
  Same as 7   Dejsirilert S, 
2009 
9* 30 patients 
300 environmental 
isolates 
2008 
(15 d) 
BMA 
medical 
college 
PCR-based 
typing (65 
CRAB) 
4 molecular types  
Type 1 (90.7%): 
found in almost 
all kinds of 
environmental 
samples 
86.7%/ 66.7% of 30 
patients had their 
environment 
contaminated with AB / 
CRAB 
Enviroment 
contamination 
rates of AB/ 
CRAB were 
18%/ 13%) 
The most 
contaminated 
sites: cupboards 
(26.7%) 
Bedrails, bed 
sheet s (20%) 
BP cuffs 
(16.7%) 
 
Clonal spread of 
CRAB emphasise the 
importance of hand 
hygiene, contact 
precaution and 
patient’s environment 
decontamination 
Phumisantiph
ong, 2009 
10* 114 A. baumannii  
90% HAI 
7.5% colonization 
2.5% CAI 
 Phramong
kutklao 
Hospital 
PCR-based 
typing 
6 molecular types 
 
Type 2 (47.4%) most 
common and widely 
spread in 14 wards 
 67.5% MDR Aimsaad L, 
2009 
 
11* 651 nosocomial 
pneumonia patients 
198 (30.4%) A. 
baumannii 
    Most of A. baumannii 
resistant to many ATB 
including carb 
  Werarak P, 
2012 
12* 10,762 patients 
7.3% HAIs 
 
2011    Acinetobacter spp.: 
most common organism 
  Rongrungrua
ng Y, 2013 
 
Asia-Pacific, WW 
No.  Isolates  Year Hospital Typing 
Method 
Clonality  Result Non-baumannii Resistance gene Reference 
1 492 IMP-non-susceptible 
AB 
 32 
countries 
DiversiLab, 
PFGE, 
Sequence 
group 
multiplex 
8 groups (91%) ~50%  (241) WW2 
 
 OXA-23 (32%) 
OXA-58 (22%) 
OXA-40 (8%) 
ISAba1/OXA-51 
(39%) 
Higgins, 2010 
2 A. baumannii with Intra-
abdominal infections 
2003-6 (173) 
2003-
2010 
Asia-
Pacific  
  IMP-non-susceptible  
2003-6 (60.7%) 
2007-10 (39.4%) 
 *bar chart of 
susceptibility to IMP 
with IAIs NZ, HK, 
Yuag-Meng 
Liu, 2012 
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2007-10 (312) 
SMART 
Aus, 
China, 
HK, 
Malay, 
NZ, Phil, 
Spore, 
SK, TW, 
TH 
TW, CH, KO in 2003-
10 
3 411 Acinetobacter spp. 
(APAC) 
SENTRY 
2004-
2006 
17 
countries 
from 
Asia-
Pacific 
  IMP/MEM-S 
73.7/73% 
 
  Gales AC, 
2006 
4 1952 Acinetobacter spp. 
(APAC) SENTRY 
 
2006-
2009 
12 
countries 
APAC 
  IMP-S 
2006 (59.4%) 
2007 (69.4%) 
2008 (48.6%) 
2009 (37.4%) 
All (56.8%) 
 APAC showed the 
lowest rate of 
susceptibility to IMP 
Gales AC, 
2011 
5 253 A. baumannii 
(93.7%) 
A. nosocomialis (10) 
A. pittii (5) 
 
>60% A. baumannii 
causing HAP were 
resistant to all 
antimicrobial agents 
except the polymyxins 
indicting, which indicates 
that the continuing 
increase of highly MDR-
AB in Asia  ( Chung DR, 
2011) 
2008-
2009 
73 
hospitals, 
10 Asian 
countries 
MLST (108 
isolates 
tested) 
36 STs 76.9% CC92 (83) from 
all 8 countries: 18 STs  
ST92 (19) (IN, MY, 
PH, TW, TH), ST195 
(18) (TH, MY) are 
predominant  
 
CC108: prevalent in 
India (5) 
 
CC119 (3), CC254 (3), 
singleton (11) 
 
 82.5% CRAB (208) 
 
108 tested: 
ISAba1/OXA-51 6.5 
% (7) 
OXA-23 94.4% (102) 
OXA-24 6.5% (7) all 
from Taiwan 
 
All CC92 (47 tested): 
AbaR4-like (AbaR25-
I most prevalent 
(34.8%)) 
Dae Hun 
Kim, 2013 
 
